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ABSTRACT OF THE DISSERTATION

Tau Prion Strains in Cells, Mice, and Patients
By
David Winland Sanders

Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2016
Professor Marc I. Diamond

Prion-like propagation of tau aggregation may underlie the stereotyped progression of pathology
along neuronal networks in neurodegenerative tauopathies such as Alzheimer’s disease. It has
become increasingly clear that unique conformations (“strains”) of prion protein (PrP) link
aggregate structure to clinical phenotypes in human prion diseases. Intriguingly, vast phenotypic
diversity in pathological and clinical presentation is also observed in tauopathies. The
mechanisms that account for this phenotypic diversity are completely unknown. During my
dissertation work, I put forward and tested the hypothesis that distinct tau amyloid conformations
(or “strains”) are responsible for unique tauopathies. First, I found that in experimental models,
tau acts as a prion, replicating distinct strains in vitro and in vivo. I observed that tau indefinitely
propagates distinct amyloid conformations in a clonal fashion in cell culture. In collaborative
work, I found that two tau strains induce distinct pathologies in vivo as determined by successive
inoculations into three generations of transgenic mice. Remarkably, tau from these mice reviii

created the original strains upon re-introduction to cultured cells. Second, I created a panel of tau
prion strains, which have remarkably divergent biochemical and cell biology properties and
cause unique patterns of pathology and rates of progression in vivo. Finally, I used my cell
system to isolate tau strains from 29 patients with 5 different tauopathies, finding that different
diseases are associated with distinct strains. Tau thus demonstrates essential characteristics of a
prion. This likely accounts for the phenotypic diversity of tauopathies and could enable more
effective diagnosis and therapy.

ix

Chapter 1: Introduction and Perspective

1

1.1

PREFACE

This chapter contains figures from a previously published manuscript:
Sanders, D.W.*, Kaufman, S.K.*, Holmes, B.B.*, Diamond, M.I. (2016). Prions and
protein assemblies that convey information in health and disease. Neuron 89, 433-448.
*These authors contributed equally to this work.
Author contributions for the citation above: DWS, SKK, and MID made the figures for
the paper. DWS, SKK, BBH, and MID wrote the paper.
DWS wrote all text for this introduction, although select paragraphs were structured
similarly to portions of the cited review manuscript.
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1.2 NEURODEGENERATIVE DISEASES: DISPARATE
SYNDROMES WITH STRIKING SIMILARITIES
The twentieth-century featured great breakthroughs in the development of treatments for
diseases that prematurely end human lives. Antibiotics and vaccines made many
communicable diseases a relic of the past, greatly extending lifespan in the modern world
(Andre et al., 2008). However, this incredible human accomplishment has resulted in a
larger segment of the population reaching advanced age, bringing with it a new emerging
health crisis, that of neurodegenerative diseases (Holtzman et al., 2011; Sloane et al.,
2002). The most common neurodegenerative syndrome, Alzheimer’s disease, is estimated
to cost the United States close to $200 billion annually in health care costs and is
predicted to affect over 100 million people worldwide by 2050 (Holtzman et al., 2011).
Due to the fact that there are currently no treatments for this or other fatal
neurodegenerative diseases of aging, there is an urgent need to understand the
mechanisms that drive these disorders in order to inform targeted therapeutics. Only with
these biomedical advancements can we bring much needed dignity to the last years of
human life.
Understanding the similarities between these disparate diseases, which are direct
consequences of the portions of the nervous system that are affected (Seeley et al., 2009;
Zhou et al., 2012), is a critical first step. In addition to age being the primary risk factor,
each disease can be caused by rare genetic mutations (Cruts et al., 2012) but far more
commonly features sporadic origins of unclear cause. Importantly for understanding the
etiology of these diseases, they are progressive, starting in an isolated part of the nervous
system, but eventually affecting large swaths of the brain and/or spinal cord prior to death
3

(Boillée et al., 2006; Hughes et al., 1992; McKhann et al., 1984). This is in contrast to
other injuries to the nervous system, such as ischemic stroke, in which damage remains
limited to the initial region affected (Astrup et al., 1981; Hossmann, 1994). In addition to
their progressive nature, neurodegenerative diseases share a defining pathological
characteristic, which may inform mechanisms of pathogenesis: the accumulation of
fibrillar deposits of aggregated protein in the affected cells (Chiti and Dobson, 2006;
Ross and Poirier, 2004). At a microscopic level, these structures are “amyloids”, fibrils
rich in cross-beta-sheet structure that are composed of thousands of repeating subunits or
“monomers” of their cognate proteins (Eanes and Glenner, 1968; Knowles et al., 2014).
Due to this defining feature of insoluble fibrillar amyloids, neurodegenerative diseases
can be grouped based on the protein that aggregates to form their characteristic
ultrastructural deposits. Thus, they can be considered as diseases of protein aggregation
or “proteopathies” (Walker and LeVine, 2000). Categorical proteopathies, which each
comprise multiple syndromes, include the tauopathies (tau; e.g. Alzheimer’s disease)
(Lee et al., 2001), the synucleinopathies (α-synuclein; e.g. Parkinson’s disease) (Goedert,
2001), and the TDP43opathies (TDP-43; e.g. amyotrophic lateral sclerosis) (Neumann et
al., 2006). A less common infectious group of neurodegenerative diseases are the
prionopathies (prion protein; e.g. Creutzfeldt-Jakob disease or CJD) (Prusiner, 1998). A
causal role for protein aggregation in disease is supported by the fact that mutations to
genes encoding proteins that form the pathogenic amyloid deposits in each major
proteopathy, most of which enhance the ability of each protein to form amyloids
(Barghorn et al., 2000; Conway et al., 2000; Johnson et al., 2009), cause familial forms of
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the disease (Hsiao et al., 1989; Hutton et al., 1998; Polymeropoulos et al., 1997;
Sreedharan et al., 2008).
Pathology studies from the past two decades have indicated that each proteopathy’s
associated pathological lesion spreads throughout the nervous system in a hierarchical
manner, likely occurring in advance of neurodegeneration (Braak and Braak, 1991; 1995;
Braak et al., 2003; Brettschneider et al., 2013; McKee et al., 2013; Thal et al., 2002).
Thus, spread of protein aggregation to a new region of the brain is a strong predictor of
degeneration in that region (Arriagada et al., 1992). For example, in Alzheimer’s disease
(AD), accumulation of amyloid beta plaques is hypothesized to trigger the downstream
deposition of tau neurofibrillary tangles, which then drives neurodegeneration in specific
regions of the brain (Hardy and Selkoe, 2002). Tau pathology is first observed in the
locus coeruleus (Braak and Del Tredici, 2012; Braak et al., 2011) before being seen in the
hippocampus and entorhinal cortex (Braak and Braak, 1991; 1995). At this stage,
memory deficits become apparent, a condition described as mild cognitive impairment
(Petersen et al., 2006). However, although AD is classically thought of as a disease of
memory loss, the disease further progresses with fibrillar deposits of tau protein
eventually being observed in the limbic system and higher regions of the cortex (Braak
and Braak, 1991; 1995), which correlates with the more widespread emergence of
behavioral impairments, cognitive deficits, autonomic problems, and eventually death.
Until recently, however, a mechanistic paradigm to explain this hierarchical spread of
pathology and degeneration had been lacking.

5

1.3 THE PRION CONCEPT AS A MECHANISTIC PARADIGM
FOR NEURODEGENERATIVE SPREAD
The prion hypothesis (Prusiner, 1998) has provided such a testable framework to explain
these observations of neurodegenerative spread (Aguzzi and Rajendran, 2009; Brundin et
al., 2010; Goedert, 2015; Guo and Lee, 2014; Prusiner, 2013; Sanders et al., 2016; Soto,
2012; Walker and Jucker, 2015). Classically, prions (“proteinaceous infectious particles”)
have been defined by their infectious (i.e. communicable between individuals) nature
(Prusiner, 1982), as these protein-only pathogens were appreciated as causative agents in
transmissible spongiform encephalopathies of both sheep (scrapie) (CHANDLER, 1961;
PATTISON et al., 1959) and humans (kuru) (Gajdusek, 1977; Gajdusek et al., 1966). In a
series of seminal works, Stanley Prusiner and colleagues found that a self-replicating,
misfolded, beta-sheet-rich (i.e. amyloid) form (PrPSc) of the physiological prion protein
(PrPC) was the causative agent in this group of rare, infectious neurodegenerative
diseases (Basler et al., 1986; Bolton et al., 1982; Büeler et al., 1993; 1992; Cohen et al.,
1994; Pan et al., 1993; Prusiner, 1982; 1998; Prusiner et al., 1983). This finding was a
paradigm-shattering affront to scientific dogma, in that an abnormal protein, as opposed
to nucleic acids, could act as the material for inheritance of a communicable disease
(Prusiner, 1998). However, while this concept remains revolutionary, semantically
defining prions as “infectious” has obscured the fact that human prion diseases (CJD and
related ailments) today are not generally infectious, in that communication by
cannibalism (kuru, observed in the Fore people of Papua New Guinea) (Gajdusek, 1977),
infected beef products (variant Creutzfeldt-Jakob disease) (Collinge, 1999), and
iatrogenic infection (CJD) (Brown et al., 2000; 2012) has largely been halted by modern
6

medical and food safety practices. Rather, the vast preponderance (>90%) of human prion
diseases are of sporadic cause, with unknown etiology associated with aging, or feature a
genetic origin, arising from autosomal dominant familial mutations to the PrP gene
(Wadsworth et al., 2003). In both cases, PrP is hypothesized to spontaneously misfold
into a self-propagating amyloid form that spreads throughout the brain to drive
pathogenesis (Prusiner, 1998). On a superficial level, this is eerily similar to what is
observed in more common neurodegenerative diseases such as Alzheimer’s disease
(Prusiner, 1984).
While some maintain that the infectious nature of prions should be their defining
characteristic (Aguzzi and Rajendran, 2009; Brettschneider et al., 2015; Hardy and
Revesz, 2012), others argue that the term prion should be expanded to include other
proteins that form higher-order assemblies that act as heritable elements (Prusiner, 2013;
Sanders et al., 2016; Uptain and Lindquist, 2002; Walker and Jucker, 2015). Due to the
striking similarities between the pathological agents (i.e. toxic amyloids) in classic prion
diseases and other proteopathies as well as physiological assemblies of replication (i.e.
functional amyloids), it may be more useful to define prions as being “proteinaceous
nucleating particles” (Walker and Jucker, 2015) or “protein assembl[ies] that
communicate information stably via template-based amplification of a specific
conformation” (Sanders et al., 2016). We favor this expanded definition as the prion
concept provides a unifying framework by which to understand the mechanisms of
neurodegenerative spread and protein-only based elements of inheritance (Sanders et al.,
2016).
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At a biophysical level, proteins that form prions are capable of undergoing a
conformational change from a physiological form, which can be natively folded or
intrinsically disordered, to a misfolded form rich in beta-sheet structure (Chiti and
Dobson, 2006; Knowles et al., 2014). This new alternative conformation is aggregationprone and rapidly forms thermostable amyloidogenic nuclei or “seeds” that act as
templates to corrupt natively folded monomer with similar amino acid sequences (Chiti
and Dobson, 2006; Knowles et al., 2014). Monomer can thus be added to the free ends of
amyloid fibrils in a process called primary nucleation (Collins et al., 2004a; Jarrett and
Lansbury, 1993; Serio et al., 2000), and the process is amplified by fragmentation of
fibrils to produce further nuclei with additional free ends for continued growth.
Alternatively, individual amyloid fibrils can catalyze the growth of additional fibrils from
their sides in a mechanism called secondary nucleation (Cohen et al., 2013; Knowles et
al., 2009). At a conceptual level, these proteins act as biophysical switches between a
physiological, monomeric form and a self-propagating and heritable fibrillar form (or
prion).
At a cellular level, the prion hypothesis posits that fibrillar amyloids are capable of
templating their pathological forms between areas of the brain to spread throughout the
nervous system (Prusiner, 1998). For extracellular prions such as PrP (Stahl et al., 1987)
and amyloid beta (Kang et al., 1987), this could easily be envisioned to occur by bulk
flow via the interstitial fluid. Decades of research have indicated that intracerebral
inoculation of diverse species with brain homogenates from animals that have succumbed
to prion diseases invariably leads to progressive neurodegeneration, PrP prion deposition,
and ultimately death (Prusiner, 1998). In fact, more recent work has indicated that
8

recombinant PrP amyloids are sufficient to cause prion disease in mice (Colby et al.,
2009; Legname et al., 2004). Specific co-factors make this process considerably more
efficient (Deleault et al., 2007; 2012a; 2012b; Supattapone, 2014; Wang et al., 2010).
Initial studies regarding intracerebral transmissibility of AD plaques (amyloid beta
prions) in non-transgenic primates were decidedly more mixed (Baker et al., 1993;
Goudsmit et al., 1980). Despite the obvious similarities between AD and prion diseases
(Prusiner, 1984), studies regarding transmissibility and spread were largely abandoned
until the emergence of powerful, new transgenic mouse models of AD amyloid beta
pathology (Sturchler-Pierrat et al., 1997). These new models, which greatly accelerated
the study of amyloid beta plaque deposition in vivo, allowed for a decade of groundbreaking work by Jucker and Walker (reviewed in (Jucker and Walker, 2013)). These
studies demonstrated that intracerebral inoculation of amyloid beta-containing extracts
from both AD mice and AD patients greatly accelerated the progressive deposition of
plaques throughout the nervous system (Eisele et al., 2009; Fritschi et al., 2014; Langer et
al., 2011; Meyer-Luehmann et al., 2006; Rosen et al., 2012; Ye et al., 2015). Follow-up
work showed that synthetic amyloid beta fibrils were sufficient for this effect, although
induction of pathology was significantly less efficient (Stöhr et al., 2014; 2012).
Moreover, amyloid beta plaques have been observed in human patients that developed
iatrogenic CJD, suggesting that amyloid beta prions may be transmissible between
humans by surgical contamination (Frontzek et al., 2016; Jaunmuktane et al., 2015).
Nevertheless, there is no evidence to date to suggest that iatrogenic transmission of
amyloid beta (or other non-PrP) prions is sufficient to cause a classic AD-like
neurodegenerative phenotype (Irwin et al., 2013).
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Many prions, such as tau, α-synuclein, and TDP-43, primarily form intracellular amyloid
deposits (Grundke-Iqbal et al., 1986; Neumann et al., 2006; Spillantini et al., 1997).
Nevertheless, hierarchical accumulation of associated amyloid deposits is observed in
tauopathies (Braak and Braak, 1991; 1995; Braak et al., 2011; 2006), synucleinopathies
(Braak et al., 2003), and TDP43opathies (Brettschneider et al., 2013). Indeed, imaging
studies suggest that dysfunction in such diseases occurs along specific neuronal networks
(Seeley et al., 2009), most parsimoniously explained by the trans-synaptic spread of a
pathogenic agent (e.g. a prion) (Raj et al., 2012; Zhou et al., 2012). The idea that a prion
could escape a first-order neuron, adhere to a second-order neuron, gain access to the
cytoplasm of the second-order neuron, and convert cognate monomer to a prion form was
met with rightful skepticism. Nevertheless, trans-synaptic spread and intracellular
conversion of PrP prions (Borchelt et al., 1992; Fraser, 1982; Fraser and Dickinson,
1985; Scott et al., 1992; Taraboulos et al., 1990a; 1990b) provided precedent for this
concept, although evidence that this occurred outside of the secretory pathway (i.e. in the
intracellular space) was lacking. Further, this mechanistic paradigm would potentially
explain how active immunization could decrease pathology in transgenic mouse models
of tauopathy (Asuni et al., 2007) and synucleinopathy (Masliah et al., 2005) and why αsynuclein amyloids accumulated in the neurons of young dopaminergic grafts implanted
into patients with Parkinson’s disease (Kordower et al., 2008; Li et al., 2008)
A flood of studies over the past decade have provided overwhelming evidence that the
prion model is indeed correct in cellular and rodent models of intracellular proteopathies
(Brundin et al., 2010; Frost and Diamond, 2010; Goedert, 2015; Guo and Lee, 2014;
Holmes and Diamond, 2012; Sanders et al., 2016; Walker and Jucker, 2015). Initial
10

studies on α-synuclein suggested that monomeric and potentially aggregated forms of the
protein could be endocytosed and exocytosed by cells in culture (Lee et al., 2005; 2008a;
2008b). Pioneering cell culture studies then demonstrated that tau (Frost et al., 2009a), αsynuclein (Desplats et al., 2009; Luk et al., 2009), and huntingtin (Ren et al., 2009)
aggregates can be endocytosed by cells, where they access the intracellular space, and
seed cognate monomer to adopt the prion state. Later studies indicated that this was true
in a variety of models (dividing cells, primary neurons) of intracellular prion (tau, αsynuclein, SOD1, polyQ, TDP-43) propagation (Grad et al., 2011; 2014; Guo and Lee,
2011; 2013; Münch et al., 2011; Nekooki-Machida et al., 2009; Nonaka et al., 2013;
2010; Pokrishevsky et al., 2016). Meanwhile, a parallel study demonstrated that
intracerebral inoculation of brain homogenate containing tau prions resulted in the
seeding of intracellular neurofibrillary tau tangles, which spread to distant sites in
transgenic mice (Clavaguera et al., 2009). More remarkably, follow-up studies, which
intracerebrally inoculated transgenic mice with recombinant tau (Iba et al., 2013; 2015;
Stancu et al., 2015) and α-synuclein (Luk et al., 2012a) prions, found that co-factors were
not necessary to induce pathology. In particular, α-synuclein prions faithfully replicated
known facets of human synucleinopathy, causing rapid and reproducible death in
transgenic mice (Luk et al., 2012a; Mougenot et al., 2012) and regional atrophy in wildtype mice (Luk et al., 2012b; Masuda-Suzukake et al., 2013). In all cases, spread of
pathology appears to occur along known neuronal networks, as opposed to diffusion by
proximity, although it cannot be ruled out that this does not merely reflect trans-synaptic
spread of inoculum rather than true propagation of the prion state (Rey et al., 2013). Sitespecific expression of tau in diverse models has unequivocally demonstrated that tau can
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exit a cell and enter a synaptically connected neuron (de Calignon et al., 2012; Dujardin
et al., 2014b; Kim et al., 2010; Liu et al., 2012; Polydoro et al., 2013). Nevertheless, in
most cases, there is little evidence for true propagation (i.e. conversion of tau in the
recipient neuron to the prion state). Improved models for trans-cellular prion propagation
are sorely needed to address lingering concerns regarding the applicability of these many
phenomenological studies to mechanisms of neurodegenerative spread in patients (Walsh
and Selkoe, 2016).
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1.4 MECHANISMS OF TRANS-CELLULAR PRION
PROPAGATION
Mechanistic insights into the cellular pathways that regulate trans-cellular propagation of
prions have been gleaned from a number of studies over the past several years (Holmes
and Diamond, 2012), although in some cases, the data is conflicting. This multi-stepped
process requires specific events (Figure 1.1): escape of a prion from a first-order neuron,
binding to the surface of a second-order neuron, uptake/endocytosis, escape into the
cytosol, “corruption” of endogenous cognate monomer to the prion state, and
fragmentation/amplification (Sanders et al., 2016). While much progress has been made
regarding how prions enter cells, additional work remains to be performed to clarify the
physiologically relevant routes by which they exit neurons. A number of studies have
suggested that tau, α-synuclein, and SOD1 prions can enter cells by bulk fluid-phase
macropinocytosis (Frost et al., 2009a; Holmes et al., 2013a; Münch et al., 2011). A recent
study (Holmes et al., 2013a) suggests that this mode of uptake is dependent on cellsurface receptors called heparan sulfate proteoglycans (HSPGs) (Holmes et al., 2013a),
proteins which contain negatively charged sulfate groups (Xu and Esko, 2014) that
interact with positively-charged heparin-binding motifs present on many intracellular
prions. Furthermore, although all tau species can bind to cell-surface HSPGs, only
trimers and larger assemblies are capable of triggering the clustering of HSPGs required
to actively stimulate downstream macropinocytosis (Mirbaha et al., 2015). This is
consistent with previous data suggesting that PrP trimers are the minimum unit of
infectivity in models of prionopathy (Bellinger-Kawahara et al., 1988; Govaerts et al.,
2004; Wille et al., 2009), which also insinuates the tantalizing possibility that uptake and
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intracellular conversion is required for productive prion infectivity. Not surprisingly,
extracellular prions are also able to bind and infect cells using HSPGs (Horonchik et al.,
2005; Kanekiyo et al., 2011; Sousa and Saraiva, 2001), and a recent study suggests that
this pathway may be of critical importance to the development of amyloid beta pathology
in transgenic mice and AD patients (Liu et al., 2016). The involvement of this pathway in
the metabolism of multiple prions suggests that targeting HSPGs may be an effective
therapy for disparate neurodegenerative diseases. Finally, evidence gleaned from cell
culture experiments suggests that tunneling nanotubes, filopodia-like extensions that
connect the cytoplasm of neighboring cells, could potentially play a role in the spread of
diverse prions (Costanzo et al., 2013; Gousset et al., 2009), although additional work is
required to confirm the importance of this pathway in vivo.
Once prions enter a cell, they must escape from macropinosomes (or other membranebound compartments) to access the intracellular space to convert cognate intracellular
monomer into a self-replicating form that further amplifies the prion state. The
mechanisms(s) by which prions escape double-membraned vesicles are unclear. It is
possible that this occurs by direct penetration (Ren et al., 2009), similar to the
hypothesized pathway by which cationic peptides translocate into the cytosol
(McNaughton et al., 2009; Thompson et al., 2012). Conversely, macropinosomes may be
inherently leaky, as the details regarding their maturation are far from complete (Mercer
and Helenius, 2009; 2012). Further work will be required to test whether there are active
mechanisms that contribute to delivery of prions into the cytosol or potentially to specific
sites where prion replication may occur.
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Once translocated into the cytosol, a prion seed must encounter another cognate
monomer to amplify its structure. Whether there are active mechanisms that drive this
process in the heterogeneous environment of the cytoplasm, where most interactions will
be with different proteins, is undetermined. Equally unclear is whether there is cellular
machinery that orchestrates further fragmentation and amplification of prion seeds once
formed. In Saccharomyces cerevisiae (yeast), the Hsp104 chaperone works as a twotiered hexameric complex, which along with other co-chaperones, “disaggregates”
amyloids into additional seeding-competent nuclei (Chernoff et al., 1995; Glover and
Lindquist, 1998; Shorter and Lindquist, 2004). However, an Hsp104 homologue does not
exist in mammals. Therefore, it was thought that evolution may have selected against this
protein in more complex organisms to prevent the formation of toxic oligomers or active
propagation of prions (Murray and Kelly, 2012). Recent work suggests that this may not
be the case, as in vitro, a three chaperone (Hsp40, Hsp70, Hsp110) system can
disaggregate amorphous aggregates but not amyloids (Nillegoda et al., 2015; Rampelt et
al., 2012; Shorter, 2011). Moreover, a provocative recent paper suggests that at the right
stoichiometry, the same system can disassemble pre-formed amyloid fibrils (Gao et al.,
2015). It is also conceivable that additional seeds could be generated in lysosomes by
proteases, as HTRA1 can re-solubilize tau amyloids (Poepsel et al., 2015). Whether any
of these mechanisms occur in living cells to fragment prions and generate additional
seeding-competent nuclei remains to be determined.
To continue the process of propagation, an intracellular prion must be able to exit the
cell. Numerous studies have indicated that intracellular proteins that can form prions are
capable of accessing the extracellular space (Chai et al., 2012; Danzer et al., 2011; de
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Calignon et al., 2012; Dujardin et al., 2014b; 2014a; Emmanouilidou et al., 2010; Karch
et al., 2012; Kim et al., 2013; 2010; Lee et al., 2005; 2011; 2012; Liu et al., 2012;
Mohamed et al., 2014; Plouffe et al., 2012; Pooler et al., 2013; Saman et al., 2012; Simón
et al., 2012; Yamada et al., 2011; 2014). Alarmingly, most of these studies have
purported to present findings relevant to propagation, but only measure monomer, which
is not competent to be actively taken into second-order neurons to seed further
aggregation (Mirbaha et al., 2015). Every conceivable mechanism has been put forward
including exosomes (Emmanouilidou et al., 2010; Fevrier et al., 2004; Polanco et al.,
2016; Rajendran et al., 2006; Saman et al., 2012), ectosomes (Dujardin et al., 2014a),
active or unconventional secretion (Chai et al., 2012; Karch et al., 2012; Pooler et al.,
2013; Yamada et al., 2011; 2014), and membrane rupture following cell death (Hesse et
al., 2001; Palmio et al., 2009). Future studies will need to make use of sensitive bioassays
such as real-time quaking induced conversion (Colby et al., 2007; Wilham et al., 2010) or
cellular FRET flow cytometry (Furman et al., 2015; Holmes et al., 2014) to delineate
which mechanisms are relevant to the spread of seeding-competent prions in individual
models.
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1.5 STRAINS: DIFFERENT AMYLOID STRUCTURES DRIVE
PHENOTYPES IN PRION DISEASES

Long before the widespread acceptance of the “protein-only” prion hypothesis (Griffith,
1967; Prusiner, 1982; 1998), transmissible spongiform enechalopathies (TSEs) were
thought to be caused by “slow viruses” (Gajdusek, 1977). In addition to the heretical
notion that self-replicating protein entities could cause disease, the existence of TSE
disease strains made Prusiner’s hypothesis particularly difficult to accept for many
(Bruce and Dickinson, 1987). Pioneering studies by Dickinson, Meikle, and Fraser,
demonstrated that different scrapie agents (sheep prions) passaged in inbred mice would
result in distinct patterns and degrees of pathology (vacuolation) as well as characteristic
incubation periods prior to symptom development (Dickinson and Meikle, 1969;
Dickinson et al., 1968; 1969; Fraser and Dickinson, 1973). Later studies suggested that
specific prion strains resulted in distinct behavioral phenotypes (Bessen and Marsh,
1992a) and featured infectious agents with variable susceptibilities to thermal
deactivation (Dickinson and Taylor, 1978; Kimberlin et al., 1983). Remarkably, if using
the same genetic background and inoculate dosage, strain-specific properties can be
maintained following passage through multiple generations of mice, even over years of
experimental transmission (Bruce and Dickinson, 1987). The simplest explanation for
these observations was that despite having as essential PrP protein factor (Basler et al.,
1986), the prion agent also contained a self-replicating genetic component and its
sequence could infer distinct biological properties (i.e. strain effects) (Bruce and
Dickinson, 1987). In other words, prions might merely be very unconventional viruses
(Bruce and Dickinson, 1987). Surprisingly, however, decades of inquiry have failed to
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find a nucleic acid signature that co-segregates with specific prion strains or even the
infectious agent itself (Safar et al., 2005).
Rather, a substantial body of work now indicates that the structure of prion protein
amyloids mediates the effects of strains (Toyama and Weissman, 2011; Tycko, 2015). An
early study suggested that putative PrP amyloids purified from animals that succumbed to
unique prion strains featured different susceptibilities to protease (Kascsak et al., 1985).
However, the idea that different PrP fibril structures drive vast phenotypic differences in
prionopathy manifestation was inchoate until the publication of two pioneering studies by
Bessen and Marsh, which indicated that PrP isolated from hamsters infected by different
transmissible mink encephalopathy strains featured unique biochemical properties
(Bessen and Marsh, 1992b; 1994). Moreover, protease-resistant PrP from these strains
featured different protected cores, suggesting a structural difference at the level of PrP
amyloid replication (Bessen and Marsh, 1994). These strain-specific protease-resistant
regions could be imprinted on purified PrP in a cell-free seeding reaction (Bessen et al.,
1995). Extensive biochemical characterization of a panel of hamster prion strains
solidified the idea that different PrP amyloid conformations drove specific phenotypes
(Safar et al., 1998). Together, these observations were consistent with the idea that
templated nucleation of specific structures led to fibrils with unique biochemical
properties, which propagated throughout the brain at different rates and
disproportionately affected specific regions of the nervous system (Collinge and Clarke,
2007). But what were the differences between specific amyloid conformations that lead
to such divergent biological outcomes as short vs. long incubation period?
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Clues to this question came from a surprising model system: Saccharomyces cerevisiae
(yeast). This simple single-celled eukaryote features a multitude of proteins that can
undergo transitions from a monomeric to a self-propagating and heritable amyloid (i.e.
prion) form (Derkatch et al., 1996; Patino et al., 1996; Paushkin et al., 1996; Wickner,
1994). Yeast prions are typically detrimental to the organism (McGlinchey et al., 2011),
but in certain environmental situations, confer a growth advantage (Halfmann et al.,
2012; Holmes et al., 2013b; True and Lindquist, 2000; True et al., 2004). For example,
aggregation of the translation termination factor Sup35 into the prion state can result in
read-through errors which can uncover hidden phenotypic traits during times of stress
(True et al., 2004). Like mammalian prion protein, yeast prions are capable of forming
diverse stably propagating amyloid conformers or strains (King and Diaz-Avalos, 2004;
Tanaka et al., 2004). For the Sup35 prion, strain strength is defined by the degree to
which the protein loses its ability to terminate translation (Tanaka et al., 2004). In other
words, the more the protein aggregates or can seed further aggregation, the stronger the
strain. In two seminal studies (Tanaka et al., 2006; Toyama et al., 2007), Weissman’s
group determined the physical and structural basis for this phenomenon in several
prototypical strains. Surprisingly, they found that Sup35 amyloid conformers with the
fastest growth kinetics did not feature the strongest phenotype in vivo (Tanaka et al.,
2006). Rather, the ability to fragment to produce additional nucleation-competent seeds
defined the strength of the strain. This principal was verified by another group using a
different yeast prion, Rnq1 (Kalastavadi and True, 2010). In follow-up work using
hydrogen-deuterium exchange, the Weissman lab showed that the reason why strong
strains fragment more readily is that they feature a smaller amyloid core (Toyama et al.,
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2007). Amyloid conformers with small cores are more brittle and break more readily to
produce additional seeds that amplify the aggregation process (Toyama et al., 2007)
(Figure 1.2A).
These initial observations regarding the biophysical basis for yeast strain diversity
appeared to offer great insight into the vast phenotypic diversity with regard to incubation
time and disease duration observed in prion diseases. Might strong prion strains (i.e.
those that spread rapidly and produce short incubation periods) be caused by more fragile
PrP amyloid conformers? This appeared to be the case for prion strains propagated in
mice: Prusiner’s group examined the biophysical stability of 30 strain isolates and found
that there was a strong correlation (R=0.93) between the stability of the PrP amyloid
conformer in denaturant (GdHCl) and the incubation time of the agent when inoculated
into transgenic PrP mice (Legname et al., 2006). This principal was upheld by examining
the incubation periods of a variety of synthetic PrP amyloid conformations created in
vitro (Colby et al., 2009). Additional work examining putative human PrP strains initially
seemed to support this idea (Kim et al., 2012a), but recent analysis (Safar et al., 2015) has
suggested that this may not be a universal defining principal of strain strength. In at least
certain patients, lower conformational stability can be associated with longer disease
duration (Safar et al., 2015). Furthermore, the strength of certain yeast strains is
dependent on the degree of interaction with chaperone protein clients, not just
conformational stability (Stein and True, 2014a; 2014b). Thus, biophysical frangibility
alone may be insufficient to fully describe why different prion strains cause different
incubation times (Figure 1.2A). Moreover, this principal does not explain why different
strains affect different regions of the brain (Bruce et al., 1991; Carroll et al., 2016; Fraser
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and Dickinson, 1973) or unique cell types (Ayers et al., 2011; Carroll et al., 2016;
González et al., 2002; 2010) (Figure 1.2B,C).
Like in animals, human prion diseases are phenotypically diverse. They feature infectious
(kuru, variant CJD), sporadic (sporadic CJD, sporadic familial insomnia, variably
protease-sensitive prionopathy), genetic (familial CJD, fatal familial insomnia,
Gerstmann-Straussler-Scheinker syndrome), and iatrogenic (iatrogenic CJD) etiologies
(Collins et al., 2004b; Gambetti et al., 2011; Johnson, 2005; Prusiner, 1998). Individual
diseases feature striking differences related to age of onset, duration, symptom profiles,
and PrP histopathological profiles. A large body of work now indicates that this is due to
different stably propagating PrP prion strains, which amplify themselves throughout the
nervous system to produce a gestalt phenotype (Collinge and Clarke, 2007; Gambetti et
al., 2011) (Figure 1.3A). Fatal familial insomnia and familial CJD, in particular, feature
drastically different clinical (insomnia vs. myoclonus/dementia) and pathological
(thalamus vs. cortex) presentations despite specific kindreds featuring identical causative
point mutations (Medori et al., 1992; Nieto et al., 1991). Identity of a single
polymorphism in PrP at amino acid 129 regulates whether such patients develop FFI
(M129) or CJD (V129) (Goldfarb et al., 1992). A landmark paper (Telling et al., 1996)
determined why this is the case. Prusiner and colleagues inoculated transgenic mice with
brain homogenates from patients that died of familial CJD, sporadic CJD, or fatal familial
insomnia (Telling et al., 1996). They then analyzed the protease sensitivity of PrP prions
isolated from human donors and mouse recipients, finding 21 kD protease-resistant PrP
associated with both forms of CJD and 19 kD PrP associated with FFI (Telling et al.,
1996). In other words, PrP amyloids in different diseases are biochemically distinct. Two
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concurrent studies (Collinge et al., 1996; Parchi et al., 1996) solidified the idea that
conformation of PrP is a major contributor to a patient’s clinical phenotype. Gambetti’s
group found that sporadic CJD patients featured either 21 kD (type I) or 19 kD (type II)
PrP, the first of which was associated with the more common myoclonic form of CJD and
the latter of which was associated with the rarer ataxic variant (Parchi et al., 1996).
Further, like with familial prion diseases, codon 129 polymorphism contributed to disease
phenotype (Parchi et al., 2011). The second study (Collinge et al., 1996), from Collinge
and collaborators, used similar methods to show that a novel prionopathy that
disproportionately affected the young (variant CJD) was caused by a distinct PrP strain.
Further, they found that this strain was the same as that which caused bovine spongiform
encephalopathy (BSE), thus demonstrating that BSE could be transmitted to humans
(Collinge et al., 1996). Strikingly, only individuals homozygous at methionine 129
developed variant CJD (Ironside, 2012). This, along with extensive work using transgenic
mice expressing PrP from various animal species, has proved that the amino acid
sequence composition of PrP is of fundamental importance to the amyloid structures that
it can form and what monomers can be corrupted with the pathological conformation
(Collinge and Clarke, 2007). In fact, such “seeding barriers” have likely limited the
transmissibility of spongiform encephalopathies between species (Collinge and Clarke,
2007). Using common protease digestion protocols, six prion strains have been identified
in human patients, each of which is associated with unique clinical and histopathological
features (Gambetti et al., 2011). More sophisticated approaches may allow further
refinement of the conformational features that contribute to various subtypes of prion
disease (Safar et al., 2015).
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1.6 PHENOTYPIC DIVERSITY IN NON-INFECTIOUS
NEURODEGENERATIVE DISEASES

Similar to prionopathies, non-infectious human proteopathies are not homogeneous
diseases. Rather, each features considerable phenotypic diversity with regard to clinical
and pathological presentation (Halliday et al., 2011; Kovacs, 2015; Lee et al., 2001; Van
Langenhove et al., 2012). Synucleinopathies include Parkinson’s Disease, multiple
system atrophy, and dementia with Lewy bodies, each of which features α-synuclein
accumulation in different cell types and distinct regions of the brain (Halliday et al.,
2011). TDP-43 aggregation is associated with a spectrum of diseases ranging from
frontotemporal lobar dementia to amyotrophic lateral sclerosis (Van Langenhove et al.,
2012). The most striking example, however, is the tauopathies, which include over a
dozen major neurodegenerative diseases that can be differentiated by symptom profiles,
tau isoform accumulation, ultrastructural characteristics of tau fibrils, morphological
properties of tau inclusions, cell types affected, and regions of the brain afflicted by
degeneration (Kovacs, 2015; Lee et al., 2001). Human tau, a predominantly neuronal
microtubule-associated protein that promotes microtubule stabilization and
polymerization (Cleveland et al., 1977a; 1977b; Weingarten et al., 1975), is expressed
from the MAPT locus, which is alternatively spliced to produce six isoforms that differ
with respect to their number of N-terminus inserts (0N, 1N, 2N) and C-terminus tandem
repeat sequences (3R or 4R) (Goedert et al., 1989a; 1989b). The fetal brain only features
3R tau, whereas the adult brain features an equal ratio of 3R and 4R tau (Goedert and
Jakes, 1990). The evolutionary reasons for the temporal regulation of tau isoform
expression possibly relate to 4R tau’s enhanced ability to promote microtubule
23

polymerization and stabilization relative to 3R tau (Butner and Kirschner, 1991; Goedert
and Jakes, 1990). Hyperphosphorylation reduces tau’s affinity for microtubules, leading
to a larger free pool of soluble tau in the cytoplasm, thus increasing the likelihood that it
spontaneously aggregates to form fibrillar amyloids (Buée et al., 2000; 2010).
Sporadic tauopathies can be subdivided based on the isoforms of tau that accumulate in
characteristic phosphorylated tau amyloid lesions in distinct cell types (Kovacs, 2015;
Lee et al., 2001). Alzheimer’s disease (AD), the most common tauopathy, features
neuronal neurofibrillary tangles composed of 3R and 4R tau (Goedert et al., 1992;
Greenberg and Davies, 1990; Greenberg et al., 1992; Lee et al., 1991). Pick’s disease
(PiD), a frontotemporal dementia, is defined by the aggregation of 3R tau in globular
Pick bodies in neurons of the cortex and hippocampus (Iwatsubo et al., 1994; McKhann
et al., 2001; Probst et al., 1996). Conversely, corticobasal degeneration (CBD) and
progressive supranuclear palsy (PSP), both of which are movement disorders (Rebeiz et
al., 1967; STEELE et al., 1964), feature only 4R tau in neuronal filaments,
oligodendrocytic coiled bodies, and astrocytes (Feany and Dickson, 1995; Hauw et al.,
1990; Komori, 1999; Komori et al., 1998; Yamada et al., 1992). These two diseases differ
with respect to astrocytic pathology: CBD primarily features astrocytic plaques, whereas
PSP is differentiated by the presence of tufted astrocytes (Komori et al., 1998).
Regardless, there is thought to be significant overlap between these diseases with regard
to clinical and pathological features (Feany et al., 1996). Similar to PSP and CBD,
argyrophilic grain disease (AGD) only features insoluble 4R tau (Ferrer et al., 2008;
Tolnay et al., 1997), but unlike other tauopathies, it does not feature acetylated tau in its
characteristic grain-like inclusions (Grinberg et al., 2013). Other less common sporadic
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tauopathies exist, and each features characteristic tau pathological profiles (Kovacs,
2015; Lee et al., 2001). Furthermore, each tauopathy differs with respect to selective
neuroanatomical patterns of tau aggregate deposition, which likely contribute to their
distinctive clinical phenotypes (Arnold et al., 2013). Even within the same syndrome,
there is great variability with respect to progression rate (Armstrong et al., 2000; Huang
et al., 2014; Mann et al., 1992; Thalhauser and Komarova, 2012). The mechanistic
reasons for these diverse clinical and pathological observations are completely
unexplored.
Genetic tauopathies also feature vast phenotypic diversity in presentation (Lee et al.,
2001; Reed et al., 2001; van Swieten et al., 1999). Frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17) is a rare autosomal dominant
neurodegenerative disease caused by point mutations to MAPT that enhance tau’s
propensity to form amyloids or disrupt the isoform ratio between 3R and 4R tau
(Barghorn et al., 2000; Hutton et al., 1998). Seven point mutations have been described
that affect at least two kindreds (Cruts et al., 2012). Amongst these, mean age-of-onset
can vary between 33.7 (P301S) and 62 (ΔK280), with disease durations between 4.2
(P301S) and 19 (ΔK280) years (Cruts et al., 2012). Furthermore, some mutations are
associated with mixed 3R/4R tau pathology whereas others only feature 4R (Reed et al.,
2001). Like for sporadic tauopathies, individual tau mutations are associated with distinct
histopathological profiles with discrete cell types and regions of the brain being affected
as well as characteristic clinical presentations (e.g. memory loss, personality changes,
language impairments) (Reed et al., 2001). The mechanistic underpinnings for the
spectrum of presentations associated with FTDP-17 remain to be elucidated.
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1.7 THE CURRENT PERSPECTIVE: DO STRAINS DRIVE
DISTINCT PHENOTYPES IN TAUOPATHIES?
Striking similarities between tauopathies and prionopathies are evident. Most
importantly, each progressive proteopathy features neuroanatomical spread of their
characteristic fibrillar lesions and vast phenotypic diversity in clinical and pathological
presentation. Overwhelming evidence now indicates that self-replicating PrP prion strains
drive phenotypic diversity in human prion diseases (Figure 1.3A). This begs the question
of whether conformationally distinct tau prion strains contribute to the manifestation of
specific tauopathies (Figure 1.3B). For this to be conceivable, a number of criteria must
be met:
1.) Tau must form different amyloid conformations in vitro.
2.) These tau amyloid conformations must stably replicate in cells (i.e. they
must act as bona fide prion strains).
3.) Tau strains must continue to replicate the same structure when introduced
into a new cellular environment.
4.) Specific tau strains must be isolatable and stably propagate through living
organisms and across synapses.
5.) Tau must be capable of producing the diversity of strains required to
underlie the numerous clinical tauopathies (potentially, over a dozen).
6.) Tau strains must be able to differentially affect specific cell types and brain
regions as well as cause characteristic neuronal and glial inclusions.
Furthermore, they must spread at different rates. That is, specific strains must
be able to produce distinguishable experimental tauopathies in model
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organisms.
7.) Tau strains must co-segregate with specific human tauopathies.
When I began my doctoral studies in Marc Diamond’s lab, only the first criterion had
been met for tau amyloids. Specifically, we had previously shown that tau could form
different amyloid conformations in vitro, which stably replicate certain features in
subsequent seeding reactions (Frost et al., 2009b). Other groups had also shown amyloid
polymorphism with respect to tau fibrils produced in vitro (Aoyagi et al., 2007; Dinkel et
al., 2011; Siddiqua and Margittai, 2010). Similar diversity with regard to fibrillar
structures has been observed for amyloid beta (Lu et al., 2013; Paravastu et al., 2008;
2006; Petkova et al., 2005; Tycko, 2015) and α-synuclein (Bousset et al., 2013; Gath et
al., 2014; Guo et al., 2013; Peelaerts et al., 2015) induced to fibrillize in a test tube under
specific environmental conditions (e.g. high vs. low salt, quiescent vs. shaking
incubation). Moreover, inoculation of brain homogenates containing amyloid beta from
various sources into transgenic mice induces the formation of extracellular plaques with
distinct characteristics (Heilbronner et al., 2013; Meyer-Luehmann et al., 2006), and
extracts from different patients seed fibrils with distinct structures (Lu et al., 2013).
However, to have clinical significance for diseases that manifest themselves over years or
even decades, prion strains must faithfully replicate with tremendous fidelity for
significant periods of time, producing predictable pathology upon serial inoculation in
vivo. Such strain behavior had yet to be reported for amyloids other than PrP.
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1.8

SUMMARY

Neurodegenerative diseases are syndromes of protein aggregation (i.e. proteopathies),
resulting from the accumulation of characteristic amyloid deposits in specific cells and
regions of the brain. Considerable evidence accrued from in vitro and in vivo studies over
the past decade supports the hypothesis that common non-infectious proteopathies
progress due to the hierarchical “prion-like” spread of protein aggregates along neuronal
networks. However, the reasons why these diseases feature such vast diversity in clinical
and pathological presentation have yet to be elucidated. It is now known that different
PrP amyloid conformations or prion strains drive phenotypic diversity in the
prionopathies (Figure 1.2). This dissertation seeks to determine whether this is also the
case for sporadic tauopathies, which each feature disease-specific accumulations of tau
fibrils in specific cell types (neurons and/or glia) and regions of the brain. By using cell
culture and transgenic mouse models along with patient samples, the work described here
unequivocally demonstrates that tau can form a multitude of distinct strains that stably
propagate through living systems to drive specific pathological phenotypes. Moreover, it
demonstrates that specific strains co-segregate with specific tauopathies, thus suggesting
that discrete tau amyloid conformations likely contribute to the etiology of unique
tauopathies. This work has fundamental implications for how we differentiate and treat
human tauopathies.
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1.9

FIGURES

Figure 1.1. Steps in trans-cellular propagation. Trans-cellular propagation of prions is
likely to involve escape from a first-order cell, binding to a second-order cell, uptake into
a second-order cell, seeding of native monomer, and fragmentation and amplification of
the seeded aggregates. (A) Escape of prions from a first-order cell could occur by direct
release into the extracellular space. This may be driven by unconventional secretion, cell
death, or membrane penetration. (B) Alternatively, prions could escape in exosomes, or
(C) could directly move to neighboring cells via tunneling nanotubes. (D) In the
exosomal pathway, cell entry would presumably occur via vesicle fusion. (E) More
likely, prions bind to heparan sulfate proteoglycans (HSPGs) to trigger macropinocytosis.
(F) It is theoretically possible that prions gain entry by another form of receptor-mediated
endocytosis, although there is not clear evidence for this. (G) Prions escape the lumen of
vesicles to encounter cognate monomer. (H) The seed acts as a template for recruitment
of monomer to amplify the prion structure. This likely involves a replication machinery
that may also be involved in fibril fragmentation to amplify the number of seeds, which
then repeat the cycle of propagation to other cells.
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et al., 2013; Gousset et al., 2009), although additional work is
required to confirm the importance of this pathway in vivo.
After internalization, prions serve as templates to convert
monomer into an aggregate (Desplats et al., 2009; Frost et al.,
2009a; Luk et al., 2009; Münch et al., 2011; Ren et al., 2009). Recombinant and AD-derived tau aggregates exhibit precise size
requirements for cell surface binding, uptake, and seeding of
intracellular protein (Mirbaha et al., 2015). Upon size fractionation, all tau assemblies, including monomer and dimer, bind
cell surface HSPGs. However, only tau trimers and larger assemblies mediate cellular uptake and seeding (Mirbaha et al., 2015).
These findings are consistent with a report that tau trimers are
the minimal unit toxic for neuronal cells (Tian et al., 2013) and
with molecular modeling studies that hypothesized that tau
forms a three-stranded helical fiber based upon trimers (Ruben
et al., 1991). PrP trimers also constitute the minimal apparent
unit for infectivity (Bellinger-Kawahara et al., 1988; Govaerts
et al., 2004; Wille et al., 2009), although PrP monomer in a pathogenic conformation may be toxic in certain conditions (Zhou
et al., 2012b). Taken together, it seems likely that trimers are
the smallest assemblies that can mediate trans-cellular propagation of the prion state. It is unknown whether
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Figure 1.2. Prion replication mechanisms and network involvement link strains to
biological phenotype. The various steps in replication of a prion provide an explanation
for how strains might exhibit different rates of progression, types of neuropathology, and
involvement of specific networks. (A) Biophysical and biochemical parameters govern
strain replication efficiency. A single protein monomer can adopt multiple potential
amyloid configurations, illustrated by squares vs. triangles. Strain-specific fibril stability
and the interaction with chaperone/replication machinery may determine the
fragmentation rate and production of seeds. This likely determines the rate of spread and
disease progression, with strong strains featuring more rapid phenotypes. (B) A strain
must propagate pathology by entering a neuron and initiating seeding and subsequent
replication of a particular structure. The newly formed aggregates will accumulate in
certain regions of the cell, possibly through interaction with specific factors, and may be
differentially transported in axons. Finally, strains may have differential rates of release
and/or toxicity at the cell membrane/synapse that govern transfer to other cells. Each of
these steps may be influenced by strain conformation. (C) Unique strains may target
different cell types and neural networks to cause syndromic variation. Aggregate
conformers (square vs. triangle) may target one cell type more readily than another. This
could be based on parameters discussed above: cell entry, replication, and trans-cellular
propagation rates. Distinct neuronal networks might thus be vulnerable to particular
strains.
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different PrP prion agents contained their own self-replicating
genomes and were merely acting as very unconventional viruses. Extensive searching, however, failed to find a nucleic
acid that governed strain phenomena (Safar et al., 2005). Two
pioneering studies instead suggested that strain variation derives from PrP amyloid conformers with distinct protease-resistant core regions (Bessen and Marsh, 1994; Telling et al.,
1996). More extensive characterization of32a panel of hamster
PrP prion strains (Safar et al., 1998) solidified this hypothesis,
and different PrP strains probably cause distinct human prion
diseases (Collinge et al., 1996).
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Figure 1.3. Do strains account for phenotypic diversity in tauopathies? (A) It is now
well established that different fibrillar conformations (i.e. strains ) of PrP underlie unique
clinical manifestations of the prionopathies. (B) This dissertation examines whether
unique tauopathies (e.g. Alzheimer’s disease, corticobasal degeneration, Pick’s disease,
progressive supranuclear palsy, argyrophilic grain disease, etc.) are caused by specific tau
amyloid conformations (strains), which stably propagate throughout the nervous system
to elicit the myriad unique features characteristic of each disease.

33

A
PrP#Seed#

PrP#Monomer#

PrP#Fibril#

Strain#A#

+

Sporadic Creutzfeldt-Jakob
Disease

Strain#B#

+

Variant Creutzfeldt-Jakob
Disease/BSE

Strain#C#

+

Fatal Familial
Insomnia

Templated Seeding

Clinical Phenotype (Strain)

B
Tau$Seed$ Tau$Monomer$

Tau$Fibril$

+

Alzheimer’s Disease

+

Corticobasal Degeneration

+

Pick’s Disease

Templated Seeding

Clinical Phenotype (Strain?)

Figure 1.3

34

Chapter 2: Distinct Tau Prion Strains
Propagate in Cells and Mice and Define
Different Tauopathies
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2.1

PREFACE

This chapter contains a previously published manuscript:
Sanders, D.W.*, Kaufman, S.K.*, DeVos S.L., Sharma, A.M., Mirbaha, H., Li, A.,
Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., Miller, T.M., Grinberg, L.T.,
Seeley, W.W., Diamond, M.I. (2014). Distinct tau prion strains propagate in cells and
mice and define different tauopathies. Neuron 82, 1271-1288. *These authors contributed
equally to this work.
Author contributions for the citation above: D.W.S. and S.K.K. contributed equally to
this work. D.W.S. performed all cell culture and biochemistry experiments. S.K.K.
performed all animal experiments. S.L.D. provided technical assistance and guidance for
animal inoculations. A.M.S. aided with biochemistry. H.M. and A.L. contributed
unpublished reagents. S.J.B. helped with cell-culture experiments and performed blind
scoring. A.C.F., J.R.T., and L.C.S. performed electron microscopy. L.T.G. and W.W.S.
analyzed and selected human samples. D.W.S., S.K.K., S.L.D., T.M.M., and M.I.D.
designed experiments. D.W.S., S.K.K., and M.I.D. analyzed results and wrote the
manuscript.
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2.2

ABSTRACT

Prion-like propagation of tau aggregation may underlie the stereotyped progression of
neurodegenerative tauopathies. True prions stably maintain unique conformations
(“strains”) in vivo that link structure to patterns of pathology. We now find that tau meets
this criterion. Stably expressed tau repeat domain indefinitely propagates distinct amyloid
conformations in a clonal fashion in culture. Reintroduction of tau from these lines into
naïve cells re-establishes identical clones. We produced two strains in vitro that induce
distinct pathologies in vivo as determined by successive inoculations into three
generations of transgenic mice. Immunopurified tau from these mice re-creates the
original strains in culture. We used the cell system to isolate tau strains from 29 patients
with 5 different tauopathies, finding that different diseases are associated with different
sets of strains. Tau thus demonstrates essential characteristics of a prion. This may
explain the phenotypic diversity of tauopathies and ultimately could enable more
effective diagnosis and therapy.
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2.3

INTRODUCTION

Tauopathies are a diverse group of neurodegenerative diseases defined by accumulation
of fibrillar deposits of the microtubule-associated protein tau (MAPT) (Lee et al., 2001).
Alzheimer’s disease (AD), the most common tauopathy, affects >30 million people
worldwide and will afflict >120 million by 2050 (Holtzman et al., 2011). MAPT
mutations cause dominantly inherited tauopathies (Hutton et al., 1998), and most increase
the propensity of tau to form amyloids (Barghorn et al., 2000), which are paracrystalline
protein assemblies rich in beta-sheet structure (Bonar et al., 1969). Most tauopathy cases
are sporadic, with variable clinical and pathological presentation (Lee et al., 2001).
The prion hypothesis posits that pathological aggregates of the mammalian prion protein
(PrP) cause infectious, sporadic, and familial neurodegenerative diseases (Prusiner,
1998). In contrast, yeast prions are adaptive and confer phenotypic diversity and rapid
evolution of new traits in times of stress (True and Lindquist, 2000). Both yeast and
mammalian prions form strains, which are encoded by distinct fibrillar structures (Safar
et al., 1998; Toyama et al., 2007). Prion strains determine the incubation periods of
disease in humans (Kim et al., 2012a) and mice (Legname et al., 2006). In addition,
human prion strains are thought to underlie clinical symptoms and pathological
presentation (Collinge and Clarke, 2007).
The hypothesis that common neurodegenerative diseases such as AD could be caused by
a prion-like mechanism was suggested three decades ago (Prusiner, 1984). Recently,
however, experimental work on diverse amyloids has generated new interest (Frost and
Diamond, 2010; Guo and Lee, 2014). Human neurodegenerative diseases target unique
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neural networks (Braak and Braak, 1995; Seeley et al., 2009), an observation most
parsimoniously explained by the network-based spread of a toxic agent (Raj et al., 2012;
Zhou et al., 2012). Prior studies suggest that tau aggregates spread among cells via
templated conformational change (Frost et al., 2009a; Holmes et al., 2013a). In vivo work
supports this model (Clavaguera et al., 2009; de Calignon et al., 2012; Iba et al., 2013;
Kim et al., 2010; Liu et al., 2012) as has similar work with other intracellular amyloids
such as α-synuclein (Desplats et al., 2009; Hansen et al., 2011; Luk et al., 2009; 2012a)
and extracellular amyloids including amyloid beta (Eisele et al., 2009; Meyer-Luehmann
et al., 2006).
Bona fide prions are defined by propagation of distinct conformational strains in vivo, and
prior studies have hinted at prion-like strain properties of non-PrP human amyloids. For
example, amyloid beta protein forms at least two distinct, self-propagating fibrillar
conformations in vitro (Petkova et al., 2005) and in vivo (Lu et al., 2013). Others have
demonstrated propagation in vitro of distinct tau (Frost et al., 2009b; Siddiqua and
Margittai, 2010) and α-synuclein conformers (Bousset et al., 2013; Guo et al., 2013;
Sacino et al., 2013). While provocative, these prior studies have not demonstrated that
non-infectious proteopathic seeds act as true prions. Specifically, it has not been shown
that distinct conformations or “strains” are capable of transmission into a living
cell/organism, propagation through multiple generations, extraction, and re-introduction
to naïve cells/organisms to replicate the same structural phenotype (Collinge and Clarke,
2007). This is important not for semantic reasons, but because if prion mechanisms
underlie human disease, only stably propagating strains can account for stereotyped
clinical presentation and network spread. In this study we have found that tau acts as a
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prion by these criteria, and, further, that individual human tauopathies are associated with
unique strains.
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2.4

MATERIALS AND METHODS

Molecular cloning. The restriction endonucleases BamHI (5’) and NotI (3’) were used to
remove YFP from the pEYFP-N1 vector (Clontech) and separately insert CBG-Cluc and
CBG-Nluc, both derived from the pFRB vector (kind gift from the David PiwnicaWorms lab) (Naik and Piwnica-Worms, 2007). Tau RD (aa 244-372 of the 441 aa fulllength tau 4R2N with the following variants: I277P/ΔK280/I308P or 2P, WT, P301L,
P301S, P301L/V337M or LM) was PCRed out of the pEYFP vector and placed upstream
of each of the split-luciferase constructs using EcoRI (5’) and KpnI (3’), thus generating
p-tau RD-Cluc and p-tau RD-Nluc.
For lentiviral constructs, a backbone containing the ubiquitin C promoter IRES-Venus
(FCIV FM5) (generously provided by the Jeffrey Milbrandt laboratory) (Araki et al.,
2004) was modified to remove IRES-Venus by digestion with BsrGI (5’) and BamHI
(3’). DNA was extracted from agarose gel using Qiagen Gel Extraction Kit. Ends were
blunted using DNATerminator End Repair Kit (Lucigen) and the resulting product was
purified using Qiagen PCR purification Kit. The blunted product was re-ligated using T4
DNA ligase (New England Biolabs) to create a new plasmid called FM5. The following
constructs were then subcloned from the pEYFP vector using NheI (5’) and AscI (3’): tau
RD(ΔK280/I277P/I308P) (2P)-YFP, tau RD(WT)-YFP, tau RD(ΔK280)-YFP, tau
RD(P301L/V337M) (LM)-YFP, alpha synuclein(WT)-YFP, huntingtin Exon 1(Q25)YFP, tau RD-Cluc (various mutants), tau RD-Nluc (various mutants), tau RD
P301L/V337M (LM)-HA, full-length tau 4R1N P301S, full-length tau 4R1N P301SYFP, full-length tau 4R1N WT, full-length tau 4R1N WT-YFP.
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To create a plasmid expressing tau RD(LM)-YFP under the TRE (tetracycline response
elements) promoter, tTA was subcloned into FM5 using AgeI (5’) and EcoRI (3’) to
generate FM5-Ub-tTA. The TRE-Tight promoter was then PCRed using PacI (5’) and
NheI/BsrGI/PacI (3’). PacI digestion was then used to subclone the PCR product into
FM5-tTA and sequencing confirmed proper orientation, thus generating the FM5-TREUb-tTA plasmid (FM5 Tet Off). Finally, NheI (5’) and BsrGI (3’) were used to subclone
tau RD(LM)-YFP into FM5-TRE-Ub-tTA to generate FM5 Tet Off-tau RD(LM)-YFP.
All restriction endonucleases were obtained from New England Biolabs.
Protein purification and fibrillization. Amyloid beta (1-42) fibrils were a generous gift
from the John Cirrito laboratory: peptide was synthesized by Pepnome and monomer was
re-suspended in HFIP, which was subsequently evaporated away under nitrogen gas. The
resulting monomer was resuspended at 5 mM in DMSO prior to dilution to 100 µM in 10
mM HCl/150 mM NaCl. Fibrils were prepared by incubating at 37°C for 24 hours. They
were then stored at -20°C until use.
Synthetic huntingtin exon1 N17-Q35 peptide was synthesized at the Keck Biotechnology
Resource Laboratory of Yale University. Peptide was solubilized in formic acid prior to
being dialyzed into phosphate buffer solution. Re-solubilized monomer was fibrillized at
room temperature at a concentration of 100 µM for 24 hours. Resulting fibrils were stored
at -20°C until use.
α-synuclein fibrils were a generous gift from the Paul Kotzbauer laboratory.
Recombinant α-synuclein WT protein was produced in E. coli using previously published
methods (Giasson et al., 2003; Huang et al., 2005): the purified protein was then dialyzed
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overnight in 10 mM Tris-HCl (pH=7.6)/1 mM DTT/50 mM NaCl. Recombinant
monomer at a concentration of 2 mg/mL was then incubated with 100 mM NaCl and 20
mM Tris-HCl (pH=8.0) at 37°C for 72 hours with shaking (Eppendorf Thermomixer,
1000 rpm) to induce fibrillization. The fibril mixture was then centrifuged at 15,000xg
for 15 minutes to separate fibrils (pellet) from monomer (supernatant). Following
manufacturer’s protocol, the concentration of α-synuclein in the supernatant was
calculated using a BCA protein assay. The decrease in protein in the supernatant
following centrifugation was used to calculate the monomer-equivalent concentration of
α-synuclein in the pellet (fibrils). Fibrils were stored at a concentration of 80 µM at -20°C
until use.
Recombinant tau RD-HA monomer was prepared as previously described (Frost et al.,
2009b; Goedert and Jakes, 1990) by expressing pRK172-Tau RD-HA in Rosetta
(DE3)pLacI competent cells (Novagen). Monomer was lyophilized and stored at -80°C as
single-use aliquots. Monomer was re-suspended in 25 mM DTT for one hour. The
reduced protein was then fibrillized at a final concentration of 8 µM in 2.5 mM DTT/10
mM HEPES (pH=7.4)/100 mM NaCl/8 µM heparin (tau buffer) at 37°C without
agitation. Fibrils were stored at a concentration of 8 µM at -20°C until use.
Cell culture. HEK293 and HEK293T cell lines were all grown in Dulbecco’s modified
Eagle’s medium (Gibco) supplemented with 10% fetal bovine serum (HyClone), 1%
penicillin/streptomycin (Gibco), and 1% glutamax (Gibco). Cell lines were maintained
and passaged in 10 cm dishes at 37°C, 5% CO2, in a humidified incubator.
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Lentivirus production. Lentivirus was prepared as described previously (Araki et al.,
2004): HEK293T cells were plated at a concentration of 1x106 cells/well in a 6-well
plate. 18 hours later, cells were transiently co-transfected with PSP (1200 ng), VSV-G
(400 ng), and FM5 (400 ng) plasmids using 6 µL FuGene HD (Promega). 72 hours later,
conditioned media was harvested and centrifuged at 1000xg for 5 minutes to remove
dead cells and debris. Supernatant was stored at -80°C until use. For primary neuron
transduction, lentivirus was concentrated 10x using lenti-X concentrator (Clontech) with
the concentrated pellet being re-suspended in PBS with 25 mM HEPES, pH 7.4.
Stable HEK293 cell line generation. HEK293 cells were plated at a concentration of
100,000 cells/well in wells of a 6-well plate. 18 hours later, 1 mL of media was removed
and replaced with 1.5 mL conditioned media containing lentivirus. For the split-luciferase
aggregation reporter line, cells were co-transduced with 750 µL of tau RD-Cluc and 750
µL tau RD-Nluc lentivirus. These amounts were used for all mutant tau RD splitluciferase pair lines with lentivirus being made in the same batch to ensure roughly
equivalent viral titers. For all stable lines, cells were given 5 days to amplify to
confluency in the presence of virus. At this point, cells were re-plated in a 10 cm dish and
were grown to confluency. For cell lines featuring protein with a fluorescent tag,
epifluorescence microscopy was used to confirm that all cells were expressing
fluorescent protein. Polyclonal cell lines were then stored in liquid nitrogen until use.
To generate monoclonal lines, polyclonal cell populations were diluted sparsely in 10 cm
dishes. Colonies were given 9 days to amplify, at which point cloning cylinders (Bel-Art
Products) were used to isolate single colonies. Monoclonal cultures were serially
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amplified to confluency using 12-well then 6-well then 10 cm dishes. Resulting
monoclonal lines were frozen in liquid nitrogen until use.
Liposome-mediated transduction of amyloids into HEK293 cells. A previously used
fibril-transduction protocol (Nekooki-Machida et al., 2009) was used with minor
modifications: polyclonal HEK293 cells stably expressing either tau RD
ΔK280/I277P/I308P(2P)-YFP, tau RD(WT)-YFP, tau RD(ΔK280)-YFP, tau RD
P301L/V337M(LM)-YFP, α-synuclein(WT)-YFP, huntingtin exon 1(Q25)-YFP, FL tau
4R1N P301S-YFP, or FL tau 4R1N P301S were plated at 250,000 cells/well in 12-well
plates. Tau buffer (2.5 mM DTT/10 mM HEPES (pH=7.4)/100 mM NaCl/8 µM heparin)
or indicated fibrils were then combined with OptiMEM (Gibco) to a final volume of 100
µL. 96 µL OptiMEM and 4 µL lipofectamine-2000 (Invitrogen) was then added to the
OptiMEM mixture to a final volume of 200 µL. After a 20-minute incubation, liposome
preparations were added to cells so that fibrils were at the following final concentrations:
tau RD (400 nM), α-synuclein (400 nM), amyloid beta (1-42) (1 µM), huntingtin exon 1
N17(Q35) (1 µM), or tau buffer (400 nM tau fibril equivalent). 18 hours later, cells were
washed, trypsinized, and re-plated in wells of a 6-well plate. Once confluent, cells were
plated on coverslips (thickness = 0.09 to 0.12 mm; Carolina Biologicals) for imaging and
quantification (time = Day 6). For transductions involving FL tau, fixed cells were
stained with AT8 (see immunocytochemistry methods).
Quantification of percent cells positive for inclusions. For inclusion-elimination time
course experiments, cells were passaged every two days for 50 days, plating cells for
fixation on every other passage. Cells were fixed by incubating with 4% PFA in PBS for
15 minutes. Coverslips were washed twice and stained with DAPI (1:3000 dilution from
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1 mg/mL stock) for 5 minutes. Coverslips were mounted on Prolong Gold Antifade
Reagent (Invitrogen), sealed with nail polish, and placed at 4°C prior to analysis. To
quantify percent cells positive for inclusions, a total of 10 fields, each with 150+ cells,
were analyzed per condition. The number of cells per field was determined by counting
the number of DAPI-positive nuclei. Then, cells with inclusions were counted and a
percentage was calculated. Mean and standard error were subsequently determined and
plotted.
Isolation of monoclonal tau prion strains induced by recombinant tau RD fibrils. A
monoclonal HEK293 cell line stably expressing tau RD(LM)-YFP was generated. Cells
were plated at 240,000 cells/well in a 12-well plate. 24 hours later, 400 nM tau RD-HA
fibrils were transduced using lipofectamine-2000 (Invitrogen) as previously described. 18
hours later, cells were washed, trypsinized, and re-plated in a 6-well plate. At confluency
(Day 3), cells were diluted sparsely in 10 cm dishes so that there were less than 100 cells
per dish. Cells were given 9 days to amplify into colonies. At Day 12, epifluorescence
microscopy was used to mark colonies featuring cells with inclusions. Cloning cylinders
(Bel-Art Products) were used to isolate single clones, which were subsequently serially
amplified to confluency in 12-well, then 6-well, and 10 cm dishes. At Day 30, cells were
either plated on coverslips for fixation and confocal analysis or were frozen down in
single-use pellets at -80°C for later analysis.
Confocal analysis. All confocal microscopy was performed using a Zeiss LSM 5
PASCAL system coupled to a Zeiss Axiovert 200M microscope. A pinhole size of 0.8
µm was used for the collection of all images. Images were processed minimally using
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ImageJ. When post-hoc processing was performed, the same modifications were made
across all images collected for a single experiment.
Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE). SDD-AGE was
performed as previously described (Kryndushkin et al., 2003) with minor modifications.
Cell pellets were thawed on ice, lysed by triturating in PBS containing 0.05% Triton-X
and a cOmplete mini protease inhibitor tablet (Roche), and clarified by 5-minute
sequential centrifugations at 500xg and 1000xg. Low-SDS 1.5% agarose gels were
prepared by dissolving agarose in buffer G (20 mM Tris-Base, 200 mM glycine, in
ddH2O) with 0.02% SDS. For each condition, 5 µg of clarified cell lysate was incubated
with 0.02% SDS sample buffer for 7 minutes prior to loading. SDD-AGE was ran in
Laemmli buffer (Buffer G with 0.1% SDS) at 125 V for 90 minutes or until dye front
reached the bottom of the gel. Protein was transferred at 100 V for 90 minutes at 4°C to
Immobilin P (Millipore) using a custom-modified SDS-PAGE transfer cassette (Bio-Rad)
for accommodation of the thick agarose gel. Membranes were probed for tau RD using
rabbit polyclonal anti-tau ab64193 (1:4000, AbCam) overnight, washed four times with
TBS-T, counter-probed with goat anti-rabbit HRP (1:4000, Jackson Immunotherapy) for
1.5 hours, and were washed an additional 4 times. Finally, membranes were imaged by
exposure to ECL Prime Western Blotting Detection System (Fisher Scientific) for 3
minutes and development using a digital Syngene imager.
Sedimentation analysis and densitometry. Clarified cell lysate was prepared as
described above (see SDD-AGE). 10% of the lysate was set aside as the total fraction; the
rest was centrifuged at 100,000xg for 1 hour. The supernatant was placed aside and the
pellet was washed with 1.5 mL PBS prior to ultracentrifugation at 100,000xg for 30
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minutes. The supernatant/wash was aspirated and the pellet was re-suspended in RIPA
buffer with 4% SDS and 100 mM DTT with the aid of boiling. Bradford assay (Bio-Rad)
with BSA standard curve was used to normalize all protein concentrations with additional
0.05% Triton-X in PBS being used for dilution. 1 µg of total protein was loaded per well
on a 4-15% SDS-PAGE gel (Bio-Rad). For all samples besides the negative control
(Clone 1), supernatant was loaded at a 3:1 ratio relative to pellet and total fractions; for
Clone 1, a 1:1 ratio was used. Gels were ran at 120 V for 60 minutes and protein was
transferred to Immobilin P (Millipore) using a semi-dry transfer apparatus (Bio-Rad).
Membranes were blocked for an hour with 5% milk, probed with rabbit polyclonal antitau ab64193 (1:4000, AbCam) overnight, washed four times with TBS-T, counter-probed
with goat anti-rabbit HRP (1:4000, Jackson Immunotherapy) for 1.5 hours, and were
washed an additional 4 times. Finally, membranes were imaged by exposure to ECL
Prime Western Blotting Detection System (Fisher Scientific) for 3 minutes and
development using a digital Syngene imager. Densitometric units were calculated using
Syngene GeneTools software with manual band quantification, normalizing against
background. Units were then corrected for loading ratios. For calculating densitometric
ratios, blots were performed in triplicate and statistical analysis was performed using oneway analysis of variance with Bonferroni’s multiple comparison test.
Split-luciferase complementation assay. Polyclonal HEK293 cells stably expressing tau
RD(LM)-Cluc and tau RD(LM)-Nluc were plated at 240,000 cells/well in 12-well plates
24-hours prior to cell lysate transduction. Clarified cell lysate was prepared as previously
described (see SDD-AGE) and was normalized to final protein concentrations of 2 µg/µL
using PBS with 0.05% Triton-X to dilute. 20 µg (10 µL) of each cell lysate was diluted
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with 90 µL OptiMEM (Gibco) and incubated with 96 µL OptiMEM and 4 µL
lipofectamine-2000 (Invitrogen) for 20 minutes. Liposome preparations were then added
to cells (each condition performed in quadruplicate) and 18 hours later, cells were
washed, trypsinized, and re-plated in quadruplicate in a 96-well plate. 24 hours later,
media was aspirated from wells and replaced with luciferin solution (150 µg/mL Dluciferin potassium salt, Gold Biosciences, in Dulbecco’s phosphate-buffer saline,
Gibco). Cells were incubated with luciferin solution for 3 minutes at 37°C prior to
reading luminescence with a TecanM1000 fluorescence plate reader. Luminescence reads
were first averaged across technical replicates (n=4) and subsequently averaged across
biological replicates (n=4 experiments unless otherwise noted) to determine standard
errors of the mean. One-way analysis of variance with Bonferroni’s multiple comparison
test was used for statistical analysis. For cross-seeding experiments, the same protocol
was used with minor exceptions: different stable split-luciferase cell lines were used;
recombinant tau RD-HA fibrils were transduced at a concentration of 1 µM; 50 µg of
aged transgenic P301S brain (age=12 months) was transduced.
Protease digestion. Pronase (Roche) was diluted in PBS to a final concentration of 1
mg/mL and single-use aliquots were stored at -80°C. Clarified cell lysate was prepared as
previously described (see SDD-AGE) and protein concentrations were normalized to 1.7
µg/µL, unless otherwise noted. 17 µg (10 µL) of cell lysate was added to 10 µL of
pronase at a concentration of 100 µg/mL (diluted in PBS) for a final volume of 20 µL and
a final pronase concentration of 50 µg/mL. Cell lysates were digested at 37°C for one
hour. Reactions were quenched by addition of 20 µL 2x sample buffer (final SDS
concentration of 1%) and boiling for 5 minutes. 15 µL of each sample was loaded onto a
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10% Bis-Tris NuPAGE gel (Novex by Life Technologies) and were ran at 150 V for 65
minutes. Protein was transferred to Immobilin P (Millipore) using a semi-dry transfer
apparatus (Bio-Rad) and membranes were probed for tau RD as described above.
X-34 staining of amyloids. To visualize amyloids, cells were stained with X-34, a
derivative of Congo Red (Styren et al., 2000): Cells were fixed with 4% PFA in PBS for
15 minutes, washed twice with PBS, and permeabilized with 0.25% Triton-X/PBS for 30
minutes. They were then incubated with 1 µM X-34 (generous gift from the John Cirrito
lab) in X-34 staining buffer (60% PBS/39% ethanol/0.02 M NaOH) for 15 minutes.
Stained cells were rinsed briefly with staining buffer 3x followed by two 5-minute
washes with PBS. Coverslips were mounted on Prolong Gold Antifade Reagent
(Invitrogen), sealed with nail polish, and placed at 4°C prior to analysis.
Toxicity assays. To assess relative toxicity of Clone 9 and Clone 10 amyloids, cell
growth propensity when lacking or containing tau RD inclusions was examined.
Monoclonal HEK293 cells stably expressing tau RD(LM)-YFP were plated at 240,000
cells/well in a 12-well plate. 24 hours later, cells were transduced with 20 µg clarified cell
lysate (Clone 9, Clone 10). 18 hours later, transduced cells were re-plated in a 6-well dish
and grown to confluency. On Day 3, cells were plated sparsely on coverslips and were
given 6 days to amplify into colonies. On Day 9, cells were fixed with 4% PFA and
DAPI stained. For each condition, 80 inclusion-positive and 80 inclusion-negative
colonies were quantified by size (number of DAPI-stained nuclei per colony). Average
colony size was plotted and one-way analysis of variance with Bonferroni’s multiple
comparison test was used to assess statistical significance.
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Concurrently, at Day 3, Clone 1-, Clone 9- and Clone 10-transduced cells were passaged
onto either coverslips or into a new 6-well plate. Every three days, cells were passaged,
with cells being fixed and DAPI-stained at Days 4, 17, and 30. Percent cells positive for
inclusions at each time point were quantified and plotted as previously described. Oneway analysis of variance with Bonferroni’s multiple comparison test was used to assess
statistical significance.
For LDH and cell growth toxicity experiments, a polyclonal HEK293 cell line stably
expressing tau RD(LM)-HA was generated and transduced with 20 µg clarified cell lysate
(Clone 1, Clone 9, Clone 10) or sham treatment in 12-well plates (quadruplicate). 18
hours later, each biological replicate was re-plated at 1:100 dilution in 100 µL total
volume in technical quaduplicates in 96-well plates. 72 hours later, confluency was
assessed with a Hoechst stain. Media was removed and transferred to new 96-well plates
and LDH assay (Roche) was performed according to manufacturer’s protocol. One-way
analysis of variance with Bonferroni’s multiple comparison test was used to assess
statistical significance.
Preparation of cells for ultrastructural analysis by transmission electron
microscopy. Cells were pelleted at 15,000 rpm for 5 minutes and fixed in 2.5%
glutaraldehyde in 0.1 M mono/disodium phosphate buffer, pH 7.4, for 1 hour at room
temperature and then at 4oC on a rotator overnight. After buffer rinsing, the pellets were
then post-fixed in 1% (w/v) osmium tetroxide in 0.1 M mono/disodium phosphate buffer,
pH 7.4, for 2 hours at room temperature before being rinsed in distilled water and then
dehydrated in an ethanol series. After 2x20 min in propylene oxide and infiltrating
overnight in 1:1 propylene oxide:TAAB low viscosity resin (TAAB Laboratories Ltd.,
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Aldermaston, UK), the pellets were further infiltrated in resin over several days, with
several resin changes, before polymerizing at 60oC for 16 hours. The pellets were then
sectioned and stained with 0.5% (w/v) aqueous, 0.22 mm-filtered uranyl acetate at room
temperature for 1 hour.
Preparation of cells for immunogold labelling. Cells were spun at 15,000 rpm and
pellets were fixed in fixed in 4% formaldehyde/0.1% glutaraldehyde in 0.1 M
mono/disodium phosphate, pH 7.4, for one hour at room temperature and then at 4°C on
a rotator overnight. The following procedures were all carried out at 4°C: the fixed pellets
were washed in 0.1 M mono/disodium phosphate and dehydrated in an ethanol series,
followed by 2:1, then 1:2 100% ethanol/Unicryl resin (British BioCell International,
Cardiff, UK) for 30 minutes each. Finally, the pellets were infiltrated in complete Unicryl
resin, with several changes over a few days, and light-polymerized as previously
described (Thorpe, 1999).
Immunogold labelling. Thin sections were cut and collected upon TEM support grids
and then blocked for 30 minutes at room temperature in normal goat serum (1:10 dilution
in PBS+ (PBS, pH 8.2, modified by the addition of 1% BSA, 500 µL/L Tween-20, 10
mM Na-EDTA, and 0.2 g/L sodium azide)). They were then left in the primary antibody,
HJ 9.3 mouse monoclonal (10 mg/ml), overnight at 4o C. The following day, the grids
were given three rinses in 1 mL PBS+ for 2 minutes each and then placed into the
secondary antibody, 10 nm gold particle-conjugated goat anti-mouse IgG (1:10 dilution
in PBS+) for one hour and then rinsed in PBS+ three times for 10 minutes each, followed
by four rinses in distilled water for 5 minutes each. Finally, subsequent to drying, the
grids were stained in 0.5% (w/v) aqueous, 0.22 mm-filtered uranyl acetate for 1 hour.
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Imaging by transmission electron microscopy. Grids were examined using a Hitachi7100 transmission electron microscope operated at 100 kV. Digital images were captured
via an axially mounted (2000x2000 pixel) Gatan Ultrascan 1000 charge-coupled device
camera (Gatan, Abingdon, UK) and subsequently examined using ImageJ software.
Immunocytochemistry. HEK293 cells were fixed in 4% PFA (Vimentin and AT8 stains)
or 100% ice-cold methanol (γ-tubulin and PML stains) for 15 minutes followed by
permeabilization with 0.25% Triton X-100 for 30 minutes. Coverslips were then blocked
in blocking solution (10% fetal goat serum, 25 mg/mL BSA, 0.25% Triton X-100, PBS)
for one hour at room temperature. For primary stains, coverslips were exposed to one of
the following in blocking buffer overnight at 4°C: mouse monoclonal anti-vimentin V9
(1:50, Santa Cruz), mouse monoclonal anti-phospho-tau AT8 (1:400, ThermoScientific),
mouse monoclonal anti-γ-tubulin GTU-88 (1:2500, Sigma Aldrich), or mouse
monoclonal anti-PML PG-M3 (1:100, Santa Cruz). Following washes, stained coverslips
were counterstained with either Alexa Fluor 488-tagged goat anti-mouse antibody (1:400
in blocking buffer, Life Technologies) or Alexa Fluor 546-tagged goat anti-mouse
antibody (1:400 in blocking buffer; Life Technologies) for 1 hour at room temperature.
Coverslips were then washed, DAPI-stained, mounted using Prolong Gold Antifade
Reagent (Invitrogen), sealed with nail polish, and placed at 4°C prior to analysis by
confocal microscopy.
Primary cortical neuron culture and Triton X-100 extraction. For primary cortical
neuron culture, the cortex of embryonic day 18.5 mouse embryos was isolated and
digested with 2 mg/mL papain (Worthington Biochemistry) and 0.1% DNase I
(Invitrogen). Neurons in Neurobasal media (Gibco) containing serum-free B-27
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(Invitrogen) and GlutaMAX (Invitrogen) were plated in 24-well dishes with coverslips
pre-treated with 10 µg/mL poly-D-lysine (Sigma Aldrich). Day 1 post-plating (DIV1), 20
µL of indicated 10x concentrated lentivirus was added per well. On DIV3, 25 µg cell
lysate (10 µg/µL sonicated in PBS, clarified and sterilized with 0.22 micron filter) or
equivalent amount of PBS, was added to wells. On DIV17, 14 days after inoculation with
clarified lysates, neurons were fixed with 4% PFA/4% sucrose/PBS containing or lacking
1% Triton X-100 for 30 minutes, a slight modification from a previously described
protocol for extracting soluble cytoplasmic proteins for easy visualization of insoluble
inclusions (Volpicelli-Daley et al., 2011). After 30 minute permeabilization with 0.25%
Triton X-100 in PBS for 30 minutes, coverslips were placed in blocking solution (10%
fetal goat serum, 25 mg/mL BSA, 0.25% Triton X-100, PBS) for one hour at room
temperature. Coverslips were then exposed to mouse monoclonal anti-phospho-tau AT8
(1:400, ThermoScientific) overnight at 4°C in blocking solution. Following washes,
stained coverslips were counterstained with Alexa Fluor 546-tagged goat anti-mouse
secondary (1:400 in blocking buffer; Life Technologies) for 1 hour in blocking solution
at room temperature. Coverslips were then washed, DAPI-stained, mounted using
Prolong Gold Antifade Reagent (Invitrogen), sealed with nail polish, and placed at 4°C
prior to analysis by confocal microscopy.
Reversing aggregated state using doxycycline in Tet off background. A monoclonal
HEK293 cell line stably expressing tau RD(LM)-YFP under the TRE repressor (Tet Off)
was generated and plated at 240,000 cells/well in wells of a 12-well plate. 24 hours later,
20 µg clarified lysate from Clone 10 cells was transduced using lipofectamine-2000
(Invitrogen). 18 hours later, cells were re-plated into a 6-well plate. On Day 3, cells were
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plated sparsely in a 10 cm dish and on Day 12, cloning cylinders (Bel-Art Products) were
used to select three clones containing inclusions (these clones were picked in order of
identification using an epifluorescence microscope). The three clones, annotated Clone
10-1, Clone 10-2, and Clone 10-3, were amplified to confluency in 12-well then 6-well
then 10 cm plates and were frozen down in liquid nitrogen. All featured a similar
morphology (large juxtanuclear inclusion, no nuclear inclusions) to the original Clone 10.
Clone 10-1 was plated in a 6-well plate and media containing 30 ng/mL doxycycline was
used to turn off expression for 0, 1, 2, 3, 5, or 7 days. At this point, all cells were replated on coverslips, and were given two days to recover in media lacking doxycycline,
thus turning tau RD(LM)-YFP expression back on. At this point, cells were fixed with
4% PFA in PBS and DAPI stained, analyzing percent cells positive with confocal
microscopy as described above (n=10 fields, each with >150 cells).
Animals. Transgenic mice expressing human 4R1N P301S tau under the murine prion
promoter (Yoshiyama et al., 2007) were obtained from The Jackson Laboratory and
maintained on a B6C3 background. Mice had food and water ad libitum and were housed
with a 12 hour light/dark cycle. All protocols involving animal use were approved by the
institutional animal care and use committee at Washington University in St. Louis. For all
experiments, conditions were gender-matched (Table S1).
Murine hippocampal injections. P301S and non-transgenic littermates were
anesthetized with isoflurane as previously described (Devos and Miller, 2013). Mice
were bilaterally injected into the hippocampus (from bregma: −2.5 mm posterior, +/-2
mm lateral, −1.8 mm ventral) with either 2 µL of 5 µg/µL lysate/homogenate or 2 µL of
2.5 µg/µL recombinant tau RD fibrils at an infusion rate of 0.2 µL/minute. 10 µL gas55

tight syringes (Hamilton) and 30 gauge needles with a 60° bevel from the vertical
(Hamilton) were used for all injections.
Tissue collection. Mice were anesthetized with isoflurane and perfused with chilled 1x
PBS with 0.03% heparin. Brains were rapidly removed and for Generations 0-2
transected mid-sagittally. The right hemisphere was micro-dissected into hippocampus,
brainstem, cortex, and frontal sections and subsequently snap-frozen and stored at −80°C
until further use. The left hemisphere was post-fixed in 4% paraformaldehyde at 4°C for
24 hours and then transferred to 30% sucrose. For Generation 3 mice, whole brains were
post-fixed as described above.
Serial Inoculations. Hippocampi (right hemisphere) from all Generation 0 mice were
micro-dissected and homogenized: while still frozen, samples were sonicated in 1:4 w/v
TBS with cOmplete protease inhibitors (Roche) and phosSTOP (Roche) using an OmniRuptor 250 probe sonicator at 30% power for 20, 10-second cycles. Crude homogenates
were then clarified by centrifugation at 15,000xg for 15 minutes and supernatants were
frozen down at -80°C until use. Homogenates were standardized by Bradford assay to
final protein concentrations of 5 µg/µL. Hippocampi from the same cohort (e.g. Clone 1)
were pooled and 2 µL (i.e. 10 µg) was bilaterally injected into the hippocampi of
transgenic P301S mice (Generation 1) as per before (n=3-4 for all inoculation cohorts).
Four weeks later, generation 1 mice were sacrificed and the procedure was repeated for
generation 2 mice (n=3-4 for all cohorts). For generation 3 mice, 10 µg total protein was
unilaterally injected into the right hippocampus so that both ipsilateral and contralateral
spread could be examined 5-weeks later (n=2 per cohort).
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Histology and Immunohistochemistry. 50 µm sections were taken through the entire
left hemisphere using a freezing microtome. Slices were first blocked for one hour with
10% goat serum and 3% milk in TBS with 0.25% Triton X-100 (blocking buffer). For
DAB stains, brain slices were incubated with either biotinylated AT8 antibody (1:500,
ThermoScientific); MC1 antibody (1:500, kind gift from Peter Davies laboratory); or
rabbit anti-Iba1 (1:500, Wako Chemicals USA), all overnight in blocking buffer at 4°C.
For secondary staining of MC1, slices were incubated with biotinylated goat anti-mouse
F(ab’)2 fragment (1:1000 in blocking buffer, Jackson Immunoresearch). For secondary
staining of Iba1, slices were subsequently incubated in biotinylated goat anti-rabbit IgG
(1:500 in blocking buffer, Sigma) for one hour at room temperature. Using the
VECTASTAIN Elite ABC Kit (Vector Labs), all stained slices were then incubated at
room temperature for 30 minutes, followed by DAB development using the DAB
Peroxidase Substrate Kit with the optional nickel addition (Vector Labs). Histological
images and z-stacks were captured using the Olympus Nanozoomer 2.0-HT (Hamamatsu)
and analyzed with the NDP viewer software (Hamamatsu). Counts of neurons with AT8positive tangle-like structures in CA1/CA3 of the hippocampus were performed by a
blinded individual. One-way analysis of variance with Bonferroni’s multiple comparison
test was used to assess statistical significance.
For immunofluorescence stains, slices were placed in blocking solution for one hour and
were then incubated in blocking solution with either AT8 antibody (1:500,
ThermoScientific) or rabbit anti-Iba1 (1:500, Wako Chemicals USA) overnight at 4°C.
Slices were then incubated with either Alexa Fluor 488-tagged goat anti-mouse antibody
(1:2000, Life Technologies) in the case of AT8 or Alexa Fluor 546-tagged goat anti57

rabbit antibody (1:2000, Life Technologies) for one hour at room temperature in blocking
solution. Slices were subsequently stained with DAPI as described above and mounted
onto coverslips with Fluoromount G (Sigma Aldrich). Slices were imaged by confocal
microscopy.
For X-34 staining, sections were incubated in PBS with 0.25% Triton X-100 for 30
minutes, followed by a 20 minute incubation with X-34 (10 µM final concentration) in
40% ethanol, 60% PBS and 1/500 volume of 10 N NaOH. Slices were subsequently
rinsed in 40% Ethanol/60% PBS at 3 x 2 minutes followed by rinse for 2 x 5 minutes in
PBS. Slices were finally mounted with Fluoromount-G (Sigma Aldrich). Slices were
imaged with a Nikon Instruments Eclipse E800 microscope.
Immunoprecipitation of full-length tau from strain-inoculated mice. 1:50 HJ8.5 (kind
gift from the David Holtzman lab) was added to 120 µL (600 µg) hippocampal
homogenates freshly thawed on ice. Homogenate and antibodies were incubated
overnight at 4°C with rotation. 18 hours later, 50 µL of protein-G agarose beads (Pierce)
were added and samples were again incubated overnight at 4°C with rotation. 24 hours
later, samples were centrifuged at 2000xg for 3 minutes at 4°C. Supernatant was
discarded and replaced with 500 µL Ag/Ab gentle binding buffer (Pierce). This
centrifugation/wash step was repeated three times. After the final aspiration, proteins
bound to beads were eluted using 50 µL low pH elution buffer (Pierce) by incubating at
room temperature for 5 minutes. Samples were centrifuged at 2000xg for 3 minutes and
supernatants were collected. This elution step was repeated to give a total volume of 100
µL. Finally, 10 µL 1 M Tris-Base pH 8.5 was added to the eluate to neutralize the elution

58

buffer. When seeding of eluate and crude homogenate were compared, volumes were
standardized. Eluted samples were stored at -80°C until use.
Analysis of seeding potential of immunoprecipitated tau from strain-inoculated
mice. Seeding activity of immunoprecipitated full-length tau was examined using splitluciferase complementation and inclusion counts for both generation 0 (un-pooled) and
generation 2 (pooled by cohort) mice. IPed material from 60 µg brain homogenate was
transduced into split-luciferase cells, following the protocol previously described. Four
separate experiments were performed for IPed samples from each brain, each read in
quadruplicate 48-hours post-transduction of lysate. Average seeding ratios were
calculated for each sample, comparing luminescence versus sham-inoculated cells
(lipofectamine-2000 alone). Luminescence values were averaged within mouse cohorts
and compared by one-way analysis of variance with Bonferroni’s multiple comparison
test was used to assess statistical significance.
For inclusion counts, IPed full-length tau from 60 µg brain homogenate-equivalent was
transduced into tau RD(LM)-YFP cells in a 12-well plate. 24 hours later, cells were replated onto coverslips. At 96 hours, cells were fixed. Six fields, each with 100+ cells,
were analyzed per mouse and averages were calculated for each. These averages were
then collapsed within cohorts and compared by one-way analysis of variance with
Bonferroni’s multiple comparison test to assess statistical significance.
Re-introduction of strains passaged through mice into naive tau RD-YFP cells. IPed
FL tau from 60 µg brain homogenate from transgenic tau P301S mice (Generation 0 =
un-pooled, Generation 2 = pooled) was transduced into tau RD(LM)-YFP cells in a 12-

59

well plate. 24 hours later, cells were re-plated into a 6-well plate. At confluency, cells
were sparsely plated on coverslips and were given 8 days to amplify into discrete
colonies. Cells were then fixed with 4% PFA and DAPI-stained. Colonies with inclusions
were imaged by confocal microscopy. Inclusion-positive colonies were scored as either
containing or lacking nuclear inclusions. For generation 0 mice, 20+ colonies were scored
per mouse and percentage with each phenotype was calculated. For generation 2 mice, 10
coverslips, each with 15+ inclusion-positive colonies, were scored per cohort. Values
were averaged within cohorts and compared by student’s t-test.
For isolation of monoclonal lines, this protocol was repeated except inoculated cells were
re-plated sparsely into 10 cm dishes following confluency in the first 6-well plate.
Monoclonal inclusion-positive lines were isolated as described previously. For
Generation 0 mice, one representative colony was blindly picked and amplified per
mouse. For Generation 2 mice, 12 colonies were blindly picked and amplified per cohort.
Each monoclonal line was examined by inclusion morphology/confocal, pronase
digestion, and split-luciferase complementation as described previously.
Human patient case selection and neuropathological methods. Cases were selected
from the Neurodegenerative Disease Brain Bank (NDBB) at the University of California,
San Francisco (UCSF). The NDBB receives brain and spinal cord materials from patients
enrolled in UCSF Memory and Aging Center longitudinal clinical research programs.
The fresh brains were cut into ~1 cm coronal slabs, which were alternately fixed in 10%
neutral buffered formalin for 72 hours or rapidly frozen, providing tissues preserved with
both methods bilaterally for every cut surface. Neuropathological diagnoses were made in
accordance with consensus diagnostic criteria (Hyman et al., 2012; Mackenzie et al.,
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2010) using previously described histological and immunohistochemical methods (Kim
et al., 2012b). Cases were selected based on neuropathological diagnosis. Blocks (~0.5
g) were dissected from frozen brain slabs, targeting regions for each diagnostic group in
which all patients showed no less than a mild-to-moderate tau inclusion burden in the
apposed fixed tissue block: middle frontal gyrus (6 AD, 6 PSP, and 6 CBD); inferior
temporal cortex (6 AGD) and anterior orbital gyrus (5 PiD). Among the six AGD cases, 2
carried a primary diagnosis of AGD (AGD1 and AGD2) whereas the others carried a
primary diagnosis of FTLD-TDP but had incidental AGD (AGD3, AGD4, AGD5,
AGD6). The inferior temporal gyrus was chosen for AGD to capture AGD tau while
avoiding comorbid AD-related tau as much as possible. See Table S2 for patient
characteristics and scoring of morphologies.
Brain homogenate preparation and clarification. Human brain samples were shipped
from UCSF to Washington University on dry ice. Tau knock-out mouse (Jackson Labs,
STOCK Mapttm1(EGFP)Klt/J) brain (male, 12 months of age) was harvested and stored
at -80°C. While still frozen, 0.5 gram sections were sonicated in 5 mL TBS with
cOmplete protease inhibitors (Roche) and phosSTOP (Roche) using an Omni-Ruptor 250
probe sonicator at 30% power for 20, 10-second cycles. Crude brain homogenates were
then clarified by centrifugation at 15,000xg for 15 minutes and supernatants were frozen
down at -80°C until use.
Immunoprecipitation of tau from human samples and mouse tau knock-out brain.
1:100 HJ9.3 and 1:100 HJ8.5 (kind gifts from the David Holtzman lab) were added to 1
mL 10% weight/volume brain homogenates freshly thawed on ice. Homogenate and
antibodies were incubated overnight at 4°C with rotation. 18 hours later, 50 µL of
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protein-G agarose beads (Pierce) were added and samples were again incubated overnight
at 4°C with rotation. 24 hours later, samples were centrifuged at 2000xg for 3 minutes at
4°C. Supernatant was discarded and replaced with 500 µL Ag/Ab gentle binding buffer
(Pierce). This centrifugation/wash step was repeated three times. After the final
aspiration, proteins bound to beads were eluted using 50 µL low pH elution buffer
(Pierce) by incubating at room temperature for 5 minutes. Samples were centrifuged at
2000xg for 3 minutes and supernatants were collected. This elution step was repeated to
give a total volume of 100 µL. Finally, 10 µL 1 M Tris-Base pH 8.5 was added to the
eluate to neutralize the elution buffer. Eluted samples were stored at -80°C until use.
Isolation of brain homogenate-derived tau RD prion strains. Monoclonal Tet Off-tau
RD(LM)-YFP cells were plated at 240,000 cells/well in 12-well plates. 24 hours later, 30
µL clarified brain homogenate/70 µL OptiMEM (crude approach) or 100 µL eluted tau
(IP approach) was incubated with 96 µL OptiMEM/4 µL lipofectamine-2000 for 20
minutes prior to addition to wells. 18 hours later, transduced cells were re-plated in 6well plates. On Day 3, cells were plated sparsely in 10 cm plates (<100 cells/plate).
Conditions with rounded, dying cells were noted at this time as “toxic.” On Day 12,
clones containing inclusions were isolated for each condition. As many positive/mosaic
clones as could be identified were picked. Differences in sample size between conditions
reflect efficiency of seeding and amplification. Clones were serially passaged to
confluency in 12-well, then 6-well, then 10 cm plates. At Day 30, cells were frozen down
in liquid nitrogen or plated on cover slips for assessment of morphology by confocal.
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2.5

RESULTS

Homotypic seeding of tau depends on beta-sheet structure. Amino acid sequence
disparities impair cross-seeding between PrP moieties from different species, leading to
“seeding barriers” (Collinge and Clarke, 2007). To test the fidelity of hetero- vs.
homotypic seeding for tau, we expressed several amyloidogenic proteins and exposed
them to a variety of fibrillar seeds. Prolonged expression of full-length (FL) tau can be
toxic to dividing cells. Thus for tau, we expressed the aggregation-competent core,
termed the repeat domain (tau RD; aa 244-372 of the 441 aa FL tau 4R2N) (Wischik et
al., 1988). We generated polyclonal HEK293 cell lines stably expressing tau RD-YFP, asynuclein-YFP, or huntingtin (htt) exon 1(Q25)-YFP (see Figure 2.2A for construct
diagrams). Inclusions did not occur in any line without exposure to exogenous fibrils.
However, upon transduction of fibrils (Aβ (1-42), htt exon 1 N17(Q35), a-synuclein, tau
RD) using liposomes (Nekooki-Machida et al., 2009), we observed homotypic but not
heterotypic seeding for each amyloidogenic protein (Figure 2.1A; Figure 2.2B for
quantification), consistent with sequence-specific templating. Prior reports have indicated
that in certain cases, a-synuclein aggregates can cross-seed FL tau (Giasson et al., 2003;
Guo et al., 2013; Waxman and Giasson, 2011). Cross-seeding has also been reported
between other amyloidogenic proteins (Ma and Nussinov, 2012). Thus, we tested this for
both YFP-tagged and untagged versions of FL tau 4R1N P301S. We observed only
homotypic seeding and no cross-seeding of tau by a-synuclein or any other amyloid
(Figure 2.2C,D). This is consistent with sequence-specific templating, although we

63

cannot rule out the possibility that different amyloid conformers are capable of
heterologous seeding, as has previously been reported (Guo et al., 2013).
Amyloids typically feature a cross beta-sheet conformation (Bonar et al., 1969). We
exploited two proline substitutions (I277P/I308P) in tau that block its ability to enter into
this quaternary form (Bergen et al., 2001) to test whether inclusion formation requires
this property. Polyclonal HEK293 cell lines stably expressing tau RD-YFP with no
mutations (WT); P301L/V337M (LM: pro-aggregation); ΔK280 (pro-aggregation); or
ΔK280/I277P/I308P (2P: anti-aggregation) were transduced with tau RD fibrils. All
formed inclusions except tau RD(2P)-YFP, confirming that beta-sheet structure is
required for tau RD inclusion formation in our model system (Figure 2.1B).
Stable inheritance of tau RD aggregates. Seeded htt exon 1 (Ren et al., 2009),
Sup35NM (Krammer et al., 2009), SOD1 (Münch et al., 2011), and a-synuclein (Bousset
et al., 2013) form persistent intracellular inclusions in cultured cells. We tested this for
tau RD. We transduced tau RD fibrils or buffer into polyclonal tau RD(LM)-YFP
(hereafter, referred to as tau RD) cells, chosen for their superior ability to be seeded
relative to tau RD(WT)-YFP, and quantified the percentage of cells with inclusions on
every other passage. Transduced fibrils induced tau RD inclusions that persisted >50 days
post-exposure (Figure 2.1C). We hypothesized that the aggregated state was stably
inherited, since inclusion-containing cells formed local clusters (Figure 2.1D). To test
this, we sparsely diluted fibril-transduced tau RD cells to isolate individual colonies.
These were composed of either 100% inclusion-negative (Figure 2.1E) or 100%
inclusion-positive (Figure 2.1F) cells, indicating stable inheritance of the aggregated
state.
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Tau RD propagates conformationally distinct strains. Only prion protein (PrP)
(Birkett et al., 2001) and certain fungal prions (e.g. Sup35 [PSI+]) (Derkatch et al., 1996)
unequivocally propagate distinct conformational states, or strains, in cell culture. To test
the ability of tau RD to propagate distinct conformers, we diluted fibril-transduced
monoclonal tau RD cells and isolated individual clones that stably propagated inclusions
(Figure 2.3A). Previous work with the Sup35 protein has indicated that inclusion
morphology is a proxy for biochemically distinct yeast prion strains in dividing
mammalian cells (Krammer et al., 2009). We thus characterized 20 tau RD clones based
on inclusion morphology, numbered in order of isolation. Most (Figure 2.4A) featured
small juxtanuclear inclusions with many nuclear speckles, exemplified by Clone 9
(Figure 2.3B). Clone 10 alone propagated a single, large juxtanuclear inclusion (Figure
2.3B). We confirmed that stably propagated tau RD inclusions were amyloids as Clones 9
and 10, but not inclusion-negative Clone 1, bound X-34, a Congo red derivative that
stains beta-sheet structures (Figure 2.3C).
To characterize the clones biochemically, we first used semi-denaturing detergent
agarose gel electrophoresis (SDD-AGE), a method that differentiates strains based on
aggregate size (Kryndushkin et al., 2003). Tau RD species from Clone 10 were larger
than those propagated by Clone 9 (Figure 2.3D). Thus, the Clone 10 fibrils may not be as
readily fragmented into smaller species (Tanaka et al., 2006). Next, we used
sedimentation analysis to differentiate the strains (Tanaka et al., 2006). Clone 1 had
entirely soluble tau RD, whereas Clones 9 and 10 had insoluble tau RD (Figure 2.3E).
Clone 10 featured more soluble tau RD than Clone 9. To probe for structural differences,
we used limited proteolysis as has been used previously for differentiating PrP
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conformers (Bessen and Marsh, 1994). Cell lines propagating aggregates (Clones 9, 10)
featured pronase-resistant species between 10 and 13 kDa as well as between 20 and 25
kDa in size (Figure 2.3F). Clone 9 produced a smear between 10-13 kDa, while Clone 10
produced a clear doublet. These studies indicated clear differences in biochemical
characteristics of the clones, consistent with distinct strain conformations.
Prion strains often have different seeding efficiencies, which can result in variable
incubation times in vivo (Legname et al., 2006). Thus we compared the clones, modifying
a pre-existing split-luciferase complementation assay (Naik and Piwnica-Worms, 2007)
for use as a tau aggregation sensor (Figure 2.2A). Clone 1 contained no seeding activity.
However, inclusion-containing lines seeded robustly, especially Clone 9, which seeded
more than Clone 10 (Figure 2.3G). Differences in seeding were not an artifact of cell
confluency, as determined by normalizing to cell number in seeding experiments (Figure
2.4B).
Next, we compared the toxicities of Clone 9 and 10. Although Clone 9 lysate initially
seeded a greater number of cells, these were rapidly eliminated relative to those induced
by Clone 10 (Figure 2.3H). Furthermore, cells containing Clone 9-derived inclusions
grew more slowly than those derived from Clone 10 (Figure 2.3I). While growth rate of
non-transfected HEK293 cells was not affected by inoculation with Clone 9 lysate,
growth of tau RD cells was impaired following the same treatment (Figure 2.4C). This
was not seen for Clone 10. Finally, an LDH assay suggested that Clone 9 lysate is toxic
to tau RD cells relative to a sham treatment (Figure 2.4D).

66

A previous study reported that tau from human brain can induce aggresome structures in
vitro (Santa-Maria et al., 2012). Thus, we examined the subcellular localization of
inclusions associated with Clones 9 and 10. Based on anti-vimentin stains (Figure 2.4E),
electron microscopy (Figure 2.4F), and anti-γ-tubulin stains (Figure 2.4G), we conclude
that juxtanuclear Clone 10 inclusions are canonical aggresomes, unlike the inclusions of
Clone 9. Although polyglutamine intranuclear inclusions colocalize with PML bodies
(Yasuda et al., 1999), intranuclear Clone 9 inclusions did not (Figure 2.4H). Thus, Clones
9 and 10 propagate conformationally distinct tau prion strains, with different
consequences for the cell. To test the fidelity of strain inheritance, we passaged them
continuously for 6 months. Inclusion morphologies (Figure 2.3J) and limited proteolysis
patterns (Figure 2.3K) associated with Clones 9 and 10 were unaltered. Thus, tau RD
prion strains are robust, maintaining their phenotypes indefinitely in cell culture.
Transfer of strain phenotype to naïve cells. To rule out an effect of cell background on
strain formation, we transduced Clone 9 and 10 lysates into naïve monoclonal tau RD
cells, isolating 6 colonies (A-F) for each (Figure 2.5A). We evaluated derivative clones
(9C was lost in passage) by inclusion morphology (Figure 2.5B); SDD-AGE (Figure
2.5C); sedimentation analyses (Figure 2.5D, 2.6B); seeding activity (Figure 2.5E); and
limited proteolysis (Figure 2.5F). In all cases, derivative clones matched their associated
progenitors, indicating that tau RD prion strains are encoded by conformation,
independent of cell background. Faithful templating into naïve cells also occurred after
passive addition of lysates to media (Figure 2.6A), thus indicating that bypassing
physiological uptake is not necessary for templating. With a Tet Off line to control tau
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RD expression, we demonstrated that the aggregate-positive phenotype can be cured by
stopping expression for 7 days and then restarting it (Figure 2.6C,D).
To rule out an artifact of using artificial truncated tau RD and dividing cell model
systems, we examined FL tau inclusion formation in primary cortical neurons. Neurons
expressing FL tau P301S-YFP formed detergent-resistant inclusions following treatment
with Clone 9 or 10 but not Clone 1 or PBS (Figure 2.5G). Clone 9 seeded very robustly
relative to Clone 10 (Figure 2.6E). Clone 9 lysate created inclusions throughout the soma
and processes of neurons with untagged and YFP-tagged FL P301S tau, whereas Clone
10 lysate primarily seeded inclusion bodies confined to the soma (Figure 2.5, 2.6F,G).
Corroborating prior studies (Aoyagi et al., 2007; Miyasaka et al., 2001), we observed a
seeding barrier between WT tau and P301 mutants (P301L, P301S). Specifically,
aggregates from Clones 9 and 10, which feature both the P301L and V337M mutations,
never seeded aggregation in neurons expressing FL tau WT-YFP (Figure 2.5H) and FL
tau WT (no tag) (data not shown). This seeding barrier was confirmed to be asymmetric
by using a panel of split-luciferase tau RD mutant pairs (Figure 2.6H), which
demonstrated that WT tau RD can seed all forms of RD (WT, P301L, P301S,
P301L/V337M), whereas P301 mutants cannot seed WT.
Tau strains induce unique pathologies in transgenic tau P301S mice. Inoculation of
recombinant fibrils into transgenic P301S mice (Yoshiyama et al., 2007), which express a
form of mutant tau associated with dominantly inherited tauopathy, rapidly induces
pathology within weeks (Iba et al., 2013). Thus, we tested whether tau strains formed in
cell culture would have similar effects. We inoculated equivalent amounts of lysate from
Clones 1, 9, and 10, as well as recombinant tau RD fibrils (RF) bilaterally into the
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hippocampi of 3-month old mice (Figure 2.7A). For all experiments, conditions were
gender-matched (Figure 2.17). After 3 weeks, RFs induced tangle-like pathology when
assessed by AT8 (Figure 2.7B,C), an antibody against FL phospho-tau, as previously
reported (Iba et al., 2013). Clone 9 and 10 induced unique pathologies, whereas Clone 1
did not cause any detectable abnormality (Figure 2.7C,D). While Clone 9 induced tanglelike inclusions throughout CA1 and CA3, Clone 10 induced AT8-positive puncta in
mossy fiber tracts (Figure 2.7D). Staining with MC1, an antibody against
conformationally-altered tau (Jicha et al., 1997) confirmed these differences (Figure
2.8A). X-34, an amyloid dye, primarily recognized Clone 9 pathology (Figure 2.8A),
although light staining was observed in CA1 of Clone 10-inoculated mice. Pathological
differences could not be explained by differences in the amount of total or insoluble tau
RD inoculated (Figure 2.8E,F). Injected WT mice never developed pathology (Figure
2.8B), possibly due to a seeding barrier between inoculated tau RD and WT murine tau
(Figure 2.5H, 2.6E,H).
P301S mice inoculated with Clone 10 uniquely accumulated elongated Iba1-positive rod
microglia (Figure 2.7E), which aligned end-to-end parallel to CA1 pyramidal axons
(Figure 2.8C). Such unique coupling of rod microglia has been observed in a rodent
traumatic brain injury model, and may be protective for injured axons (Ziebell et al.,
2012). WT mice inoculated with Clone 9 and 10 did not feature this pathology, indicating
that endogenous human P301S tau is required for this induced microglial phenotype
(Figure 2.8D).
Tau strains are stably propagated through multiple generations in mice. Prions can
be stably passaged in vivo (Bruce et al., 1994). Thus, we performed serial inoculation of
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brain homogenates into naïve P301S mice (Figure 2.9A). Brain homogenate from WT or
P301S mice inoculated with Clone 1, 9 or 10 (termed generation G0) was inoculated into
naïve P301S mice (generation G1). After 28 days, brains were collected for histology and
biochemistry, and the process was repeated in a second round of P301S mice (generation
G2). Immunohistochemistry demonstrated identical pathology for each generation of
mice: Clone 9 serial propagation induced AT8-positive, tangle-like pathology in CA1 and
CA3 regions, whereas Clone 10 serial propagation induced AT8-positive puncta in the
mossy fiber tracts of the hippocampus (Figure 2.9B,C, 2.10A). Clone 1 induced no
pathology in any generation (Figure 2.9B, 2.10B). Homogenate from WT mice
inoculated with the original cell tau strains (G0) did not produce pathology upon passage
into P301S mice (Figure 2.10C). Therefore, pathology observed in G1 and G2 cannot be
due to residual tau RD seeds from the original inoculum, and tau prions propagate unique
phenotypes for multiple passages in vivo.
In vivo tau strains maintain phenotypes upon passage back into cells. To conclusively
test whether tau strains are biochemically stable after passage in vivo, we isolated FL
P301S tau from micro-dissected hippocampi of injected mice (G0), using a monoclonal
antibody (HJ8.5) that binds an epitope present in FL tau but not tau RD (Yanamandra et
al., 2013). We assessed seeding activity in G0 samples by split-luciferase
complementation and inclusion counts. Only hippocampi from P301S mice (G0) injected
with tau RD aggregates contained seeding activity (Figure 2.11A, 2.12A). This did not
correlate with the amount of immunoprecipitated tau (Figure 2.12D). WT mouse
hippocampi never seeded, regardless of the inoculum. We next tested whether the strains
introduced into G0 mice could be re-isolated in tau RD cells. Scoring of single colonies
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based on morphology (containing or lacking nuclear speckles) suggested that strains were
unaltered following a single passage through mice (Figure 2.12B,C). To further confirm
this, a single representative colony associated with each mouse was blindly selected and
amplified. All G0-Clone 9 and G0-Clone 10 samples recapitulated the morphologies of
the original Clones 9 and 10 (Figure 2.11B). Limited proteolysis patterns (Figure 2.11C)
and seeding propensities were also identical (Figure 2.11D).
Similar experiments were performed following the third passage (G2). IPed tau from
pooled G2-Clone 9 and G2-Clone 10 homogenates seeded far more strongly than G2Clone 1 homogenates (Figure 2.11E). IgG-precipitated material did not seed (Figure
2.11E, 2.12E), and IPed tau seeded as strongly as crude homogenate in a split-luciferase
assay (Figure 2.12E). Tau alone thus accounts for the seeding activity reported in these
assays.
Next, we introduced IPed material from G2 mice into tau RD reporter cells and scored
colonies based on morphology prior to isolation of monoclonal lines. G2-Clone 9
colonies almost exclusively featured nuclear inclusions, whereas virtually all G2-Clone
10 colonies lacked them (Figure 2.12F). The rare inclusion-positive colonies associated
with G2-Clone 1 also featured nuclear inclusions, which suggested that some of the G2Clone 10 colonies containing nuclear inclusions could arise from an intrinsic P301Sderived strain. Monoclonal strains (n=12) were blindly selected for each G2 cohort. In all
but one case (G2-Clone 10D), inclusion morphologies matched that of the original
inoculate (Figure 2.11F, 2.12G). For both Clone 9 and 10 cohorts, 11 of 12 clones
matched their parental counterpart based on both limited proteolysis (Figure 2.11G) and
seeding activity (Figure 2.11H). Intriguingly, the two outliers (G2-Clone 9G, G2-Clone
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10D) had identical proteolysis patterns and seeding ratios, which were unique from those
of all other clones. We speculate that these clones result from an intrinsic strain within 4month P301S mice. We conclude that tau prion strains are stable across numerous
passages through cells and animals.
Spread of tau pathology to distant, synaptically connected regions. After inoculation
with recombinant tau fibrils, pathology can develop in synaptically connected regions
(Iba et al., 2013). Our preliminary observations indicated that serial inoculations with
Clone 9 induced pathology in the ipsilateral entorhinal cortex (EC) (data not shown). To
test for spread, we performed a final inoculation (G3) into the left hippocampus of P301S
mice. After five weeks, G3-Clone 9 mice had AT8-positive pathology in regions that
project to or from the hippocampus (Figure 2.13A) including ipsilateral and contralateral
EC, retrosplenial cortex (RSp), and contralateral hippocampus (Figure 2.13B-D, 2.14A)
(Andersen, 2007; Neves et al., 2008; van Groen et al., 2003). Ipsilateral EC had robust
pathology in layers II/III, whereas contralateral EC pathology occurred in deeper cortical
layers, suggesting spread along defined anatomical connections (van Groen et al., 2003).
Furthermore, pathology was observed in ipsilateral subiculum and dentate gyrus (Figure
2.14B). In contrast, G3-Clone 1 brain did not show AT8-positivity above baseline (Figure
2.13B,D). Overt spread was not observed in G3-Clone 10 mice (data not shown), perhaps
due to its decreased seeding ability (Figure 3G, 2.6E). A heat-map summarizes the brain
regions with enhanced AT8-positive pathology in G3-Clone 9 mice (Figure 2.13C).
These results agree with previous work suggesting that seeded intracellular amyloids
spread along discrete neural networks (de Calignon et al., 2012; Iba et al., 2013; Liu et
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al., 2012; Luk et al., 2012a; Zhou et al., 2012). We cannot completely exclude the
possibility that this was due to trans-synaptic spread of inoculum.
Intra-patient and inter-disease phenotypic diversity in the tauopathies. It has been
hypothesized that conformationally distinct tau prion strains may be associated with
individual tauopathies (Clavaguera et al., 2013b; Frost and Diamond, 2010), and a recent
study found that inoculation of transgenic human tau mice with brain homogenates from
patients with different tauopathies recapitulates certain pathological features of the
diseases (Clavaguera et al., 2013a). To examine whether inclusion morphology is a
reasonable indicator of distinct strains, we first used our cell model to examine brain
homogenates from three individuals with clinically distinct, pathologically verified
tauopathies (all patient samples obtained from the Neurodegenerative Disease Brain Bank
at UCSF): Alzheimer’s disease (AD), corticobasal degeneration (CBD), and argyrophilic
grain disease (AGD). We transduced immunoprecipitated (IP) or crude (CR) homogenate
into the monoclonal Tet Off HEK293 cell line (Figure 2.15A), used for its relatively high
tau RD expression and greater seeding efficacy, and characterized resulting colonies
morphologically and biochemically (Figure 2.16A-I). Each brain induced a unique
inclusion morphology, independent of the transduction method (IP vs. CR) (Figure
2.16A-D). By analyzing three representative clones derived from each brain by
sedimentation analysis (Figure 2.16E), seeding (Figure 2.16F,G), and limited proteolysis
(Figure 2.16H,I), we concluded that morphology reliably differentiates biochemically
distinct strains. Next, we expanded our analysis to include IPed tau from patients with
AD (n=6); AGD (n=6); CBD (n=6); Pick’s disease (PiD, n=5); and progressive
supranuclear palsy (PSP; n=6) (Figure 2.18). Excepting PiD, a three-repeat tauopathy,
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these are predominantly four-repeat (AGD, CBD, PSP) or mixed-repeat (AD)
tauopathies that differ in the morphology and distribution of neuronal and glial tau
inclusions (Lee et al., 2001). We transduced IPed tau from each sample into the
monoclonal Tet Off cell line and isolated clones with inclusions (Figure 2.15A). We
identified six morphological phenotypes: 1) No seeding; 2) Toxic (all cells with
inclusions died and clones could not be isolated); 3) Mosaic (unstable prion strain); 4)
Ordered; 5) Disordered; 6) Speckles (Figure 2.15B). We blindly scored all clones based
on tau RD inclusion morphology. This revealed distinct strain compositions across the
diseases (Figure 2.15C). AD patient samples revealed remarkable homogeneity,
suggesting a predominant strain. Other disorders revealed inter-patient variation. Some
patients featured homogeneous strain composition (e.g. certain patients with AGD, PSP),
whereas others exhibited considerable heterogeneity. With few exceptions (e.g. AD1AD4; AGD2; CBD5; PiD3), most patient samples produced two or more strains. The
range of phenotypes associated with single patients suggests a diversity of patient-derived
tau prion strains. Since the cell-based strain isolation system can likely amplify only a
subset of strains, these data suggest that a disease-associated ensemble or “cloud” of
conformations exists within individual patients. Nevertheless, certain tauopathies can be
differentiated by their strain composition.
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2.6

DISCUSSION

Summary. Many papers describing “prion-like” behavior of proteins associated with
neurodegenerative diseases have been published in the last several years. In the case of
tau, fibrils transmit its aggregated state from the outside to the inside of a cell (Frost et
al., 2009a; Holmes et al., 2013a), suggesting that this mechanism could account for the
stereotyped progression of tauopathies. This model of disease was subsequently
supported in vivo with reports of trans-synaptic spread of pathology (de Calignon et al.,
2012; Kim et al., 2010; Liu et al., 2012) and protein-only induction of tau inclusions (Iba
et al., 2013). Work with other intracellular amyloids (Desplats et al., 2009; Holmes and
Diamond, 2012; Münch et al., 2011; Ren et al., 2009) has suggested that prion-like
transmission can explain the progression of many neurodegenerative diseases.

Whether or not various non-infectious amyloids are “true” prions has become a
contentious subject of debate. Some define prions as being capable of inter-organism
transmission of pathology and by the ability to survive freely in the environment (Aguzzi
and Rajendran, 2009). To date, there exists no evidence that this definition can be applied
to proteins other than PrP and serum amyloidosis A protein (Solomon et al., 2007). This
restrictive definition, based on early research into prion diseases such as kuru and scrapie,
potentially ignores a rich biology that mechanistically unites many common diseases.
Importantly, we now know that the vast majority of human prion diseases have noninfectious etiology, and that their great phenotypic heterogeneity can be attributed to
strains (Collinge and Clarke, 2007). With respect to prion-like intracellular amyloids in
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humans, recent data indicate that homogenates from distinct tauopathies may reproduce
certain pathological features of the diseases in transgenic mice, which is consistent with
strain behavior (Clavaguera et al., 2013a). Other studies explicitly suggest the existence
of α-synuclein strains, based on the production of different a-synuclein conformers in
vitro (Bousset et al., 2013; Guo et al., 2013; Sacino et al., 2013). However, to account for
phenotypic diversity at a systems level, a prion strain must replicate with remarkable
reliability for extended periods of time. A stringent test of this is to ensure that the strain
is stable, isolatable, and replicates its phenotype through living systems with high fidelity
(Bruce et al., 1994; Prusiner, 1998). Until now, these characteristics have not been linked
to a mammalian protein other than PrP. Based on these criteria, our data strongly suggest
that tau should be considered a bona fide prion. Fittingly, we also find that different
tauopathies are associated with different strains. This has direct implications for
understanding the phenotypic diversity of tauopathies.

Tau as a prion in cell culture and mice. We began this work by establishing a
monoclonal HEK293 cell line that stably expresses the tau repeat domain fused to YFP.
In the absence of tau aggregate exposure, these cells propagate only tau RD monomer
(“naïve” cells). Induction of aggregation with recombinant fibrils, however, created
clonal lines (Clone 9 and Clone 10) that indefinitely propagate unique aggregate
structures, or strains, from mother to daughter cells. These strains differ with respect to
inclusion morphology, aggregate size, sedimentation profile, seeding capacity, protease
digestion patterns, toxicity, and subcellular localization. Importantly, these properties are
cell-independent, as we re-created the strains by protein transfer into naïve cells.
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Furthermore, the distinct inclusion morphologies we observed may represent specific
cellular responses to different aggregate conformations, consistent with their unique
patterns of compartmentalization. The cell culture system established here may thus
prove useful to detect, propagate and characterize additional tau prion strains, as well as
to understand the cellular mechanisms that govern strain replication, subcellular
localization, degradation, and toxicity.
In vivo, we found that strains 9 and 10 induce unique pathological phenotypes in
transgenic P301S mice. Moreover, Clone 10 lysate uniquely results in the formation of
rod-shaped microglia, which indicates that distinct tau conformers initiate different
physiological responses in vivo. More remarkably, we report that the morphological
phenotypes breed true through multiple generations of mice, the first time this has been
observed for an amyloid other than PrP. We recognize that pathological phenotypes can
be prone to bias in detection. Thus, we passaged strains back to naïve tau RD-YFP cells,
conclusively demonstrating the robust inheritance of tau conformations. This data also
indicates that the repeat domain is sufficient to encode strains that are unaltered by
templating of their structure to FL tau. Therefore, the reported cell model is useful for
detecting and propagating physiologically relevant tau prion strains. Finally, using
unilateral inoculation of Clone 9 lysate, we show that tau aggregation propagates along
known anatomical connections, supporting conclusions of previous studies (de Calignon
et al., 2012; Iba et al., 2013; Liu et al., 2012). More importantly, however, these cellular
and in vivo studies indicate for the first time that a mammalian protein amyloid other than
PrP templates itself with high fidelity through living systems.
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Tau prion strains in human tauopathy brains. Knowing that tau acts as a prion in
experimental models, we examined whether this concept could explain phenotypic
diversity observed in tauopathies. Brain samples from three patients with distinctive
tauopathies induced diverse self-propagating tau prion strains in culture. Our initial work
with these novel strains indicated that inclusion morphology is a reliable surrogate for
more labor-intensive biochemical characterization. This led us to assess the
morphological phenotypes of tau strains derived from numerous patients (n=29) across a
spectrum of tauopathies (AD, AGD, CBD, PiD, PSP). Each of the diseases was
associated with several cellular inclusion morphologies, although certain diseases (AD,
CBD, PiD) are more homogeneous than others (PSP, AGD). It is noteworthy that AD
pathology is characteristically more uniform than other tauopathies (Duyckaerts et al.,
2009; Feany et al., 1996), and the tau strains isolated from AD brains were by far the
most homogeneous. The isolation of multiple conformers from individuals suggests that a
tau aggregate ensemble exists within each person, and that standard methodologies (e.g.
histopathology, inoculation into mice, protease digestion) will be insufficient for a
nuanced understanding of this conformational complexity. Similar to what has been
reported for PrP amyloids (Collinge and Clarke, 2007; Li et al., 2010) and virus
quasispecies (Eigen, 1996), we speculate that these clouds of tau conformers are prone to
selective pressures at the cellular level, which may have implications for therapies that
target extracellular tau (Holmes et al., 2013a; Yanamandra et al., 2013).
Although we have now succeeded in categorizing multiple distinct strains, the cell-based
isolation method can only detect those that successfully template to tau RD-YFP and
propagate without overt cellular toxicity. The inability to re-select Clone 9 derivatives in
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the Tet-Off background illustrates this problem. On the other extreme, strains that do not
propagate with high fidelity may be lost prior to clonal selection. For example, the strains
present in several AGD and PiD samples were not stable in cell culture, making detailed
characterization of these strains difficult using our model system. Furthermore, it is likely
that seeding barriers between tau from patient brain (consisting of various tau isoforms
and post-translationally modified species) and tau RD in cell culture limits the strains we
can detect. Our observation of an asymmetric seeding barrier between P301 mutants and
WT tau underscores this limitation, as does recent work indicating similar barriers
between three-repeat (3R) and four-repeat (4R) tau (Dinkel et al., 2011). Despite some
limitations, the model system presented here has many advantages over standard animal
inoculations, as it is less resource-intensive and can parse multiple conformations from a
single isolate. Finally, knowledge of the existence of multiple strains in vivo may allow
us to characterize them on molecular terms and diagnose patients with much greater
precision, possibly by determining structures and conformational epitopes specific to
individual diseases. This could help facilitate therapeutic strategies tailored toward the
underlying protein pathology.
Expanding the spectrum of prion diseases. Our data, along with cell culture (Holmes
and Diamond, 2012), pathological (Clavaguera et al., 2013b) and imaging (Greicius and
Kimmel, 2012) studies are consistent with the model of cell-cell “transmission” of
neurodegenerative diseases throughout the nervous system. Our finding of multiple selfpropagating conformations in experimental and patient-derived tau preparations suggests
that tau should be defined as a prion, because it encodes self-catalyzing conformational
information that it propagates indefinitely with high fidelity. Importantly, however, there
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is no evidence to suggest that AD or other tauopathies are infectious in the classical
sense, as they are not known to be communicable between individuals. The infectious
property of PrPSc might reflect its anomalous biochemical stability or expression profile,
whereas a host of other cell biological and biophysical properties, especially the ability to
encode self-propagating conformers, will more appropriately unify the growing family of
“prion-like” proteins. Indeed, the vast majority (>95%) of human prion diseases appear to
be genetic or sporadic, indicating that infectivity should not be a restrictive criterion. We
predict that strains associated with distinct clinical phenotypes will also be identified for
synucleinopathies and ALS/FTLD spectrum disorders, both of which feature diversity in
pathological presentation (Halliday et al., 2011; Van Langenhove et al., 2012).
Understanding disparate amyloid neurodegenerative diseases in light of this model should
create new possibilities for common diagnostic and therapeutic approaches.
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2.7

FIGURES

Figure 2.1. Homotypic seeding produces stably propagated tau RD inclusions. (A)
Polyclonal HEK293 lines stably expressing YFP-tagged tau RD, α-synuclein, or htt
exon1(Q25) were transduced with buffer, or fibrils of Ab, Htt, α-syn, or tau RD. Cells
were DAPI-stained on Day 6. Only homotypic seeding occurred. (B) Polyclonal HEK293
lines stably expressing tau RD-YFP with no mutations (WT), ΔK280 (pro-aggregation),
ΔK280/I277P/I308P (2P; anti-aggregation), or P301L/V337M (LM; pro-aggregation)
were transduced with either buffer or tau RD fibrils. Upon fibril transduction, all form
inclusions, except for 2P. (C) Tau RD(LM)-YFP cells transduced with either buffer or
tau RD fibrils were passaged every two days. On every other passage, the percentage of
cells with inclusions was quantified (n=10 fields, each with 150+ cells per condition).
Inset highlights inclusion-positive cells at later time points. Error bars represent S.E.M.
(D) At Day 50 following exposure to fibrils, inclusion-positive cells were visible. (E-F)
At Day 3 following exposure to fibrils, tau RD(LM)-YFP cells were diluted sparsely on
coverslips and grown for 8 days. Colonies were either 100% inclusion-negative (E) or
100% inclusion-positive (F).

81

Tau Prion Strains in Cel

Transduced Fibrils

A

Aβ

αSyn

Htt

Tau RD

Htt Q25-YFP
αSyn-YFP

Stable Cell Line

Tau RD-YFP

Buffer

B

∆K280

LM

Buffer

2P

(A) Polyclonal HE
sing YFP-tagged t
exon1(Q25) were tra
of Ab, Htt, a-syn, o
stained on day 6
occurred. See Figure
Figure S1B for quant
S1D for similar homo
(FL) 4R1N tau P301S
(B) Polyclonal HEK
tau RD-YFP with
(proaggregation), D
aggregation), or P
gregation) were tran
tau RD fibrils. Upon
inclusions, except fo
(C) Tau RD(LM)-YFP
buffer or tau RD fibr
days. On every othe
cells with inclusions
each with 150+ cel
lights inclusion-posi
Error bars represent
(D) At day 50 follow
sion-positive cells w
(E and F) At day 3 fo
RD(LM)-YFP cells w
erslips and grown fo
100% inclusion-neg
positive (F).

Fibrils
% Cells with Inclusions

Transduced Reagent

WT

C

= Contains
Inclusions

Stable Tau RD-YFP Cell Line

Figure 1. Homot
Stably Propagated

40

10
8
6
4
2
0
20

30
20

400 nM Fibrils
Buffer

30

40

D

E

50

10
0

0

10
20
30
40
Days Post-Treatment

50

and Clarke,
Figure
2.1 2007). This is important not for semantic reasons, but
because if prion mechanisms underlie human disease, only stably propagating strains can account for stereotyped clinical presentation and network spread. In this study, we have found that
tau acts as a prion by these criteria, and, further, that individual
human tauopathies are associated with unique strains.
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Figure 2.2. Constructs and lack of cross-seeding. (A) Diagrams illustrating constructs
used in this study. (B) Quantification of seeding efficiency of fibril and cell line pairs.
Ten fields, each with 150+ cells, were quantified per condition. Percent positive averages
are followed by the S.E.M. (C) Polyclonal HEK293 lines stably expressing FL tau 4R1N
P301S (with or without YFP tag) were transduced with buffer, Ab, Htt, α-syn, or tau RD
fibrils. Cells were stained for phospho-tau (AT8) on Day 6. Only homotypic seeding was
observed. (D) Quantification of seeding efficiency of fibrils transduced into FL tau
P301S cell lines. Ten fields, each with 150+ cells, were quantified. Percent positive
averages are plotted. Error bars represent S.E.M.
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Figure 2.3. Generation of stably inherited tau RD prion strains. (A) A monoclonal
HEK293 line stably expressing tau RD(LM)-YFP (hereafter referred to as tau RD) was
transduced with tau RD fibrils. At Day 3, cells were diluted sparsely in a 10 cm dish. At
Day 12, inclusion-positive colonies were identified and picked, amplifying to confluency
in separate 10 cm dishes. At Day 30, cells were re-plated for confocal analysis or
harvested for subsequent experiments. (B) Confocal analysis of morphologically distinct
tau RD prion strains. Clone 1 does not contain inclusions. Clone 9 contains nuclear
speckles and a small juxtanuclear inclusion. Clone 10 features one very large
juxtanuclear inclusion and no nuclear speckles. (C) Clones 1, 9 and 10 were stained with
X-34, an amyloid dye. X-34 staining is only observed in Clone 9 and Clone 10, indicating
that the propagated aggregates are amyloids. (D) SDD-AGE demonstrates that Clone 10
features larger aggregates than Clone 9. (E) Sedimentation analysis was performed on
Clones 1, 9, and 10. Pellet (P) was isolated from supernatant (S) by ultracentrifugation.
For Clones 9 and 10, supernatant was loaded at a 3:1 ratio to pellet and total (T) to allow
clear detection; Clone 1, a 1:1 ratio. Clone 1 has all tau RD in the supernatant, whereas
Clone 9 has almost all tau RD in the pellet. Clone 10 has mixed solubility. (F) Limited
proteolysis (pronase) digests all tau RD in Clone 1, but reveals protease-resistant tau RD
peptides between 10 and 13 kDa as well as between 20 and 25 kDa in Clone 9 and 10.
Unlike Clone 9, Clone 10 digestion produces a doublet, consistent with a distinct
conformation. (G) A split-luciferase assay reports differential seeding efficiency of tau
RD prion strains. A polyclonal HEK293 line expressing both tau RD-CLuc and tau RDNluc was transduced with lysate from the three clones. Clone 1 does not seed
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aggregation. Clone 9 seeds robustly, whereas Clone 10 seeds significantly less. Averages
of four separate experiments are shown, each read in quadruplicate 48 hours posttransduction (error bars = S.E.M, * = p<0.05, **** = p<0.0001). (H) Inclusion
elimination rates differ between clones. After transduction with lysate from Clone 9 or
10, the percentage of cells containing inclusions was quantified on days 4, 17, and 30
(n=10 fields, each with 150+ cells per condition). Cells with inclusions derived from
Clone 9 are eliminated more rapidly from the population. Error bars = S.E.M, **** =
p<0.0001. (I) Clone 9-transduced cells grow more slowly. After transduction of stable
cells, colonies with inclusions derived from Clone 9 have fewer cells than colonies with
inclusions derived from Clone 10. Colonies without inclusions have identical cell
numbers (error bars = S.E.M, **** = p<0.0001). (J) Clones 1, 9, and 10 maintain
distinctive morphologies after 6 months in culture. (K) Structural characteristics (limited
proteolysis digestion patterns) of strains are propagated with high fidelity over six
months.
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Figure 2. Generation of Stably Inherited Tau RD Prion Strains
(A) A monoclonal HEK293 line stably expressing tau RD(LM)-YFP (hereafter referred to as tau RD) was transduced with tau RD fibrils. At day 3, cells were diluted
sparsely in a 10 cm dish. At day 12, inclusion-positive colonies were identified and picked, amplifying to confluency in separate 10 cm dishes. At day 30, cells were
replated for confocal analysis or harvested for subsequent experiments.
(B) Confocal analysis of morphologically distinct tau RD prion strains. Clone 1 does not contain inclusions. Clone 9 contains nuclear speckles and a small
juxtanuclear inclusion. Clone 10 features one very large juxtanuclear inclusion and no nuclear speckles. See Figure S2A for other clones.
(C) Clones 1, 9, and 10 were stained with X-34, an amyloid dye. X-34 staining is only observed in clone 9 and clone 10, indicating that the propagated aggregates
are amyloids.
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Figure 2.4. Morphologies of all clones and strain-specific properties of Clones 9 and
10. (A) Confocal images of representative cells from all 20 clones. Nuclear aggregates
are present in all clones except Clone 1 (no inclusions) and Clone 10 (one large
juxtanuclear inclusion with no nuclear inclusions). (B) Normalization of luminescence
based on Hoechst stain reveals that differences in seeding ratios between Clones 9 and 10
are not due to differences in cell confluency (error bars = S.E.M). (C) Lysates were
transduced into either non-transfected (NT) cells or those stably expressing tau RD(LM)HA. Clone 1 and 10 lysate do not affect cell numbers as measured by Hoechst stain at
Day 4. However, Clone 9 lysate significantly reduces the number of cells in the tau
RD(LM)-HA background, revealing that Clone 9’s toxicity is dependent on expression of
tau RD(LM) (error bars = S.E.M, **** = p<0.0001). (D) Tau RD(LM)-HA cells were
transduced with lysates from Clones 1, 9, and 10. LDH levels in the media were
measured at Day 4 and compared to those of lysed cells (toxic control). Clone 9 is
especially toxic relative to sham-treated cells (error bars = S.E.M, ** = p<0.01). (E)
Clones 9 and 10 were stained for vimentin, which forms a cage around aggresomes.
Vimentin cages are observed around the large juxtanuclear inclusion of Clone 10 cells
but not around the inclusion of Clone 9, indicating the Clone 10 aggregates form
canonical aggresomes, whereas Clone 9 inclusions do not. (F) Transmission electron
microscopic analysis of Clone 10 cells reveals large aggresome structures indenting the
nuclear envelope. Clone 9 cells feature small, round, nuclear inclusions. Immuno-EM
confirms that both types of inclusions contain tau RD. (G) Co-localization of
juxtanuclear Clone 10 but not Clone 9 inclusions with γ-tubulin, a marker of the
microtubule-organizing center (MTOC), suggests that only the former are true
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aggresomes. Arrowheads point to juxtanuclear tau RD inclusions, whereas arrows point
to MTOCs. (H) Staining of nuclear PML bodies, organizing centers for degradation of
nuclear aggregates, demonstrates that Clone 9 nuclear inclusions are in a unique
compartment.
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Figure 2.5. Tau RD aggregates transfer strain conformations into naïve cells. (A)
Lysates from Clones 9 and 10 were transduced into naïve tau RD-YFP cells and
monoclonal inclusion-containing cells were isolated and amplified. Six secondary clones
were generated for each condition, but one (Clone 9C) failed to amplify. (B)
Morphologies of primary clones are maintained in secondary cell lines. (C) SDD-AGE of
lysates from both primary and secondary clones demonstrates similar aggregate sizes in
secondary clones relative to the primary ones. A line separates gels run separately. (D)
Sedimentation analysis was performed. Secondary clones feature similar sedimentation
patterns to the clones from which they were derived. (E) Split-luciferase
complementation demonstrates similar seeding efficiencies in secondary lines vs. parental
lines. Averages of four separate experiments are shown, each read in quadruplicate 48hours post-transduction of lysate (error bars = S.E.M, **** = p<0.0001). (F) Limited
proteolysis shows that all Clone 10 derivatives feature a doublet whereas Clone 9
derivatives are associated with an unresolvable band between 10 and 13 kDa. Clone 9
derivatives feature a more resistant band between 20 and 25 kDa. (G) Lysates from
Clones 9 and 10, but not Clone 1, induce detergent-resistant FL tau P301S-YFP species,
which co-localize with AT8 (red) in primary cortical neurons. Clone 9 induces tangle-like
structures throughout the soma and neuritic processes. Clone 10 primarily seeds punctatelike structures in the soma. (H) Clone 9 and Clone 10 lysates containing tau
RD(P301L/V337M)-YFP, do not seed inclusion formation in neurons expressing WT FL
tau.
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Figure 3. Tau RD Aggregates Transfer Strain Conformations into Naive Cells
(A) Lysates from clones 9 and 10 were transduced into naive tau RD-YFP cells and monoclonal inclusion-containing cells were isolated and amplified. Six
secondary clones were generated for each condition, but one (clone 9C) failed to amplify.
(B) Morphologies of primary clones are maintained in secondary cell lines. See also Figure S3A, which demonstrates that this templating of morphology is not
dependent on liposome-mediated transduction of lysate.
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Figure 2.6. Templating in absence of liposomes, reversibility of aggregated
phenotype, and seeding barriers between tau with different point mutations. (A) Tau
RD prion strains template themselves into the inside of the cell without the use of
liposomes. 30 µg of clarified Clone 9 and Clone 10 lysate were passively added to
separate populations of naïve tau RD-YFP cells. Three monoclonal cell lines were
isolated for each. Morphologies of primary clones were recapitulated in these lines (P =
passive origin). (B) Three blots were used to construct panels in Figure 2.5D (T=total,
S=supernatant, P=pellet). (C) Clone 10 was transduced into a new monoclonal Tet Offtau RD-YFP HEK293 cell line, and monoclonal derivatives were isolated as described in
Figure 2.5A. Tau RD expression was turned off for the indicated period of time
(T=days), prior to re-plating in normal media for 48 hours. (D) Quantification of
inclusion clearance (n=10 fields, each with 150+ cells, per time point). Repression of tau
RD-YFP transcription for 7 days is required to revert all cells to the soluble state (error
bars represent S.E.M.). (E) Zoomed-out views of fixed and Triton X-extracted primary
neurons expressing either FL tau P301S-YFP or FL tau WT-YFP reveal that tau RD
strains seed mutant but not WT tau aggregation (green=YFP, red=AT8). Furthermore,
Clone 9 seeds FL tau P301S more robustly than Clone 10, consistent with split-luciferase
complementation data (Figure 2.3G). (F) Clone 9 and 10 lysates seed the formation of
phosphorylated (AT8-positive, red), detergent-resistant, untagged FL tau P301S species
in primary neurons. Similar to FL tau P301S-YFP, Clone 10 inoculation results in
detergent-resistant species confined primarily to the soma; Clone 9, throughout the
neuron. (G) Clone 9 lysate induces tangle-like insoluble tau inclusions in neuritic
processes of both neurons expressing YFP-tagged and untagged versions of FL tau
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P301S. These structures are much less common in Clone 10-inoculated neurons (data not
shown). (H) Polyclonal HEK293 lines expressing different pairs of split-luciferase-tagged
tau RD mutants were generated and transduced with lysate from Clones 1, 9, or 10; 1 µM
recombinant tau RD fibrils; or 50 µg brain homogenate from aged tau P301S transgenic
mice. Whereas all treatments besides Clone 1 seed tau RD featuring P301L, P301S, or
P301L/V337M (“LM”) mutations, only recombinant tau RD WT fibrils seed tau RD WT.
This demonstrates that there is an asymmetric seeding barrier between tau containing and
lacking P301 mutations. No treatment seeds tau RD 2P, consistent with this mutant’s
inability to form beta-sheet structure and amyloids. Averages of four separate
experiments are shown, each read in quadruplicate 48-hours post-transduction of lysate
(error bars = S.E.M).
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Figure 2.7. Clone 9 and 10 induce unique tau and microglia pathology in P301S
mice. (A) Lysates (10 µg total protein) were injected bilaterally into the hippocampi of 3month P301S and wild-type (WT) mice. 21 days post-injection, left hemispheres were
collected for histology; right hemispheres for homogenization. (B) Recombinant tau RD
fibrils (RF) induce tangle-like, AT8-positive tau pathology near the injection site in CA1
(scale bars: hippocampus – 1 mm; inset – 100 µm). (C) Quantification of tangle-like,
AT8-positive cell bodies within the hippocampus (CA1 and CA3) of WT and P301S
mice. P301S mice injected with Clone 9 lysate have significantly more AT8-positive cell
bodies than those injected with Clone 1, Clone 10, or RF (error bars = S.E.M., * =
p<0.05, ** = p<0.01). WT mice do not develop pathology after injection. (D) P301S mice
were inoculated with Clone 1, Clone 9, or Clone 10 lysate. Representative whole
hippocampus images are shown with the corresponding CA3 z-stacks. Arrowheads in
Clone 9 CA3 insets highlight an AT8-positive cell body that can be seen throughout both
z-stack images. The arrow and arrowhead in Clone 10 CA3 insets each represent a
different AT8-positive puncta that is visible in only one z-stack plane (scale bars:
hippocampus – 1 mm; CA3 – 100 µm; CA3 inset and AT8 IF – 25 µm; n=3-4 per clone).
(E) Iba1 staining of microglia in CA1 of inoculated P301S mice indicates that only Clone
10 induces the formation of rod microglia, which extend highly polarized processes into
CA1.
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(A) Lysates (10 mg total protein) were injected bilaterally into the hippocampi of 3 month P301S and WT mice. At 21 days postinjection, left hemispheres were
collected for histology and right hemispheres for homogenization. See Table S1 for description of mice used in all experiments.
(B) Recombinant tau RD fibrils (RF) induce tangle-like, AT8-positive tau pathology near the injection site in CA1 (scale bars represent hippocampus – 1 mm and
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Figure 2.8. Tau RD prion strains induce distinct pathologies in transgenic P301S but
not WT mice. (A) Inoculated P301S mice were stained for conformationally-altered tau
(MC1) or amyloid (X-34). MC1 staining corroborates morphologies of AT8-positive
structures. Strong X-34 positivity is only seen in Clone 9-inoculated mice, although weak
signal is seen in the CA1 region of Clone 10-inoculated animals. (B) WT littermates were
injected with Clone 1, Clone 9, or Clone 10 lysate. No induced AT8-positive pathology
was evident. Representative examples are shown. (C) Rod microglia, which are exclusive
to Clone 10-inoculated P301S mice, form columns perpendicular to the cell layer of CA1.
(D) Rod microglia are absent in all cohorts of inoculated WT mice, indicating that their
formation is dependent on seeding of intracellular FL tau P301S by Clone 10 aggregates.
(E) Amounts of insoluble Clone 9 and Clone 10 tau RD do not differ significantly
(densitometric quantification, n=4 measurements, error bars = S.E.M.). (F) Total tau RD
does not differ between the three cell lines used to inoculate mice (densitometric
quantification, n=4 measurements, error bars = S.E.M.).
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Figure 2.9. Tau strains passage stably through multiple generations of P301S mice.
(A) Lysates (10 µg protein) were injected bilaterally into the hippocampi of 3-month
P301S mice (Generation 0/G0). 21 days post-injection, brains were collected for
histology and homogenization. Hippocampal homogenate (10 µg) was then bilaterally
inoculated into a new round of 3-month P301S mice (Generation 1/G1) followed by a 28day incubation before the process was repeated for a new cohort of 3-month P301S mice
(Generation 2/G2). At G0 and G2, hippocampal homogenates were IPed (anti-tau 8.5;
epitope = aa 25-30; outside RD region) and inoculated into the original tau RD-YFP line
to test the fidelity of strain inheritance (G0 and G2 clones). For each cohort, n=3-4
animals. (B-C) AT8 staining (DAB = B and immunofluorescence = C) reveals that the
morphological phenotypes of phosphorylated tau inclusions breed true through multiple
generations of tau P301S mice.

100

Neuron
Tau Prion Strains in Cells, Mice, and Patients

A

21 days

Original clones

28 days

Generation 0

28 days

Generation 1

Generation 2

P301S Clone 9

P301S Clone 10

C

P301S Clone 9

P301S Clone 10

CA3

CA3

CA1

CA1

P301S Clone 1

Secondary Clones

Generation 0

Generation 0
B

IP

Generation 1

Generation 1
P301S Clone 9

P301S Clone 10

P301S Clone 9

P301S Clone 10

CA3

CA3

CA1

CA1

P301S Clone 1

Generation 2

Generation 2
P301S Clone 9

P301S Clone 10

P301S Clone 9

P301S Clone 10

CA3

CA3

CA1

CA1

P301S Clone 1

Figure 5. Tau Strains Passage Stably through Multiple Generations of P301S Mice
(A) Lysates (10 mg protein) were injected bilaterally into the hippocampi of 3-month-old P301S mice (Generation 0/G0). At 21 days postinjection, brains were
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Figure 2.10. Whole hippocampi used to generate images in Figure 2.9 and
elimination of seeding following passage through non-transgenic mice. (A) Images of
whole hippocampi for representative mice inoculated with indicated
lysates/homogenates. Boxes indicate regions that were highlighted in Figure 2.9. (B)
AT8 immunofluorescence of CA1 and CA3 regions for serial inoculation of Clone 1. (C)
Residual tau RD-YFP seeds do not account for passage of strain phenotypes through
multiple generations of mice as inoculated WT mice (Generation 0), which do not form
insoluble FL tau, do not seed pathology when passaged into Generation 1 P301S mice.
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CA3

Figure 2.11. Strains transfer faithfully to cell culture after passage through
Generation 0 and Generation 2 mice. (A) IPed material was transduced into tau RDYFP cells prior to passage onto coverslips. At 96 hours, cells were fixed. Only Clone 9-,
Clone 10-, and RF-inoculated mice seed inclusions robustly. WT mouse homogenates
never seed aggregation. Ten fields, each with 100+ cells, were analyzed per brain, and
averages were collapsed within cohorts (error bars = S.E.M., **** = p<0.0001). (B)
Inclusion morphologies are maintained following passage through P301S mice (G0).
IPed FL tau from individual P301S mice inoculated with Clone 9 or Clone 10 was
transduced into tau RD-YFP cells, and a single representative clone per mouse was
isolated and amplified. All G0-derived clones continue to propagate the original
phenotypes. (C) Limited proteolysis reveals that G0 clones feature similar banding
patterns to the original parental lines, with G0-Clone 10 featuring a doublet between 1013 kDa (vs. smear for G0-Clone 9) and a band between 20 and 25 kDa that is slightly
smaller than G0-Clone 9 bands. (D) Split-luciferase complementation demonstrates
similar seeding efficiencies in G0 clones relative to original parental lines. Averages of
four separate experiments are shown, each read in quadruplicate 48-hours posttransduction of lysate (error bars = S.E.M, **** = p<0.0001). (E) IPed material from
pooled G2 mice was transduced into naïve tau RD-YFP cells prior to passage onto
coverslips. At 96 hours, cells were fixed. Seeding of inclusion formation is significantly
greater for G2-Clone 9 and G2-Clone 10 mice than G2-Clone 1 mice. G2-Clone 1 tau
induces inclusions on rare occasions (~1% of cells). Seeding is specific to tau as IgGprecipitated material never seeds. Ten fields, each with 150+ cells, were analyzed per
condition (error bars = S.E.M., * = p<0.05, **** = p<0.0001). (F) Inclusion
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morphologies are maintained following passage through three generations of mice. IPed
full-length tau from pooled G2 homogenates was transduced into tau RD-YFP cells, and
12 clones per cohort were isolated. Representative examples are shown. The two clones
boxed in red feature similar limited proteolysis digestion patterns and seeding ratios to
each other, which are unique from all 22 other clones. (G) Limited proteolysis reveals
that G2 clones feature similar banding patterns to their parental lines, with G2-Clone 10
featuring a doublet between 10-13 kDa (vs. smear for G2-Clone 9) and a band between
20 and 25 kDa that is slightly smaller than G2-Clone 9 digests. Two clones (boxed in
red), one for each cohort, are unique in featuring bands at 15 and 25 kDa. (H) Splitluciferase complementation demonstrates similar seeding efficiencies in G2 clones
relative to original parental lines. Seeding ratios were averaged across clones, each of
which was read in quadruplicate 48-hours post-transduction of lysate (error bars = S.E.M,
**** = p<0.0001). Boxed in red are two outlier clones (9G and 10D), which also feature
unique inclusion morphologies and limited proteolysis digestion patterns.
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Figure 6. Strains Transfer Faithfully to Cell Culture after Passage through Generation 0 and Generation 2 Mice
(A) IP material was transduced into tau RD-YFP cells prior to passage onto coverslips. At 96 hr, cells were fixed. Only clone 9-, clone 10-, and RF-inoculated mice
seed inclusions robustly. WT mouse homogenates never seed aggregation. Ten fields, each with 100+ cells, were analyzed per brain, and averages were
collapsed within cohorts (error bars represent SEM, **** = p < 0.0001). See also Figure S6A for split-luciferase complementation data.
(B) Inclusion morphologies are maintained following passage through P301S mice (G0). IP FL tau from individual P301S mice inoculated with clone 9 or clone 10
was transduced into tau RD-YFP cells, and a single representative clone per mouse was isolated and amplified. All G0-derived clones continue to propagate
the original phenotypes. See also Figures S6B and S6C for quantification of colony morphologies prior to monoclonal cell line isolation and Figure S6D for
quantification of total IP tau used in G0 experiments.
(legend continued on next page)
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Figure 2.12. Strain phenotypes are maintained in cell culture following passage
through Generation 0 and Generation 2 mice. (A) Clone 9-inoculated hippocampi
(G0) seed robustly relative to other homogenates based on split-luciferase
complementation. FL tau was IPed from micro-dissected tau P301S and WT hippocampi
inoculated 21 days prior with indicated cell lysate. IPed material from 60 µg total brain
homogenate was transduced into split-luciferase cells, following the protocol outlined in
Figure 2.3G. Four separate experiments were performed for each sample, each read in
quadruplicate 48-hours post-transduction of lysate. Luminescence values were averaged
within mouse cohorts (error bars = S.E.M, **** = p<0.0001). (B) Inclusion morphologies
are maintained following passage through P301S mice. IPed FL tau from P301S mice
inoculated with Clone 9 or Clone 10 was transduced into tau RD-YFP cells in a 12-well
plate. 24 hours later, cells were re-plated into a 6-well plate. At confluency, cells were
sparsely plated on coverslips and were given 8 days to amplify into discrete colonies.
Colonies with inclusions were imaged. Representative examples are shown. Monoclonal
strains were also isolated and examined with additional assays (see Figure 2.11B-D). (C)
Quantification of inclusion morphologies following passage through P301S mice.
Inclusion-positive colonies were scored as either containing or lacking nuclear inclusions.
20+ colonies were scored per mouse, and percentage of each phenotype was calculated.
These values were averaged within cohorts (error bars = S.E.M., **** = p<0.0001). (D)
Quantification of total tau IPed from G0 mice inoculated with indicated cell lysates
(densitometric quantification, n=4 measurements, error bars = S.E.M., * = p<0.05). (E)
Split-luciferase complementation reveals that IPed tau from G2 brain seeds similarly to
crude homogenate. IPed material from 60 µg brain homogenate or 60 µg crude
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homogenate was transduced into split-luciferase cells, following the protocol outlined in
Figure 2.3G. Four separate experiments were performed for each sample, each read in
quadruplicate 48-hours post-transduction of lysate (error bars = S.E.M). (F)
Quantification of inclusion morphologies following passage from G2 mice. Inclusionpositive colonies were scored as either containing or lacking nuclear inclusions. Ten
coverslips, each with 15+ inclusion-positive colonies per, were scored and averaged
(error bars = S.E.M., **** = p<0.0001, Student’s t-test). Representative colonies are
shown along with a rare instance of an inclusion-positive G2-Clone 1 colony.
Monoclonal strains were also isolated and examined with additional assays (see Figure
2.11F-H). (G) Confocal images of all 24 F2 colonies (G2-Clone 9 = 12, G2-Clone 10 =
12). All feature the same colony morphology as their parental counterpart, with the
exception of 10D, which features nuclear speckles. Red boxes surround images of strains
that feature a unique limited proteolysis digestion pattern and seeding ratio.
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Figure 2.13. Anterograde and retrograde spread of pathology to synaptically
connected regions in Generation 3-Clone 9 (G3-Clone 9) mice. (A) Schematic of
known projections to and from the hippocampus (DG = dentate gyrus; MEC/LEC =
medial and lateral entorhinal cortices; MF = mossy fibers; RSp = retrosplenial cortex;
Sub = subiculum). (B) Representative images of AT8 staining in the hippocampi of G3
mice inoculated with 10 µg of G2 brain homogenate. Spread of Clone 9 pathology to the
contralateral hippocampus is evident. (C) Summary of pathology present in G3-Clone 9
mice. Gradient represents semi-quantitative analysis of neurofibrillary tangle-like AT8
cell body positivity observed in each region (PPA = posterior parietal association area)
both 2.5 and 3.0 mm posterior to bregma. (D) AT8 histopathology observed in brain
regions with known projections to/from the hippocampus. Ipsilateral AT8 pathology is
observed in the EC and appears in cortical layers II-III, whereas contralateral pathology is
observed in deeper layers of the EC. Pathology is also observed in the retrosplenial
cortex, especially ipsilateral to the injection site.
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Figure 7. Anterograde and Retrograde Spread of Pathology to Synaptically Connected Regions in Generation 3-clone 9 Mice
(A) Schematic of known projections to and from the hippocampus (DG, dentate gyrus; MEC/LEC, medial and lateral entorhinal cortices; MF, mossy fibers; RSp,
retrosplenial cortex; Sub, subiculum).
(B) Representative images of AT8 staining in the hippocampi of G3 mice inoculated with 10 mg of G2 brain homogenate. Spread of clone 9 pathology to the
contralateral hippocampus is evident. See Figure S7A for whole brain slices.
(C) Summary of pathology present in G3-clone 9 mice. Gradient represents semiquantitative analysis of neurofibrillary tangle-like AT8 cell body positivity
observed in each region (PPA, posterior parietal association area) both 2.5 and 3.0 mm posterior to bregma.
(D) AT8 histopathology observed in brain regions with known projections to and from the hippocampus. Ipsilateral AT8 pathology is observed in the EC and
appears in cortical layers II-III, whereas contralateral pathology is observed in deeper layers of the EC. Pathology is also observed in the retrosplenial cortex,
especially ipsilateral to the injection site. See Figure S7B for subiculum and dentate gyrus images.
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Figure 2.14. Whole brain slices used in Figure 2.13 and additional sites of spread.
(A) Representative images of whole G3 brain slices stained with AT8. Black boxes
indicate position of representative images found in Figure 2.13D. (B) Representative
images of the subiculum and dentate gyrus (ipsilateral) of G3-Clone 1 and G3-Clone 9
mice.
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Figure 2.15. Diverse tau prion strains within patients and across diseases. (A)
Schematic illustrating methods used to generate patient-derived tau RD prion strains in a
monoclonal Tet Off-tau RD-YFP line. (B) Morphological phenotypes associated with tau
RD prion strains induced by patient material: no seeding, toxic, mosaic, ordered,
disordered, speckles. Representative examples are shown. (C) IPed tau from 29 patient
samples (AD = Alzheimer’s disease, AGD = argyrophilic grain disease, CBD =
corticobasal degeneration, PiD = Pick’s disease, PSP = progressive supranuclear palsy)
was transduced into tau RD-YFP cells (Tet Off) and as many inclusion-positive clones as
could be identified for each patient sample were blindly picked and amplified. Once
confluent in 10 cm dishes, morphological phenotypes were scored by a separate blinded
experimenter.
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Figure 8. Diverse Tau Prion Strains within Patients and across Diseases
(A) Schematic illustrating methods used to generate patient-derived tau RD prion strains in a monoclonal Tet Off-tau RD-YFP line. See Figure S8 for data
indicating that different inclusion morphologies are associated with different biochemical and seeding properties.
(B) Morphological phenotypes associated with tau RD prion strains induced by patient material: no seeding, toxic, mosaic, ordered, disordered, speckles.
Representative examples are shown.
(C) IP tau from 29 patient samples (AD, Alzheimer’s disease; AGD, argyrophilic grain disease; CBD, corticobasal degeneration; PiD, Pick’s disease; PSP, progressive supranuclear palsy) was transduced into tau RD-YFP cells (Tet Off) and as many inclusion-positive clones as could be identified for each patient sample
were blindly picked and amplified. Once confluent in 10 cm dishes, morphological phenotypes were scored by a separate blinded experimenter. See Table S2 for
numerical values, patient-related information, and tissue origin.
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as previously described (see SDD-AGE) and protein concentrations were
normalized to 1.7 mg/mL. 17 mg (10 mL) of cell lysate was added to 10 ml
of pronase at a concentration of 100 mg/mL (diluted in PBS) for a final
volume of 20 mL. Cell lysates were digested at 37! C for one hour. Reactions
were quenched by addition of 20 ml 23 sample buffer (final SDS concentration of 1%) and boiling for 5 min. Each sample (15 ml) was run on a
10% Bis-Tris NuPAGE gel (Novex by Life Technologies) and protein was
transferred to Immobilin P (Millipore). Membranes were probed for tau
as described above. For more details, see Supplemental Experimental
Procedures.
Animals and Hippocampal Injections
Transgenic mice expressing FL human tau 4R1N P301S under the murine
prion promoter (Yoshiyama et al., 2007) were maintained on a B6C3 background. P301S and nontransgenic littermates were anesthetized with isoflurane and were bilaterally injected into the hippocampus (from bregma:
"2.5 mm posterior, ±2 mm lateral, "1.8 mm ventral) with either 2 ml of

5 mg/mL clarified lysate/homogenate or 2 ml of 2.5 mg/mL recombinant tau
RD fibrils as previously described (DeVos and Miller, 2013). For all experiments, conditions were gender-matched (Table S1). Unilateral injections
were used for G3 spread experiments. All protocols involving animal use
were approved by the institutional animal care and use committee at Washington University in St. Louis. For more details, see Supplemental Experimental Procedures.
Histology and Immunohistochemistry
Sections (50 mm) were taken through the entire left hemisphere with a freezing
microtome. For DAB stains, brain slices were incubated with indicated antibodies overnight at 4! C. Slices were then counter-stained with the appropriate
secondary. Slices were then incubated at room temperature for 30 min with the
VECTASTAIN Elite ABC Kit (Vector Labs), followed by DAB development with
the DAB Peroxidase Substrate Kit with the optional nickel addition (Vector
Labs). Histological images and z stacks were captured with the Olympus
Nanozoomer 2.0-HT (Hamamatsu) and analyzed with the NDP viewer software
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Figure 2.16. Detailed analysis of strains derived from three human samples. (A) 11
of 12 patient CBD clones isolated using both crude and IP induction (designated with a
red *) feature the same phenotype (a wispy, disordered juxtanuclear deposition). CBD-2
is unique in having nuclear speckles. (B) All isolated patient AGD clones lost the
aggregated state with time (arrow = inclusion-negative cells). Six representative clones
are shown (crude=5, IP=1). An additional 41 clones (crude=30, immunoprecipitation=11)
reverted to an inclusion-negative state at an early time point, thus having few cells with
inclusions to image at Day 40 (data not shown). All sectoring colonies feature enormous
juxtanuclear inclusions with occasional tangle-like aggregates (arrowhead). (C) All 3
Clone 10-derived lines in the Tet Off background feature large, juxtanuclear inclusions.
(D) All 12 patient AD clones (8=crude, 4=IP) feature numerous speckles, both
cytoplasmic and nuclear. (E) Sedimentation analysis was performed on three
representative clones for each patient and average supernatant to total ratios (Sup/Total)
were calculated for each using densitometric analysis (n=3 for each clone except Clone 1,
n=6). CBD clones contain significantly more material in the pellet than AD clones as
reflected by Sup/Total values averaged across clones (lower panel) (error bars represent
S.E.M, * = p<0.05). (F) Representative AD clones seed significantly more than CBD
clones. Averages of four separate experiments are shown, each read in quadruplicate 48hours post-transduction of lysate. Seeding values were then averaged across clones
(lower panel) (error bars = S.E.M, *** = p<0.001). (G) Lysates derived from all CBD
and AD clones were separately transduced into the split-luciferase aggregation-sensor
cell line and luminescence was read 48 hours later. Relative luminescence averages for
all clones are shown, each measured in quadruplicate (error bars = S.E.M, **** =
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p<0.0001, Student’s t-test). (H) Pronase digestion (100 µg/mL) of lysates from
representative clones confirms that CBD, AD, and AGD clones are biochemically distinct
from each other. AD2 is more sensitive than other clones to pronase, which suggests that
its conformation might be slightly different than other AD clones. (I) Limited proteolysis
digestion patterns are not affected by amount of insoluble tau in the digested sample.
Various amounts of CBD-4 lysate were digested, spiking with non-transfected (NT) cell
lysate to maintain a constant level of protein. Regardless of the quantity of CBD-4 lysate,
all conditions feature a band around 8 kDa in size.
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Table S1, related to Figure 4,5,7 – Characteristics of mice used in all in vivo experiments

Figure 2.17. Mice used in study.

Generation 0
Mouse
2133
2152
2153
2135
2143
2150
2170
2136
2144
2151
2171
2137
2145
2164
2138
2163
2166
2167
2168
2134
2169

Genotype
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
WT
WT
WT
WT
WT
WT

Gender
m
f
f
m
m
f
f
m
m
f
f
m
m
m
f
m
m
m
f
m
f

Mouse
2535
2536
2537
2581
2580
2583
2584
2582
2558
2579-2
2985
2992
2993
2986
2991

Genotype
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S

Gender
f
f
f
f
f
f
f
f
f
f
f
f
f
f
f

Age (Days)
95
94
94
95
94
94
90
96
95
95
91
96
95
91
96
90
90
90
90
95
90

Generation 2
Condition
Clone 1
Clone 1
Clone 1
Clone 9
Clone 9
Clone 9
Clone 9
Clone 10
Clone 10
Clone 10
Clone 10
Recombinant fibrils
Recombinant fibrils
Recombinant fibrils
Recombinant fibrils
Clone 1
Clone 1
Clone 9
Clone 9
Clone 10
Clone 10

Genotype
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S
P301S

Gender
f
f
f
f
f
f
f
f
f
f
f

Age (Days)
61
61
55
61
61
48
51
61
61
48
51

Condition
P301S G1 Clone 1 BH
P301S G1 Clone 1 BH
P301S G1 Clone 1 BH
P301S G1 Clone 9 BH
P301S G1 Clone 9 BH
P301S G1 Clone 9 BH
P301S G1 Clone 9 BH
P301S G1 Clone 10 BH
P301S G1 Clone 10 BH
P301S G1 Clone 10 BH
P301S G1 Clone 10 BH

Mouse
3253
3209
3255
3212

(Unilateral inoculation)
Genotype Gender Age (Days) Condition
P301S
m
52
P301S G2 Clone 1 BH
P301S
f
56
P301S G2 Clone 1 BH
P301S
m
52
P301S G2 Clone 9 BH
P301S
f
56
P301S G2 Clone 9 BH

Generation 3

Generation 1
Age (Days)
66
66
66
64
64
64
64
65
65
64
80
80
80
80
80

Mouse
2667
2668
2720-5
2675
2678
2794
2767
2669
2670
2764
2795

Condition
P301S G0 Clone 1 BH
P301S G0 Clone 1 BH
P301S G0 Clone 1 BH
P301S G0 Clone 9 BH
P301S G0 Clone 9 BH
P301S G0 Clone 9 BH
P301S G0 Clone 9 BH
P301S G0 Clone 10 BH
P301S G0 Clone 10 BH
P301S G0 Clone 10 BH
WT G0 Clone 1 BH
WT G0 Clone 9 BH
WT G0 Clone 9 BH
WT G0 Clone 10 BH
WT G0 Clone 10 BH
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Figure 2.18. Characteristics of patient material and morphological analysis of all

Table S2, related to Figure 8 – Characteristics of patient material and morphological analysis of all
clones isolated from patient samples

clones isolated from patient samples.

Pathology/
Brain #
AD1
AD2
AD3
AD4
AD5
AD6
AGD1*
AGD2*
AGD3^
AGD4^
AGD5^
AGD6^
CBD1
CBD2
CBD3
CBD4
CBD5
CBD6
PiD1
PiD2
PiD3
PiD4
PiD5
PSP1
PSP2
PSP3
PSP4
PSP5
PSP6
Clone1
Clone 9
Clone 10
Tau KO

Age

Sex

61
93
64
75
72
80
77
82
65
72
58
66
64
69
61
57
63
60
57
70
58
60
71
66
84
69
56
69
74
n/a
n/a
n/a
12 mos

M
F
F
F
M
M
M
M
F
M
M
M
M
F
M
F
M
M
M
M
F
F
M
M
F
M
F
F
M
n/a
n/a
n/a
M

Location
(Gyrus)
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Inf temporal
Inf temporal
Inf temporal
Inf temporal
Inf temporal
Inf temporal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Ant orbital
Ant orbital
Ant orbital
Ant orbital
Ant orbital
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
Mid frontal
n/a
n/a
n/a
Whole brain

Clones
Isolated
12
1
10
11
10
11
0
47
0
5
0
8
12
15
11
0
10
9
1
4
12
3
9
5
19
0
0
0
0
0
0
3
0

No
Seeding?

Toxic?

x
x
x

x

x
x
x
x
x
x
x

Bold = most common phenotype associated with tissue sample
* = patient carried a primary diagnosis of AGD
^ = patient carried a primary diagnosis of FTLD-TDP but had incidental AGD
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Chapter 3: Tau Prion Strains Dictate
Patterns of Cell Pathology, Progression
Rate, and Regional Vulnerability In Vivo
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3.1

PREFACE

This chapter contains a submitted manuscript:
Kaufman, S.K*. Sanders D.W.*, Thomas, T.L., Ruchinskas, A., Vaquer-Alicea, J.,
Miller, T.M., Diamond, M.I. (Submitted). Tau prion strains dictate patterns of cell
pathology, progression rate, and regional vulnerability in vivo. *These authors
contributed equally to this work
Author contributions for the citation above: D.W.S. and S.K.K. contributed equally to
this work. D.W.S. performed all cell culture and biochemistry experiments. S.K.K.
performed all animal and primary neuron experiments. T.L.T. provided technical
assistance for animal inoculations and histopathology. A.R. and J.V.-A. helped analyze
histopathological data. D.W.S., S.K.K., and M.I.D. designed experiments. T.M.M. and
M.I.D. supervised experiments. S.K.K., D.W.S., and M.I.D. analyzed results and wrote
the manuscript.
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3.2

ABSTRACT

Tauopathies are neurodegenerative disorders that affect distinct brain regions, progress at
different rates, and exhibit specific patterns of tau accumulation. The source of this
diversity is unknown. We previously characterized two tau strains that stably maintain
unique conformations in vitro and in vivo, but did not determine the relationship of each
strain to parameters such as regional vulnerability or rate of spread that define a
tauopathy. We have now isolated and characterized 18 tau strains in cells based on
detailed biochemical and biological criteria. Inoculation of transgenic tau P301S (PS19)
mice with these strains causes strain-specific intracellular pathology in distinct cell types
and brain regions, and induces different rates of network propagation. In this system,
strains alone are sufficient to account for diverse neuropathological presentations, similar
to those that define human tauopathies. Further study of these strains can thus establish a
structural logic that governs these biological effects.
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3.3

INTRODUCTION

Tauopathies are a diverse group of neurodegenerative diseases characterized by clinical
heterogeneity, progressive deposition of tau protein aggregates in characteristic brain
regions, and distinct cellular pathologies (Lee et al., 2001). The etiology of this clinical
and pathological diversity is unknown, but may hold the key to accurate diagnosis,
prognosis, and therapy. Tauopathies include Alzheimer’s disease (AD), frontotemporal
dementias (FTDs), corticobasal degeneration (CBD), progressive supranuclear palsy
(PSP), and others (Lee et al., 2001). Most tauopathies are sporadic, but dominantly
inherited mutations in the MAPT gene, which encodes the tau protein, lead to specific
FTD syndromes (Hutton et al., 1998). Disease-associated mutations enhance the ability of
tau to form amyloids, which are ordered protein assemblies rich in cross beta sheet
structure (Knowles et al., 2014), and support a causal role for tau aggregation in
pathogenesis (Barghorn et al., 2000).
In AD, the most common tauopathy (Lee et al., 2001), tau amyloid deposition occurs in
an orderly fashion, beginning in the transentorhinal cortex, spreading to synaptically
connected regions such as the hippocampus, and eventually moving to more distant
regions of the neocortex (Braak and Braak, 1991; 1995). Multiple studies have now
documented tau aggregate uptake, “seeding” (i.e. aggregate serving as a template for the
conversion of monomer to a pathological, fibrillar form), and transfer of aggregates
among cultured cells (Frost et al., 2009a; Guo and Lee, 2011; Holmes et al., 2013a;
Nonaka et al., 2010). Experimental evidence suggests that “propagation,” or the
movement of tau aggregates between connected neurons with seeding of tau monomer in
recipient cells, mediates this progression in vivo (Brettschneider et al., 2015; Sanders et
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al., 2016; Walker and Jucker, 2015). Importantly, injection of tau aggregates into mice
that express human tau protein induces tau pathology that spreads outwards along known
brain networks (Ahmed et al., 2014; Clavaguera et al., 2009; Iba et al., 2013; Peeraer et
al., 2015; Sanders et al., 2014; Stancu et al., 2015). Transgenic mice that limit the
expression of tau to the entorhinal cortex also show spread of tau pathology to distant,
connected brain regions (de Calignon et al., 2012; Liu et al., 2012). Together, these
studies suggest that propagation of an aggregated state underlies the progression of tau
pathology. These observations match the established mechanisms of propagation of
pathological prion protein (PrP) (Prusiner, 1998). Controversy exists about whether to
refer to proteins other than PrP as “prions” (Aguzzi and Rajendran, 2009; Brettschneider
et al., 2015; Prusiner et al., 2015; Sanders et al., 2014; Walker and Jucker, 2015;
Woerman et al., 2015). While tau aggregates do not appear to be infectious, we favor the
term “prion” principally because it provides a conceptual framework with which to
understand pathogenesis, therapy, diagnosis, and heterogeneity of disorders linked to
amyloid accumulation.
The pathology of tauopathies occurs in distinct brain regions (Arnold et al., 2013),
involves disparate brain networks (Raj et al., 2012; Seeley et al., 2009; Zhou et al., 2012),
and features unique tau inclusions in various cell types (Kovacs, 2015). Individuals may
develop rapid or slow neurodegeneration even within the same syndrome (Armstrong et
al., 2000; Huang et al., 2014; Mann et al., 1992; Thalhauser and Komarova, 2012). The
basis of these diverse disease patterns is unknown.
We initially observed that tau adopts multiple, stably propagating conformers in vitro,
and speculated that structural variation in amyloids could underlie different tauopathies
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(Frost et al., 2009b). We subsequently determined that tau forms discrete prion “strains”
that propagate with remarkable fidelity through living systems (Sanders et al., 2014). The
concept of prion strains derived from a realization that PrP prions can induce distinct
transmissible spongiform encephalopathies with reproducible incubation times and
patterns of neuropathology (Collinge and Clarke, 2007). It is now clear that PrP prion
strains derive from different PrP amyloid conformations, and produce predictable
incubation times and neurodegenerative phenotypes upon serial passage in vivo.
Moreover, distinct PrP strains probably account for the myriad features of individual PrP
prion diseases (Collinge et al., 1996). The concept of a strain as a stably propagating
structure that induces a specific and reproducible phenotype is critical, as it anticipates
and enables mechanistic, diagnostic, and therapeutic insights based on knowledge of a
defined molecular assembly (Sanders et al., 2016).
In addition to the distinct morphologies of tau fibrils and isoform composition of amyloid
deposits in tauopathies (Lee et al., 2001), prior studies have suggested that unique tau
amyloid structures might account for some aspects of clinical variation. Injection of
homogenate from different tauopathy brains into a mouse model that expresses fulllength human tau induced pathology that closely resembles that of the human source
cases (Clavaguera et al., 2013a). In a similar study, tau aggregates purified either from
AD or CBD brains induced distinct patterns of tau pathology that affected different cell
populations in transgenic mice that express 1N4R tau with a P301S mutation (PS19)
(Boluda et al., 2015). However, both works relied upon a limited number of patient
samples that likely contain a heterogeneous mixture of tau aggregate conformations
(Sanders et al., 2014). Thus, the structure and biochemical properties of injected tau
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aggregates could not be well defined, making it impossible to directly link amyloid
structure to pathology. Further, in the latter study, two different purification paradigms
were used for purification of AD versus CBD derived tau, which might also have affected
the phenotypes observed (Boluda et al., 2015). While these and other studies support the
idea that various tau preparations can induce distinct pathologies following stereotactic
injection, the actual cause of diversity in tauopathy syndromes has remained unclear.
Like PrP, tau forms bona fide prion strains that propagate in cells and animals (Sanders et
al., 2014). Previously, we generated two stably replicating tau prion strains based on
mother-daughter transmission of the aggregated state in HEK293 cells that stably express
mutant tau repeat domain (RD) fused to yellow fluorescent protein. We observed
maintenance of both tau prion strains through serial hippocampal inoculations in three
generations of PS19 mice. Finally, we re-established the original strain phenotypes in
culture after transduction of immuno-purified tau aggregates from homogenized mouse
brain back into the original cell line that lacked tau aggregates. This work indicated that
tau aggregate conformation alone, not brain-specific cofactors, determined the induced
pathology in vivo. It also suggested that distinct tau strains might be sufficient to explain
different pathological patterns in tauopathies. However, this work did not examine the
role of strains with regard to regional vulnerability, rate of spread, or patterns of
histopathology that constitute the basis for neuropathological discrimination of tauopathy
syndromes.
We have now isolated and extensively characterized 18 putative tau prion strains derived
from recombinant, mouse, or human sources that we propagated in tau RD-YFP HEK293
cells. We subsequently performed inoculation experiments in transgenic PS19 tau mice to
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test whether tau strains are sufficient to account for the pathological variation that is used
to characterize human tauopathies: cellular inclusion morphology, rate of spread through
brain networks, glial involvement, and regional vulnerability. This work develops a
framework to understand the relationship of tau prion structure to distinct tauopathy
syndromes.
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3.4

MATERIALS AND METHODS

Tau purification and fibrillization. Recombinant preparations of full-length (FL) 2N4R
tau protein were prepared as previously described (Goedert and Jakes, 1990). pRK172 FL
2N4R tau was expressed in Rosetta (DE3)pLACI competent cells (Novagen) and tau was
purified according to established protocols. After purification, tau was lyophilized using a
FreeZone Plus Freeze Dry System (Labconco) and stored at -80°C as single-use aliquots.
Prior to fibrillization, monomeric tau was re-suspended in 25 mM DTT for 45 minutes.
The protein was then fibrillized at a final concentration of 8 µM in tau buffer (2.5 mM
DTT/10 mM HEPES pH=7.4/100 mM NaCl/8 µM heparin, final volume of 200µL) at
37°C for 24 hours prior to addition to cells.
Cell culture. All HEK293T and HEK293 cell lines were grown in complete media:
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with 10% fetal bovine serum
(HyClone) and 1% penicillin/streptomycin (Gibco). Cells were cultured and passaged at
37°C, 5% CO2, in a humidified incubator. Dulbecco’s phosphate buffered saline (Life
Technologies) was used for washing the cells prior to trypsinization with 0.05% TrypsinEDTA (Life Technologies).
Lentivirus production. Lentivirus was prepared as previously described (Araki et al.,
2004; Sanders et al., 2014). HEK293T cells were plated at 1x106 cells/well in 6-well
plates. After 24 hours, cells were transfected with a three-component plasmid system for
virus production: VSV-G (400 ng), PSP (1200 ng), FM5 (400 ng). DNA was mixed with
7.5µL TransIT-293 (Mirus) and 250µL OptiMEM for 15 minutes prior to addition to cell
media. After 48 hours, media was harvested and spun at 500g for 5 minutes to remove
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debris. For generation of HEK293 cell lines, lentivirus-containing supernatant was stored
at -80°C prior to addition to cells. For primary neurons, lentiviral supernatant was
concentrated 50x using lenti-X concentrator (Clontech) according to manufacturer’s
protocol. The final concentrated virus was re-suspended in PBS with 25 mM HEPES (pH
= 7.4).
Stable HEK293 cell line generation. Monoclonal HEK293 cell lines were generated that
stably overexpress fusion proteins containing the tau repeat domain (amino acids 244-372
of the 2N4R isoform of tau) with various mutations (P301L, P301S, V337M) previously
shown to cause familial tauopathy (FTDP-17) (Hutton et al., 1998). Two monoclonal
HEK293 cell lines were previously described: Clone 1/DS1, which expresses tau RD
P301L/V337M-YFP (Sanders et al., 2014) and the tau RD P301S FRET biosensor
(ATCC CRL-3275), which expresses tau RD P301S-CFP and tau RD P301S-YFP
(Holmes et al., 2014). To generate additional polyclonal lines, HEK293 cells were plated
at 50,000 cells/well in a 12-well plate. After 18 hours, 300 µL conditioned media
containing lentivirus was added to the wells (RD LM FRET polyclonal: 150 µL tau RD
P301L/V337M-CFP and 150 µL tau RD P301L/V337M-YFP; RD P301S split-luciferase
polyclonal: 150 µL tau RD P301S-Cluc and 150 µL tau RD P301S-Nluc). For both
polyclonal lines, cells were given 3 days to grow in the presence of virus. Cells were then
re-plated in a 10 cm dish, grown to confluency, and stored in liquid nitrogen until use.
To generate monoclonal lines, the two polyclonal populations (RD LM FRET and RD
P301S split-luciferase) were diluted sparsely in 10 cm dishes, so that there were fewer
than 30 cells per dish. Cells were given seven days to grow into visible colonies. At this
point, cloning cylinders (Bel-Art Products) were used to isolate single colonies, which
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were passaged to new wells. Monoclonal lines were serially amplified to confluency
using 24-well then 6-well then 10 cm dishes. Upon reaching confluency in 10 cm dishes,
monoclonal lines were frozen in liquid nitrogen until use. LM10 was the tenth
monoclonal line selected from the RD LM FRET polyclonal, and was chosen due to its
ability to differentiate toxic and non-toxic strains (described below). The RD P301S-split
luciferase biosensor was selected due to its high signal to noise ratio in differentiating
lysates with and without aggregates.
Lysate production for generation of strain library. Confluent cells from 6-well plates
were harvested, pelleted, and stored at -80°C for the following cell lines (Sanders et al.,
2014): Clone 1-derived (Clone 1, Clone 9, Clone 10), OFF1-derived (AGD2/mosaic,
CBD3/disordered, CBD5/disordered, CBD3/speckles, AD1/speckles, PiD2/ordered). Cell
pellets were thawed on ice and subsequently lysed in PBS with 0.05% Triton X-100 and a
cOmplete mini protease inhibitor tablet (Roche) by triturating 10x and incubating at 4°C
for 10 minutes. Sequential 5-minute centrifugations were then performed at 500xg and
1000xg to clarify the lysate. A Bradford assay (Bio-Rad) was performed on the
supernatants, and protein concentrations were normalized to 5 µg/µL with addition of
lysis buffer. Lysates were stored at -80°C prior to addition to cells.
To produce brain homogenates, the following samples were used: transgenic P301S
mouse brain (age = 9 months), an Alzheimer’s disease patient brain (patient AD1)
(Sanders et al., 2014), and a late-stage chronic traumatic encephalopathy patient brain
that was a generous gift from Dr. Ann McKee. For each, 0.4 gram sections were
sonicated in 5 mL TBS with cOmplete protease inhibitors (Roche) using an Omni-Ruptor
250 probe sonicator at 30% power for 3-second pulses x 30 cycles. Crude homogenates
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were then clarified by centrifugation at 15,000xg for 15 minutes. The supernatants were
set aside, a Bradford was performed, and protein concentrations were normalized to 4
µg/µL with addition of TBS buffer. Homogenates were stored at -80°C prior to addition
to cells.
Generation of a library of monoclonal strains. To generate a library of isogenic tau
strains, several monoclonal tau RD P301L/V337M-YFP cell lines were examined for
their ability to stably propagate a diversity of strains. Clone 1/DS1 (Sanders et al., 2014)
was selected for its capacity to amplify both highly toxic strains and strains prone to
sectoring, which can be attributed to its intermediate level of tau RD expression. Clone 1
cells were plated at 240,000 cells/well in 12-well plates. After 24 hours, cells were
treated with 400 nM tau fibrils or 20 µg lysate/homogenate (see lysate production for
generation of strain library), and prepared as transduction complexes (4 µL
lipofectamine-2000 (Life Technologies), protein source, and OptiMEM to 200 µL
volume). After 18 hours, cells were washed, trypsinized, and re-plated in a 6-well plate.
At confluency (day 3), cells were diluted sparsely in 3 x 10 cm dishes (per condition) so
that there were less than 30 cells per dish. Cells were given 9 days to amplify into visible
colonies. At day 12, epifluorescence microscopy was used to find colonies featuring cells
with inclusions and these were marked. Cloning cylinders (Bel-Art Products) were used
to isolate up to six colonies per condition, and each individual colony was separately
amplified to confluency in 12-well, then 6-well, and 10 cm dishes. At approximately day
30, cells were either plated on coverslips for fixation and confocal microscopy or were
frozen down in single-use pellets at -80°C for analysis by seeding and protease digestion.
A total of 90 monoclonal lines were examined. Based on preliminary analysis by
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inclusion morphology, seeding, and protease digestion, 21 were selected for rigorous
analysis by both the aforementioned assays as well as sedimentation analysis and toxicity
assays. Finally, 18 lines were suspected to be distinct strains and were designated DS2 to
DS19 (DS = David/Sarah).
Fixation of cells for confocal microscopy. Cells were grown for 48 hours on coverslips
in 24-well plates. Media was removed and replaced with 4% PFA for 15 minutes. PFA
was removed and replaced with PBS. Cells were washed once with additional PBS and
DAPI-stained for 10 minutes in 0.1% Triton-X. Stain was removed and replaced with
PBS. Coverslips were mounted using Prolong Gold Antifade reagent (Life Technologies),
sealed with nail polish, and placed at 4°C prior to confocal analysis.
Confocal analysis of strains based on inclusion morphology. For confocal microscopy,
a Zeiss Axiovert 200M microscope was coupled to a Zeiss LSM 5 PASCAL system. For
the collection of all images, a pinhole size of 0.8 µm was used. Representative images of
each monoclonal cell line were taken and were scored based on inclusion morphology:
diffuse (no aggregates), mosaic (loss of aggregated state with division), ordered (large,
dense juxtanuclear inclusion with no nuclear aggregates), speckles (small juxtanuclear
inclusion with numerous nuclear speckles), threads (long, fibril-like inclusions in
cytoplasm with rare nuclear speckles), disordered (diffuse aggregates that wrapped
around nucleus with no nuclear speckles).
Limited proteolysis. Lyophilized pronase (Roche) was re-suspended in PBS to a final
concentration of 1 mg/mL and aliquots were snap-frozen and placed at -80°C. Cell pellets
were thawed on ice and lysed in PBS with 0.05% Triton X-100 and a cOmplete mini
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protease inhibitor tablet (Roche) by triturating 10x and incubating at 4°C for 10 minutes.
Sequential 5-minute centrifugations were then performed at 500xg and 1000xg to clarify
the lysate. A Bradford assay (Bio-Rad) with BSA standard curve was performed and
protein concentrations were normalized to 4 µg/µL with addition of lysis buffer. 60 µg
(15 µL) of cell lysate was added to 15 µL of pronase (diluted in PBS) at a concentration
of 60 µg/mL for a final volume of 30 µL and a final pronase concentration of 30 µg/mL.
Cell lysates were digested at 37°C for one hour. Reactions were quenched by addition of
30 µL 2x sample buffer (4 µL BME, 11 µL 10% SDS, 15 µL 4x Laemmli buffer)
followed by five minutes of boiling. 13 µL of each sample was loaded onto a NuPAGE
10% Bis-Tris gel (Life Technologies). Gels were run at 150 V for 70 minutes. Protein
was transferred to Immobilin P (Millipore) using a semi-dry transfer apparatus (Bio-Rad).
Membranes were blocked for 1 hour in 4% milk. Membranes were probed for tau using
mouse monoclonal anti-tau 2B11 (0.7 µg/µL, Clontech) for 18 hours, washed four times
with TBS-T, counter-probed with goat anti-mouse HRP (1:4000, GE Healthcare) for 1.5
hours, and were washed four additional times with TBS-T. Finally, membranes were
exposed to ECL Prime Western Blotting Detection System (Fisher Scientific) for 2
minutes and were developed using a digital Syngene imager.
Sedimentation analysis and densitometry of strain library. Cell lysates were prepared
and clarified as described above (see Limited proteolysis) in biological quadruplicates for
each strain. A Bradford assay (Bio-Rad) with BSA standard curve was performed to
determine the protein concentrations for the 76 samples, normalizing each to 1.6 µg/µL. 1
mL of each was centrifuged at 186,000g for 60 minutes, with the remainder being set
aside as the total fraction. After centrifugation, the supernatant fraction was placed aside
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and the pellet was washed with 1 mL lysis buffer. The ultracentrifugation step was
repeated for 30 minutes, and the wash fraction was aspirated. Final pellets were resuspended in 1 mL of 4% SDS/1% BME (in PBS) with the aid of five minutes of boiling.
For each sample, 1 µg total (or equivalent volume of supernatant or pellet) was run on a
NuPAGE 10% Bis-Tris gel (Life Technologies) at 150 V for 35 minutes. Protein was
transferred to Immobilin P (Millipore) using a semi-dry transfer apparatus (Bio-Rad).
Membranes were blocked for 1 hour in 4% milk and then probed overnight with rabbit
polyclonal anti-tau ab64193 (1:5000, AbCam) and rabbit polyclonal anti-cofilin
(1:28,000, Sigma). Following four washes with TBS-T, blots were counter-probed with
goat anti-rabbit HRP (1:4000, Jackson Immunotherapy) for 90 minutes at room
temperature. Finally, blots were washed an additional four times and membranes were
imaged with a digital Syngene imager following exposure to ECL Prime Western
Blotting Detection System (Fisher Scientific) solution for two minutes. Biological
replicates were imaged separately, with four blots being developed at a time.
Densitometric units were calculated using Syngene GeneTools software with manual
band quantification. The brightness of each tau band (total, supernatant, pellet) was
normalized relative to the signal calculated for the condition’s associated total cofilin.
Ratios were then averaged across biological quadruplicates.
Split-luciferase complementation assay. A monoclonal HEK293 cell line expressing
tau RD P301S-Cluc and tau RD P301S-Nluc was generated (see Stable HEK293 cell line
generation) and plated at 24,000 cells/well in 96-well plates. After 18 hours, when the
cells were at 50% confluency, cells were transduced with cell lysate: indicated amounts
of clarified cell lysate (see Limited Proteolysis) were added in transfection complexes
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with 0.4 µL lipofectamine-2000 (Life Technologies) to each well. 60 hours after addition
of lysate, media was aspirated and replaced with luciferin solution (150 µg/mL Dluciferin potassium salt, Gold Biosciences, in Dulbecco’s phosphate-buffer saline,
Gibco). Cells were incubated in luciferin solution for two minutes at 37°C prior to
reading luminescence with a Tecan M1000 fluorescence plate reader. Each condition was
performed in biological quadruplicate with each replicate being performed on a separate
plate to control for differences between plates. Seeding ratio was calculated relative to
sham control for an individual plate. Seeding ratios were then averaged across
quadruplicates and standard errors of the mean were calculated and plotted. Inflection
point was defined as the amount of lysate required to achieve a 50% increase in
luminescence relative to sham treatment. EC50 and peak seeding were calculated using a
non-linear regression with one-phase decay fit.
Toxicity assay. A monoclonal cell line expressing tau RD P301L/V337M-CFP and tau
RD P301L/V337M-YFP was generated and given the name LM10 (see Stable HEK293
cell line generation). LM10 cells were plated at 240,000 cells/well of 12-well plates.
After 18 hours, wells were transduced with 20 µg clarified lysate (see Limited
Proteolysis) in transfection complexes with 4 µL lipofectamine-2000. Each condition was
performed in biological triplicate. After 24 hours, media was aspirated and cells were
trypsinized and re-plated into 6-well plates. After 48 hours (i.e. 72 hours post-treatment),
media was removed, cells were trypsinized, and pelleted, followed by re-suspension in
flow cytometry buffer (HBSS with 1% FBS and 1 mM EDTA). FRET-positive
(aggregate-containing) and FRET-negative (aggregate-lacking) cells were gated
according to published protocols (Furman et al., 2015; Holmes et al., 2014). Using a
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FACS Aria II SORP cell sorter (BD Biosciences), 7000 FRET-positive cells were
collected in 1.4 mL media for each condition (DS2 to DS19). For the negative control
(DS1), 7000 FRET-negative cells were sorted. 200 µL (i.e. 1000 cells) were plated in
sextuplicate for each condition in 96-well plates. Cells were given 7 days to amplify.
Cells were then harvested with 0.05% trypsin, pelleted, and fixed in 2%
paraformaldehyde (Electron Microscopy Services) for 10 minutes. Cells were re-pelleted
and re-suspended in flow cytometry buffer. A MACSQuant VYB (Miltenyi) was used to
perform FRET flow cytometry according to previously published protocols (Holmes et
al., 2014), and total FRET-positive and FRET-negative cells were counted for each
condition. Totals were averaged across technical sextuplicates and then averaged across
biological triplicates. Error bars represent the standard error of the mean for biological
triplicates.
Statistical analysis of in vitro correlations. For the correlation of toxicity, seeding, and
sedimentation metrics, normality of the data was assessed using both D’Agostino/Pearson
and Shapiro-Wilk tests. If both tests were passed, data sets were considered normal and a
Pearson correlation was performed. Else, the data sets were not considered normal and a
more conservative Spearman correlation was performed. Correlations were considered
significant if p was less than or equal to 0.05.
Primary neuron culture and staining. Cortical and hippocampal neurons were isolated
from E18.5 CD1 mice and cultured according to previous literature (Yano et al., 2014).
Briefly, neurons were incubated with 0.5% trypsin in HBSS with glucose (1:6 dilution)
for 20 minutes at 37°C. Subsequently, neurons were triturated and passaged through a 70
µm filter, followed by plating 100,000 cells per well on poly-D lysine- or
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polyethyleneimine (PEI)-coated plates for cortical or hippocampal cultures respectively.
Neurons were treated at DIV3 with 2 µL of 50x-concentrated 1N4R Tau P301S-YFP
lentivirus (see Lentivirus production) per well of a 96-well plate. Neurons were
subsequently treated at DIV6 with 10 µg of cell lysate or PBS. Neurons were examined
for intracellular aggregates each day with an epifluorescence microscope (Nikon Eclipse
TI), and scored using a 0-5 scale (No seeding – Peak seeding). Neurons were fixed at 5, 8
or 11 days post lysate addition with a modified triton-X extraction to remove soluble tau
protein (Volpicelli-Daley et al., 2011). Briefly, cells were incubated with 4% PFA/4%
sucrose in PBS with 1% Triton-X 100 for 30 minutes. Cells were subsequently washed
and stained with MC1 antibody (1:500; Peter Davies) in 10% NGS in PBS overnight at
4°C. Cells were washed and treated with anti-mouse IgG 546 (1:400, Life Technologies),
and stained with DAPI. Cells were imaged with the In Cell Analyzer 6000 at 40x
resolution with the assistance of the UTSW HTS Core facility.
Primary neuron seeding assay. Hippocampal neurons were plated at 75,000 cells per
well on PEI-coated plates. At DIV3, cells were treated with 1 µL of 50x concentrated
TauRD P301S-CFP and 1 µL of TauRD P301S-YFP lentivirus. AT DIV6, cells were
treated with 10 µg of cell lysate or an equivalent volume of PBS. Cells were subsequently
incubated for four days. A MACSQuant VYB (Miltenyi) flow cytometer was used to
assess FRET-positive neurons according to previously published literature (Furman et al.,
2015; Holmes et al., 2014).
Cell lysate production for animal inoculation experiments. DS1-19 cell lines were
grown in 3 x 10 cm dishes until 90% confluency. Cells were trypsinized, re-suspended in
media and centrifuged at 500xg. Cell pellets were washed with 1x PBS and stored at 138

80°C until use. Pellets were thawed on ice and re-suspended in 1x PBS with cOmplete
protease inhibitors (Roche) using an Omni-Ruptor 250 probe sonicator at 30% power for
30, 3-second cycles. The probe sonicator was washed with 100% ethanol and ddH2O
between cell lines. Strains were subsequently centrifuged at 1000xg, normalized to 7
µg/µl by Bradford assay (Bio-Rad) and stored as aliquots at -80°C until use.
Sedimentation analysis and densitometry of injected lysates. Sonicated and clarified
cell lysate was thawed on ice, and diluted to 2 µg/µL in 1x PBS with cOmplete protease
inhibitors (Roche). Samples were subdivided into a total protein and ultracentrifuge (UC)
aliquots. The UC aliquots were centrifuged at 186,000xg for 90 minutes. Supernatant was
removed and stored with the total lysate aliquot at -80°C until use. Pellets were washed
with 1x PBS and centrifuged at 186,000xg for an additional 30 minutes. Pellets were resuspended to their original volume. SDS-PAGE was performed on total, soluble or
insoluble fractions of each cell line (1:2:1 ratio) using 5-20% gradient acrylamide gels.
Gels were transferred as described above. Membranes were cut at the 20 kilo-Dalton
ladder mark and incubated at 4°C overnight with a rabbit polyclonal anti-tau antibody
(1:4000, Abcam ab64193) or a rabbit polyclonal anti-cofilin antibody (1:4000; Sigma).
Anti-rabbit ECL HRP conjugated secondary antibody (1:4000, GE Lifesciences) was
added for one hour, and blots were developed using ECL Prime Western Blotting
Detection System (Fisher Scientific). Washes were performed as described above.
Densitometry was performed by measuring the mean grey value (mgv) of bands with
ImageJ, and normalizing to cofilin mgv. Samples were averaged across biological
triplicate. A one-way ANOVA with Bonferroni’s multiple comparisons correction was
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performed by comparing DS1-1 to each sample. A one-way t-test was performed to
directly compare DS10 and DS4.
Animal tissue collection. P301S or WT mice were anesthetized with isoflurane and
perfused with chilled PBS + 0.03% heparin. Brains were post-fixed in 4%
paraformaldehyde overnight at 4°C and then placed in 30% sucrose in PBS until further
use.
Histology. Brains were sectioned at 50 µm using a freezing microtome. Slices were first
blocked for one hour with 5% milk in TBS with 0.25% Triton X-100 (blocking buffer).
For DAB stains, brain slices were incubated with biotinylated AT8 antibody (1:500,
Thermo Scientific) overnight in blocking buffer at 4°C. Slices were subsequently
incubated with the VECTASTAIN Elite ABC Kit (Vector Labs) in TBS prepared
according to the manufacturer’s protocol for 30 minutes, followed by DAB development
using the DAB Peroxidase Substrate Kit with the optional nickel addition (Vector Labs).
Slices were imaged using the Olympus Nanozoomer 2.0-HT (Hamamatsu). For astrocyte
staining, slices were permeablized in 0.25% Triton X-100 in TBS, followed by blocking
with 3% milk and 10% normal goat serum (NGS) for 30 minutes, followed by incubation
with AT8 (1:500, Thermo Scientific) and GFAP (1:500, Dako) overnight at 4°C. Slices
were incubated with 1:500 anti-mouse 488 and anti-rabbit 546 antibodies (Life
Technologies), followed by imaging using a Zeiss LSM780 inverted confocal
microscope.
Quantification of Tau pathology. Images of AT8 DAB stained slices were collected as
above. A blinded analysis of the level of tau pathology was performed using a semi-
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quantitative 0-3 scale (no pathology, mild, moderate, and severe, respectively) as
previously reported (Lace et al., 2009). Briefly, images of each brain slice were
randomized and blinded to the scorer. Individual brain regions in each slice were
assessed for AT8 positive neuronal inclusions. Scores were recorded unless a slice was
damaged such that the region of interest was not present in the slice. The level of
pathology was averaged among biological replicates for each region within a condition.
For the regional vulnerability experiments (Figure 3.9), pathology was normalized by
subtracting the average DS1 pathology in a region, and heat maps were generated with
discrete bins for different pathology levels as described within the figure. For the time
course experiments (Figure 3.12), averages were plotted as a heat map with a gradient
from 0 to 3 as reported in the figure. Heat maps were generated using MATLAB.
P301S FRET Flow Seeding assay. Bilateral hippocampus, sensory cortex, or thalamic 1
mm punches were isolated from mice injected with DS1, 4, 6, 7, 9, 10 or diluted DS6 and
DS9, 8-weeks post inoculation. Samples were placed into 1xTBS at a dilution of
1mm3/mL (v/v) and sonicated with a water bath sonicator (Qsonica Q700MPX with
Chiller and tubing set) at 4°C at 50% power for 30 minutes. Seeding assays were
performed as previously described (Furman et al., 2015; Holmes et al., 2014). Briefly, 2.5
µL of each sample was added in triplicate to wells of a 96-well plate onto the tau RD
P301S FRET biosensor cell line. Cells were incubated for 48 hours and then trypsinized,
fixed with 2% PFA in 1x PBS, and incubated in flow cytometry buffer. A FACS
LSRFortessa SORP was used to perform FRET flow cytometry as previously described
(Furman et al., 2015; Holmes et al., 2014). Integrated FRET density (IFD = percent cells
positive for FRET multiplied by the median fluorescent intensity of FRET-positive cells)
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was averaged for every condition and normalized to lipofectamine-2000 (sham) IFD. A
one-way ANOVA with Bonferroni corrections was performed for each region by
comparing DS1 ipsilateral IFD to all other conditions within that region.
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3.5

RESULTS

Generation of a library of tau strains. In previous work, we created a monoclonal
HEK293 cell line (initially termed Clone 1, now DS1) that stably expresses the repeat
domain (amino acids 244-372) of 2N4R tau with two disease-associated mutations
(P301L and V337M) (Sanders et al., 2014). Importantly, these cells never produce
aggregates unless stimulated by tau seeds in the culture medium. Exposure to exogenous
seeds converts intracellular tau to an aggregated form, which propagates as a stable
phenotype from mother to daughter cells. We extensively characterized two
biochemically distinct tau strains in vitro and in the PS19 mouse tauopathy model (Clone
9/DS9 and Clone 10/DS10) and further found that distinct inclusion morphologies
associate with unique tauopathy syndromes (Sanders et al., 2014). However, the range
and diversity of amyloid structures that tau could adopt in this cellular context was not
known.
We thus treated DS1 cells with tau aggregates from diverse recombinant, mouse, and
human brain samples (Figure 3.1A). We isolated and amplified 90 monoclonal cell lines
that stably propagated tau aggregates and froze them for later analyses. Following
preliminary analyses by several assays (inclusion morphology, limited proteolysis,
seeding by tau split-luciferase complementation as described previously (Sanders et al.,
2014)) we rigorously analyzed 21 cell lines. This indicated that we had isolated 18
putatively distinct strains (DS2-DS19; see Figure 3.2A for origin of each strain). These
strains featured several striking differences in their subcellular distribution of aggregated
tau (Figure 3.1B): a single, large juxtanuclear inclusion (Ordered: DS3, 10, 14, 19),
prominent nuclear inclusions (Speckles: DS4, 5, 7, 8, 9, 12, 16, 17, 18), aggregated tau
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that failed to organize into ordered inclusions (Disordered: DS11, 13), fibril-like ribbons
of aggregated tau throughout the cytoplasm (Threads: DS6, 15), and one strain that
sectored with time, reverting from the aggregated state to the soluble diffuse state
(Mosaic: DS2). Importantly, with the exception of the mosaic strain DS2, every daughter
cell featured the same inclusion morphology even after months of passage, suggesting
that each monoclonal cell line stably propagated a single strain.
To examine whether the tau inclusions were composed of structurally distinct tau
amyloids, we used limited proteolysis, an assay previously shown to differentiate prion
strains derived from PrP (Bessen and Marsh, 1994) and tau (Sanders et al., 2014). We
thus determined a “fingerprint” for each strain based on the regions of tau protected from
digestion by pronase (Figure 3.1C). This assay suggested that while cell lines with
different inclusion morphologies always propagated different strains, inclusion
morphology alone could not discriminate all strains. For example, despite appearing
equivalent by microscopy, many speckled strains featured different limited proteolysis
fingerprints.
Tau strains show unique seeding profiles in dividing cells and neurons. Next, we
examined the ability of the individual strains to seed natively folded tau using a tau RD
P301S split-luciferase complementation assay (Mirbaha et al., 2015; Sanders et al.,
2014). When saturating concentrations of lysate from each strain were introduced directly
into the cytoplasm of dividing cells, induction of luminescence ranged from 0.3 to 80fold increase in seeding at saturation vs. background, termed the “seeding ratio” (Figure
3.1D). We observed no association between inclusion morphology and seeding. For
example, two ordered strains were strong seeders (DS10, 14), whereas two others were
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weak (DS3, 19). Importantly, the relative seeding abilities of individual tau strains were
largely recapitulated when lysates were applied to primary hippocampal neurons
expressing Tau RD P301S FRET biosensor proteins (Holmes et al., 2014) (Figure 3.1E).
We also observed these relative differences upon expression of full-length 1N4R P301SYFP in primary hippocampal neurons, suggesting common effects on either truncated or
full-length tau. Strains also showed different lag phases in neurons that express fulllength tau (Figure 3.1F-G, 3.2B). The five strains that seeded most strongly in the splitluciferase assay (DS5, 6, 9, 14, 15) induced intra-neuronal tau aggregation (Triton-X
insoluble, MC1-positive inclusions) within three days. Several of the weakest seeders
(DS3, 7, 11, 12, 13, 16, 19) failed to cause tau pathology even after eight days. Moreover,
certain strains (e.g. DS6) exhibited slightly longer lag periods than other strains (DS9)
with respect to peak seeding, yet reached a high level of pathology five days after
addition of cell lysate (Figure 3.1F,G). We observed similar lag phase differences and
inclusions in primary cortical neurons (data not shown). Thus, strains feature significant
differences in their abilities to trigger aggregation of full-length tau, independent of seed
uptake and cell type.
Seeding activity correlates with toxicity in dividing cells. To investigate the
relationship between seeding activity and toxicity, we first performed a detailed titration
of cell lysates (30 pg to 10 µg) from the 18 putatively distinct strains. We determined the
EC50 and peak seeding ratio for each strain using the tau split-luciferase complementation
assay. Strains differentially seeded tau monomer in cell culture as reflected by their peak
seeding ratios (Figure 3.3A,B). Different strains displayed >10x range for EC50 (DS9:
287 ng; DS3, 4908 ng) (Figure 3.3B). Peak seeding and EC50 strongly anti-correlated
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(Figure 3.3C), suggesting that peak seeding accurately reflects a strain’s potency in
triggering tau aggregation.
We then compared the toxicity of strains to their seeding potential. To determine relative
toxicities we generated a cell line (LM10) that expresses a mutant tau RD FRET pair
(CFP/YFP) at high levels, and assessed the growth potential of cells propagating various
strains after first isolating aggregate-positive cells by FRET FACS (Holmes et al., 2014).
Several ordered and mosaic strains (DS2, 3, 10, 19) lost the aggregated state with
repeated cell division (“sectored”) (Figure 3.3D). All others stably propagated the
aggregated state, but exhibited growth defects relative to LM10 cells that lacked tau
aggregates (Figure 3.3E). Strains that sectored, a possible correlate of low seeding, were
the least toxic. All three seeding metrics (peak seeding, EC50, and inflection point)
correlated with inhibition of growth (Figure 3.3F, Figure 3.4A-B). In other words, strains
that seeded more efficiently were significantly more toxic to cells expressing high levels
of monomeric tau.
To test the possibility that variable levels of insoluble or total tau contributed to the
differences in seeding and toxicity across strains, we performed sedimentation analyses to
determine the level of soluble, insoluble, and total tau for all 18 strains (Figure 3.3G).
While each strain (DS2-19) contained the majority of tau in the insoluble fraction (Figure
3.3G-H), different strains featured variable levels of insoluble (Figure 3.3I) and total
(Figure 3.4C) tau. Importantly, however, neither total nor insoluble tau levels correlated
with seeding (Figure 3.3J, 3.4D) or toxicity (Figure 3.3K, 3.4E). Thus, structural
differences among strains, rather than soluble/insoluble tau levels per se, account for
seeding activity and toxicity in dividing cells.
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Diversity of pathology induced by tau strains. We hypothesized that to account for
variation in tauopathies, individual tau strains should produce a wide array of
pathological phenotypes in vivo. To test whether individual tau strains can produce such
diversity, we inoculated cell lysate from each strain (DS1-DS19) into a tauopathy mouse
model (PS19) that expresses 1N4R tau with the FTDP-17-associated P301S mutation
from the prion promoter (Yoshiyama et al., 2007) (Figure 3.5A). We subsequently
examined the pattern and level of pathology induced eight weeks after inoculation
(Figure 3.5B-J).
Pathology varied greatly between strains, and was often, but not always, consistent with
seeding activity observed by the tau split-luciferase assay and in primary neuron culture
(Figure 3.1D-G). Strains with low seeding activity (DS2, 3, 11, 19) produced a “rare
seeding” phenotype in vivo, with limited AT8 pathology localized in CA1 of the
ipsilateral hippocampus (Figure 3.5G). These strains appear different in terms of their
AT8 subcellular localization (soma versus axonal pathology in DS2 and 11), but this may
reflect different levels of maturation of tau aggregates (e.g. pretangles and tangles).
Several strains induced low, yet consistent tangle-like pathology in CA1 of the
hippocampus (DS4, 8, 12, 13, 16, 17) (Figure 3.5H). Interestingly, DS12, 13, and 16,
which derive from CBD patient homogenate, induced pathology in vivo despite not
producing pathology in primary neuron cultures that express full-length tau (Figure 3.1F).
This contrasts with DS4, 8 and 17, which derive from recombinant fibrils or AD brain
homogenate and readily induced pathology both in cultured primary hippocampal
neurons and in vivo (Figure 3.5H, 3.2A, B). Strains with the highest seeding activity in
culture (DS5, 6, 9, 15) caused widespread tangle-like tau pathology throughout several
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hippocampal regions (Figure 3.5I, J). These robust strains also consistently induced the
spread of tau pathology to distant regions such as the entorhinal cortex (EC) and
contralateral hippocampus (Figure 3.6B).
Several strains caused unique pathology in the hippocampus. DS10 typically produced
AT8-positive “dots” in the mossy fiber tracts of the ipsilateral and contralateral
hippocampus, while mostly sparing CA1 pyramidal neurons (Figure 3.5C, 3.6C) as was
observed in previous work (Sanders et al., 2014). DS14, which shared the same ordered
cellular phenotype as DS10 (Figure 3.1B), also produced mossy fiber dots (Figure 3.5D).
However, this strain showed higher seeding activity in culture (Figure 3.1D-F), and
additionally induced CA1 tangle-like pathology in the ipsilateral and contralateral
hippocampus (Figure 3.6C).
DS7 produced “wisps” that resemble neuropil threads (Figure 3.5E) while inducing
weaker AT8 pathology in the main axon branches. This contrasted with several other
speckled phenotype strains, which primarily induced AT8 pathology in the main axon
(Figure 3.5H-I). DS18 produced wisps, mossy fiber dots, and “grains,” which are AT8
positive puncta found throughout the hippocampus (Figure 3.5F). DS18-inoculated mice
also developed grain pathology in the contralateral hippocampus and wisps in the EC,
indicating these specific phenotypic features can spread to distant regions (Figure 3.6D).
Critically, strains with matching limited proteolysis fingerprints (Figure 3.1C) produced
similar histopathology in vivo (DS3 and 19; DS6 and 15; DS12 and 16) (Figure 3.5F,
3.5G, 3.5I). These strain pairs (which may propagate identical tau aggregate
conformations) displayed similar seeding activity and toxicity levels, and induced similar
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phenotypes in primary neuron culture (Figures 3.1-3.4). Importantly, DS6 and 15 derive
from distinct aggregate sources (aged PS19 mice and recombinant fibrils, respectively),
indicating that these strain-based phenotypes are conformation-specific rather than
source-specific (Figure 3.2A).
Specific strains reliably induce astrocytic pathology. Several tauopathies, including
CBD and PSP, feature unique glial cell pathology, while others do not feature astrocytic
or oligodendrocyte tau inclusions (Kovacs, 2015). While the mechanisms that underlie
these patterns are not known, previous work suggested that inoculation of CBD patient
lysate into PS19 mice is sufficient to induce astrocytic pathology (Boluda et al., 2015).
Interpretation of this result was limited by the potential for individual patient brains to
contain multiple strains (Sanders et al., 2014), and inherent limitations in acquiring and
characterizing discrete forms of tau from patient samples (Boluda et al., 2015;
Clavaguera et al., 2013a). We thus tested whether individual tau conformation(s) could
be linked to astrocytic pathology.
Eight weeks after inoculation with DS7 and DS9, we observed tau pathology reminiscent
of astrocytic plaques in multiple animals, as noted by small AT8-positive inclusions
arranged in ring-like structures (Figure 3.7A) (Yoshida, 2014). Strains that produced
higher levels of tau pathology such as DS6 did not show similar plaque pathology at this
time point (Figure 3.7A). Co-staining with GFAP and AT8 indicated that these
accumulations consist of phospho-tau within or directly adjacent to astrocytes as is
typical of astrocytic plaques (Figure 3.7B) (Yoshida, 2014). DS12, 15, 16, and 18
induced a small degree of astrocytic plaque-like pathology at 8 weeks (Figure 3.8A-B).
Given these findings, we retrospectively quantified the number of animals with astrocytic
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plaque-like pathology after completion of the time course injection experiment described
below. DS7 or DS9 inoculations induced astrocytic plaque-like pathology in >85% of
mice by eight weeks, and 100% by 12 weeks (Figure 3.8A). The number of plaques in
each animal also increased over time. DS4 and DS6 induced this phenotype to a limited
degree by 12 weeks, but it was far less robust than the level observed in DS7 and 9
inoculated animals (Figure 3.8A, C).
While two CBD-derived strains showed a small degree of astrocytic plaque-like
pathology (DS12, 16), plaques were sparse and present in only one animal per condition
at this time point (Figure 3.8A, B). These strains may require a longer incubation time to
induce astrocytic plaque pathology, or we may have isolated a specific conformation that
does not underlie the astrocytic pathology observed in CBD brains. In summary, we
isolated two strains that reliably induce astrocytic plaque pathology in vivo. This
phenotype is independent of seeding activity, as DS7 is one of the weakest seeders we
have observed by the tau split-luciferase assay and in primary culture (Figure 3.1D-G).
Instead, specific tau conformations preferentially and predictably induce astrocytic tau
pathology.
Regional vulnerability to specific strains. Tauopathies feature accumulation of tau
pathology in distinct brain regions, yet the mechanisms that underlie these patterns are
not well understood (Arnold et al., 2013). To test whether strains differentially induce
pathology in specific brain regions, we inoculated DS1, 4, 6, 7, 9, 10 or 11 into six
locations per mouse: sensory cortex (SC), caudate/putamen (CP), visual cortex (VC),
hippocampus (Hip), thalamus (Thal), and inferior colliculus (IC) (Figure 3.9A). We
chose these strains based on their unique limited proteolysis fingerprints, the different tau
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pathology patterns that they induce in the hippocampus (Figure 3.5B-J) and their low
(DS7, 11), medium (DS4, 10) or high (DS6, 9) seeding activity in culture (Figure 3.1D,
F). Further, DS4 derives from AD and DS11 from CBD brain homogenates. Patients with
these diseases have different patterns of tau deposition (Arnold et al., 2013).
After five weeks, we quantified the level of AT8 pathology different strains induced at
each injection site in a blinded fashion (Figure 3.9B). All produced hippocampal
pathology consistent with the previous injection paradigm (Figure 3.5B-I), illustrating the
reproducibility of these phenotypes (Figure 3.9C). Strains with the strongest seeding
activity in culture (DS6, 9) produced pathology in every injected region. DS4, a mediumseeding strain, induced moderate pathology in each region except the IC. DS11 pathology
was entirely limited to the hippocampus (Figure 3.9B, C).
DS10 again induced pathology specific to the mossy fiber tracts of the hippocampus
(Figure 3.10A), with limited pathology in the caudate/putamen and thalamus. Of note, it
did not produce any pathology in the injected cortical regions. In contrast, DS7 produced
limited AT8 pathology in each targeted brain region (Figure 3.9B, C). The specificity of
DS10, despite its strong seeding activity, and promiscuity of DS7, despite its weak
seeding activity (Figure 3.1D-G), were remarkable. These studies indicate tropism of
certain strains for specific brain regions (mossy fiber tracts, cortical structures, IC) that is
independent of simple metrics such as seeding activity. This suggests complex biological
interactions that are dictated by strain structure determine regional vulnerability to a
given strain.
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Strains induce different rates of tau pathology spread along neuronal networks.
Even within a single clinical syndrome, tauopathy patients experience rapid or slow rates
of progression (Armstrong et al., 2000; Huang et al., 2014; Mann et al., 1992; Thalhauser
and Komarova, 2012). Unique PrP strains show different lag phases and rates of
neurodegeneration in animal models of prion diseases (Collinge and Clarke, 2007),
suggesting this phenomenon may be linked to specific aggregate conformations. While
several factors may contribute to the rate of degeneration observed in tauopathy patients,
rapid spread of tau pathology likely accelerates this process. Thus, we tested the
relationship between strain characteristics and different rates of spread of tau pathology.
To control for differences in insoluble material, we first quantified the insoluble tau
present in lysate from DS1, 4, 6, 7, 9, and 10 prepared for this time course experiment
(Figure 3.11A, B). As expected, each strain contained a large amount of insoluble tau.
However, we hypothesized that a strain’s ability to seed aggregation of endogenously
expressed monomeric tau would primarily determine the rate of spread of tau pathology.
We predicted that strains such as DS6 and 9 with high seeding activity in culture and in
vivo (Figure 3.1D, 3.9B-C) would produce rapid spread of tau pathology even after
inoculation of reduced levels of insoluble tau. To test this hypothesis, we included DS6
and DS9 lysate diluted 1:10 as part of this time course experiment.
We injected cell lysate from each condition into the hippocampus of young PS19 mice
and collected brains at 4, 8, and 12 weeks post-injection (Figure 3.11C). While each
strain induced tau pathology in the contralateral hippocampus, this occurred at different
time points (Figure 3.11D, E). DS6 and DS9 pathology progressed rapidly to the
contralateral hippocampus, beginning as early as 4 weeks (Figure 3.11D). DS10 induced
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mossy fiber dots and limited CA1 pathology in the ipsilateral and contralateral
hippocampus by 8 weeks (Figure 3.11D, E). DS7 wisp pathology also spread to the
contralateral hippocampus by 8 weeks (Figure 3.11D).
While dilution of DS6 and 9 decreased the initial level of pathology induced upon
inoculation, we observed tau pathology in the contralateral hippocampus at 8 weeks. In
contrast, DS4 did not show tau pathology in the contralateral hippocampus until 12 weeks
(Figure 3.11D, E). Thus, stronger strains induced more rapid spread of pathology even
with a reduced amount of insoluble tau inoculum, presumably due to more efficient
seeding and spread of endogenous tau aggregates. Interestingly, we also observed the
astrocytic phenotype in DS7, DS9, and DS9 1:10 dilution mice at 8 and 12 weeks. These
inoculation experiments were performed with cell lysate prepared specifically for this
experiment, further illustrating the reproducibility of this conformation-specific
phenotype (Figure 3.7, 3.8, and 3.11D).
To assess AT8 pathology induced by each strain, we performed a blinded analysis of
AT8 staining in slices at the level of the locus coeruleus, hippocampal injection site, and
caudate/putamen. We averaged AT8 pathology rankings for each region and displayed
them as a heat map to visualize the spread of tau pathology (Figure 3.12A). We
subsequently created a limited heat-map for each strain that focuses on specific brain
regions, several of which developed pathology over time (Figure 3.12B).
DS10 once again displayed marked neuronal specificity, with strong pathology only in
the mossy fiber tracts (Figure 3.12A, B). Blinded analysis also confirmed that DS4
exhibits slower kinetics than DS6 or 9 even when the latter strains are diluted 10-fold
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(Figure 3.12B). DS4 did not develop strong pathology outside the ipsilateral
hippocampus until 12 weeks after injection, while these stronger strains showed AT8
staining in distant brain regions by 8 weeks. DS7 induced robust pathology at the
injection site as observed previously (Figure 3.5, 3.9). Despite this, the spread of DS7
pathology was relatively slow, and appeared limited to the hippocampus (Figure 3.12A,
B). Thus, despite inducing pathology in several regions upon direct injection (Figure
3.9B, C), DS7 has limited ability to spread pathology to distant regions. In other words,
its tropism is broad, but its potential for propagation is low.
DS6 and 9 spread rapidly to specific brain regions after 4 weeks. DS6 strongly targeted
the ipsilateral retrosplenial cortex and LC, while DS9 pathology spread most strongly to
the ipsilateral entorhinal cortex and thalamus. Despite these initial differences, by 8
weeks the patterns of pathology induced by these strains largely resembled one another,
and developed within regions that have strong axonal connections to the hippocampus
(Figure 3.12B). While diluted lysate of DS6 and 9 induced lower levels of pathology at
early time points, by 12 weeks the pathology spread rapidly and followed similar patterns
to that of undiluted lysate. Further, despite having lower burdens of total insoluble tau,
these diluted lysates induced pathology that spread faster and farther than DS4, 7 or 10
(Figure 3.12B).
Finally, we performed a seeding assay on tissue from the ipsilateral and contralateral
hippocampus, thalamus, and sensory cortex at eight weeks post injection as a second
metric of tau pathology. While the split-luciferase assay is quantitative and very useful
for lysates with high seed titers, the FRET-based biosensor system we have previously
reported is more sensitive and has a larger dynamic range (Holmes et al., 2014). We
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transduced homogenized brain regions into the FRET biosensor cell line and quantified
the level of FRET produced after two days in culture. We have observed that all seeding
activity measured after inoculation of DS9 into the hippocampus of tau knockout mice
dissipates by approximately six weeks (data not shown). Thus, any signal identified at
this time point likely derives from aggregation of endogenous tau expressed in this mouse
line.
Several strains displayed robust seeding in the ipsilateral hippocampus (DS4, 6, 9, 10,
and 1:10 diluted DS6 and 9). While each of these strains spread to the contralateral
hippocampus, DS4 showed distinctly less contralateral seeding activity as a percentage of
the ipsilateral hippocampus (Figure 3.12C). Further, DS6 and 9 showed variable yet
significant seeding activity in the ipsilateral thalamus. The level of seeding observed in
DS1 inoculated mice is consistent with the level observed in this mouse model at 4-5
months of age, suggesting this signal is due to spontaneous aggregation of endogenous
tau that normally occurs within this model (Holmes et al., 2014).
DS7 showed remarkably low seeding activity despite displaying robust AT8 pathology.
This is consistent with the finding that DS7 cell lysate produces very low seeding activity
in the tau split-luciferase assay, despite a high amount of aggregated tau (Figure 3.1D,
3.3G-I). This suggests the conformation of the aggregates induced in this mouse model is
likely similar to the conformation of the original inoculum. The high seeding activity
observed in DS10-inoculated mice, despite this strain only targeting mossy fiber tracts of
the hippocampus, is also concordant with initial findings in the split-luciferase seeding
assay (Figure 3.11E, 3.12C). These results are consistent with the different rates of spread
observed by AT8 immunohistochemistry for DS4 versus DS6 and 9, while providing a
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separate metric to quantify the spread of pathology for strains such as DS10. Taken
together, we have observed clear strain-specific patterns of local pathology, local seeding,
regional vulnerability, and rates of spread throughout brain networks. These data are most
consistent with the idea that aggregate structure alone is sufficient to dictate several
important aspects of tau pathology.
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3.6

DISCUSSION

Overview of findings. Based on isolation of 18 putatively distinct tau prion strains in
vitro, we have tested whether specific tau fibril conformations can account for several
critical neuropathological features that are used to discriminate tauopathies. We
characterized these strains by various biochemical and biological metrics, including
induced morphology of cellular inclusions, seeding activity in dividing cells and primary
neurons, detergent solubility, cellular toxicity, and limited proteolysis (Figure 3.1-3.4).
We separately inoculated all 18 strains into the hippocampus of a transgenic mouse that
expresses full-length human tau harboring the P301S mutation (PS19 mice). We observed
several distinct patterns of tau accumulation in cell bodies, axons, and dendrites in the
hippocampus, amidst larger patterns of induced pathology (Figure 3.5-3.6). Some strains
(DS7 and 9) produced astrocytic tau plaques similar to those described in individuals
with corticobasal degeneration (Figure 3.7-3.8), but most did not. To test for regional
vulnerability, we injected 6 strains into 6 different brain regions, and waited 5 weeks to
evaluate pathology. Many induced pathology in all regions (DS6, 7, and 9), while others
exhibited restricted patterns in which very little or no pathology occurred despite direct
exposure of neurons to a particular strain (DS4, 10, 11) (Figure 3.9-3.10). We next tested
whether strains exhibited unique rates of propagation through the brain. In this case we
observed some correlation with in vitro parameters: strains with high seeding activity
tended to spread more rapidly through the brain, with one important exception—strain
DS10—which only spread to the contralateral mossy fiber tracts of the hippocampus
(Figure 3.11-3.12). Within the limits of our experimental system, these observations
suggest that distinct tau prion strains can account for many of the features observed in
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human tauopathies. This experimental system also allows one to make predictions that
derive from the biochemical properties of a given strain (e.g. high seeding strains induce
rapid, robust spread even upon a 1:10 dilution, as predicted in culture). More importantly,
the characterization of unique strains in vitro using reductionist cell-based assays
provides a critical step to determine the relationship between tau prion structure and
biological activity.
Limitations of this experimental approach. It is impossible at this time to directly
control strain production in vivo using transgenic mice, or to propagate tau strains
faithfully and indefinitely in vitro without using a cultured cell system. This work relies
on a cell model that expresses a truncated form of tau with a fluorescent protein tag.
However, this imperfect system has allowed us to propagate distinct tau prion strains
indefinitely in cultured cells. Likewise, in animal models, we utilized an imperfect model
that expresses full-length human tau (1N4R) that contains a disease-associated mutation
(P301S) (Yoshiyama et al., 2007). While this obviously deviates from sporadic tauopathy
that occurs in most cases, it has enabled us to rapidly and reliably induce unique tau
pathology based on local inoculation. We cannot exclude the possibility that inoculated
tau prions themselves are moving throughout the brain and inducing pathology based on
local uptake rather than true trans-neuronal propagation (Rey et al., 2013). Nonetheless,
our observations speak to a disease mechanism whereby strain-specific differences
govern seeding, propagation, and specific regional vulnerability.
The utility of studying isolated strains. Most evaluations of prion activity in vivo
involve injection of material purified from the brains of patients with different
syndromes, or the production of fibrils that have distinct ultrastructural morphologies.
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Both approaches are potentially confounded by heterogeneity of fibrillar species. Our
prior work has indicated that human tauopathy brains, even those carefully defined by
histopathology, exhibit enormous diversity of strains within and between individuals
(Sanders et al., 2014). Thus, syndromes that appear to be clinically and
neuropathologically identical are potentially quite distinct in terms of their strain
composition. This presents obvious caveats when attempting to define strains present in
human disease based principally on inoculation of purified aggregates into mice. In the
case of fibril production in vitro, a multiplicity of structures will typically form. In this
study, we isolated several unique tau strains from recombinant tau fibrils (Figure 3.2A).
Further, as fibril preps are repeatedly amplified this population will gradually change in
its composition. This has been clearly illustrated by recent studies, in which a single
preparation of a-synuclein fibrils gradually changes from one dominant structure to
another (Guo et al., 2013). In this work, we have stably propagated strains with specific
biochemical properties indefinitely in a rarified culture system based on expression of tau
RD with two disease-associated mutations fused to YFP. This has allowed us to work
with stable strain preparations that most likely represent unitary structures, and has
further enabled us to make predictions about their in vivo phenotypes based on properties
observed in culture.
Prion strains characterized in vitro. Scrapie prion strains, described over 40 years ago,
have distinct, yet reproducible patterns of incubation time, neuropathology, and
behavioral phenotypes (Collinge and Clarke, 2007). Strains are distinct amyloid
structures that faithfully replicate in a living system, and produce well-defined pathology.
Thus, if a strain is identified, it is possible to predict incubation time and resultant
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pathology (Collinge and Clarke, 2007). Recently, the term “strain” has been used widely
to refer to distinct neuropathology that results from injection of various tau or synuclein
preparations into mouse models (Bousset et al., 2013; Guo et al., 2013). Without isolation
of a single structural conformer that is stably replicated and produces a reliable
phenotype, these “strains” have limited mechanistic, therapeutic, or diagnostic
significance, as it is difficult to study them in a reductionist system or make biological
predictions based on a particular structure.
In this work we characterized multiple tau strains from recombinant, mouse, and patient
sources in vitro and in vivo. We began by isolating strains based on stable motherdaughter maintenance in clonal cells. We then determined their seeding efficiency using a
quantitative split-luciferase reporter assay. We also determined the relative solubility of
each strain, and its toxicity when introduced into a reporter cell line with relatively high
tau RD-YFP expression. We observed no correlation between seeding activity and
insoluble protein, while toxicity correlated well, albeit imperfectly with seeding activity.
Finally, we probed strain structure using limited proteolysis. This provided the most
definitive differentiation among strains in tissue culture. The characterization of multiple
tau prion strains in vitro allowed us to directly correlate their effects in vivo. Seeding
activity correlated best with induction of local and distant pathology, but this was highly
imperfect, indicating a major role for other strain-specific parameters. With further, more
detailed study, we hope to link specific structural characteristics to various steps in
pathogenesis, i.e. to discern a “logic” that predicts biological effects. For example, celltype specificity (or at least preference) might be based on differential strain binding
affinities to heparan sulfate proteoglycans (Holmes et al., 2013a). Likewise, post160

translational modifications of monomeric tau within a target cell might render it more or
less vulnerable to conversion by a specific strain.
Distinct cellular pathologies in vivo. Tauopathies are defined histopathologically by
several criteria, especially the pattern of intracellular tau accumulation: neurofibrillary
tangles, Pick bodies, threads, grains, axonal puncta, etc. (Kovacs, 2015). The presence or
absence of specific glial pathology also contributes to the definition (Yoshida, 2014).
Although we have readily observed patterns of pathology reminiscent of those described
in patients, we have not attempted to link the patterns observed in humans to those in
P301S mice, which express only a single isoform of mutant tau. Instead, we wish to
emphasize how conformational differences in tau prion strains are sufficient to create an
enormous diversity of patterns: neurofibrillary tangle-like pathology, soma versus axonal
accumulation, grain-like structures, dendritic and axonal terminal deposits that resemble
threads, and astrocytic plaque-like pathology. Further, three strain pairs (DS3/DS19;
DS12/16; and DS6/15) that displayed similar biochemical features and limited proteolysis
patterns produced similar patterns of neuropathology in vivo (Figure 3.5-3.6). These
strains served to internally validate the methods we developed, and highlight the close
relationship of strain type to induced pathology.
Rates of propagation in vivo. Neurodegenerative diseases progress at different rates for
unknown reasons. Similar to previous observations regarding PrP prion strains (Legname
et al., 2006), our data indicate that the characteristics of an individual tau prion strain are
sufficient to dictate the rate at which pathology spreads throughout the nervous system.
Seeding activity correlates with this phenomenon, but cannot explain it in isolation.
Instead, the rate of spread appears to reflect a unique interaction of specific strains with
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vulnerable cells. For example, strain DS10 seeds very strongly in vitro, but fails to
propagate pathology outside of the hippocampal mossy fibers. Likewise, DS6 seeds very
strongly in vitro, but exhibits a longer lag phase as it spreads to specific brain regions
such as the entorhinal cortex versus the retrosplenial cortex. In contrast, DS9 showed
more rapid spread to the entorhinal than the retrosplenial cortex. Taken together, our
results suggest that the rate of propagation must be strongly influenced by raw seeding
potential, i.e. the ability to convert monomeric tau upon direct introduction to the
cytoplasm via lipofectamine, but also the ability of a given strain to spontaneously enter
and replicate within a vulnerable cell.
Distinct patterns of glial pathology. Glial pathology occurs in certain tauopathies but
not others (Kovacs, 2015). The underlying cause of these differences is unknown, and has
been attributed to different tau isoforms, or other factors, but has not been predictably
recapitulated in mouse models. We observed that certain strains produce AT8-postive
pathology in patterns reminiscent of astrocytic plaques described in tauopathies, with
localization of phospho-tau inclusions along the processes of GFAP-positive astrocytes
(Yoshida, 2014). We cannot attribute these effects to tau seeding activity or toxicity, as
we observed these phenomena in DS7 (low seeding, low toxicity) and DS9 (high seeding,
high toxicity). Given that inoculates were identical with the exception of tau structure,
and the transgenic mouse model expresses only a single tau isoform, we conclude that tau
prion strains themselves dictate the resultant glial pathology.
Distinct regional vulnerabilities. The explanation of regional, or “selective” neuronal
vulnerability in neurodegenerative diseases has long confounded investigators.
Importantly, PrP prion strains have been observed to account for differential regional
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involvement of the brain (Collinge and Clarke, 2007). Within the limits of our
experimental system, our identification and characterization of distinct tau strains has
allowed us to test whether aggregate structure itself defines regional vulnerability. We
have found striking strain-specific regional differences, both in the pattern of spread from
a single hippocampal inoculum, and also in vulnerability to a direct injection. These
effects reliably tracked to individual tau strains, and were independent of the inoculum
dose itself, which might have been expected to account for vulnerability. For example,
10-fold dilution of a potent strain, DS9, produced patterns of spreading pathology very
similar to a full dose. Further, low-dose DS9 spread at a faster rate than a full dose of
DS4, even though the initial “seed burden” of DS9 was less. By contrast, strain DS10 has
relatively high seeding activity yet it selectively targets the mossy fibers of the
hippocampus, and does not convert tau in several other brain regions even after direct
inoculation.
We are not the first to observe that different tau fibril preparations produce unique
patterns of pathology. Groups have inoculated tau purified from tauopathy patient brains
or bulk brain homogenate (Boluda et al., 2015; Clavaguera et al., 2013a), and two groups
have inoculated unique synuclein preparations (Bousset et al., 2013; Guo et al., 2013;
Peelaerts et al., 2015). However, no prior studies can attribute these effects to a single,
well-characterized strain or structure, or make predictions about the behavior of a strain
in vivo from the biochemical properties of that inoculum. Given that we can now link
specific pathology patterns to single tau prion strains, the experiments described here
should enable new approaches to define how the structural characteristics of prions
dictate neuronal vulnerability.
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Implications for diagnosis and therapy. There is no effective therapy for any
tauopathy, and precise diagnosis of tauopathy syndromes currently depends on
histopathology. Our prior work suggests that this approach may have limitations, since
we observed different strain composition patterns even in brains that were considered
identical based on histopathology (Sanders et al., 2014). If distinct tau strains propagate
between cells, this predicts that certain therapeutic antibodies or small molecules that
target tau will be more effective against particular strains, and that, as for PrP, strain
evolution may confound efforts to target a specific strain type (Ghaemmaghami et al.,
2011; Giles et al., 2010; Li et al., 2010; Oelschlegel and Weissmann, 2013). The ability
to create and propagate distinct strains in vitro presents a unique opportunity to create
antibodies that target them more precisely. Further, with knowledge that distinct tau prion
strains may underlie and predict the development of unique syndromes, the development
of methods to identify and discriminate clinically relevant strains will greatly enhance
diagnostic accuracy.
Conclusion. Useful scientific models allow testable predictions, and can explain a
diversity of observed phenomena in nature. In this case, we propose a very simple idea:
tau prion strains as defined in reductionist systems can account for enormous diversity of
neuropathology. In other words, it appears possible to explain in large degree the range of
phenotypes observed in tauopathies based principally on the tau prion structure(s) that
underlie them. This study has not determined tau prion strain structure beyond
differentiation by proteolytic digestion—we can discriminate, and thus characterize
different species, but cannot draw specific structure/function correlations with regard to
replication rate, cell biology, and neuroanatomy. Nonetheless, we propose that the
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concept of tau prion strains as defined by specific conformations will have enormous
power to elucidate the structural determinants that underlie and predict the pathological
patterns of diverse human tauopathies.
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3.7

FIGURES

Figure 3.1. Generation and characterization of a tau prion strain library. (A) A
monoclonal HEK293 line stably expressing tau RD P301L/V337M (“LM”)-YFP (Clone
1/DS1) was treated with diverse sources of fibrillar tau seeds, and 90 monoclonal lines
that stably propagated tau inclusions were derived and characterized by the indicated
metrics. 18 strains were differentiated based on their unique properties in the indicated
assays. (B) Several tau inclusion phenotypes were identified in the monoclonal tau
strains: mosaic (magenta), ordered (blue), speckles (red), threads (orange), and disordered
(brown box). With the exception of the mosaic phenotype, these inclusion phenotypes
were stably propagated to daughter cells over months of division. A negative control cell
line (diffuse) featured soluble tau (green box). (C) Limited proteolysis using pronase was
used to differentiate the protected fibrillar cores in individual tau strains. Unique
“fingerprints,” along with other metrics, were indicative of structurally distinct tau prion
strains. (D) A tau RD P301S split-luciferase assay demonstrates that individual strains
have large differences in their abilities to seed the aggregation of monomeric tau when
introduced directly into the cytoplasm of dividing cells. Seeding ratio indicates relative
luminescence relative to sham treatment. Biological quadruplicates with saturating
quantities of lysate were averaged. Error bars represent S.E.M. for biological
quadruplicates. (E) Differences in seeding abilities between strains are replicated in
primary neurons. Primary hippocampal neurons expressing tau RD P301S-CFP and tau
RD P301S-YFP were treated with lysates derived from various strains. 96-hours later,
neurons were fixed, and the percentage of cells featuring seeded aggregates was
determined by FRET flow cytometry. Error bars represent S.E.M. for biological
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quintuplicates. (F) Relative seeding abilities for strains are preserved in primary neurons
expressing full-length tau. Primary hippocampal neurons expressing 1N4R tau P301SYFP were exposed to lysates from each strain and the extent of seeding was semiquantitatively determined at various time points (D = number of days) based on the extent
of visible YFP puncta (0-5: 0 = none, 5 = abundant inclusions). Strains showed variable
lag times and extent of seeding, which correlated with their ability to seed in the splitluciferase complementation assay. (G) Strains differentially induce the formation of
insoluble tau aggregates in primary neurons. Triton-X was used to remove soluble tau
and primary neurons were stained for conformationally altered tau (MC1) five or eight
days following seeding. Strains showed significant differences in their abilities to seed
further aggregation in neurons, which paralleled differences in the split-luciferase
complementation assay.
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Figure 3.1
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Figure 3.2. Origin of strains and primary neuron seeding. (A) 18 putative tau strains
propagated on a monoclonal HEK293 background (Clone 1/DS1) were derived from
diverse recombinant protein, transgenic mouse, and patient sources as indicated in the
table. Some strains were passaged from cell lines previously characterized. Strains are
color-coded based on their associated inclusion morphology. (B) Strains showed
variability in their ability to seed the formation of insoluble tau aggregates in primary
hippocampal neurons. Lysates from individual strains were added to primary neurons.
Eleven days later, neurons were fixed and Triton-X was used to extract soluble tau.
Accumulation of conformationally altered tau was assessed by MC1 staining. Strong
seeders in the tau split-luciferase complementation assay produced more insoluble tau
pathology in neurons.
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Rec Fibrils
N/A
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N/A

Abbreviations:
Rec fibrils = recombinant tau fibrils
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CTE = chronic traumatic encephalopathy
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HEK Morphology
Diffuse (1)
Mosaic (2)
Ordered (3,10,14,19)
Speckles (4,5,7,8,9,
12,16,17,18)
Threads (6,15)
Disordered (11,13)

Figure 3.3. Seeding ability but not insoluble tau levels correlates with toxicity in vitro.
(A) Strains showed large differences in their abilities to seed monomeric tau as determined
by a tau split-luciferase complementation assay. Indicated amounts of strain lysate were
transduced into tau RD P301S split-luciferase cells, seeding ratios relative to sham
treatment were determined, and titration curves were plotted using non-linear regression
with one-phase decay fit. Error bars represent S.E.M for biological quadruplicates. (B)
Based on titration curves in the tau split-luciferase complementation assay, the EC50,
inflection point, and peak seeding ratio were determined for each strain. The inflection
point represents the amount of lysate required to achieve a 50% increase in luminescence
relative to sham treatment. (C) Peak seeding significantly correlated with EC50s for the
strain library in the tau split-luciferase complementation assay. (D) Strains displayed
significant differences in toxicity. Strains were transduced in biological triplicates into cells
overexpressing both tau RD LM-CFP and tau RD LM-YFP. 72-hours later, equivalent
numbers of aggregate-containing (FRET+) cells were sorted for each condition by FRET
flow cytometry. For the negative control (DS1), aggregate-negative (FRET-) cells were
sorted. Sorted cells were given a week to proliferate in technical sextuplicates. Aggregatepositive (FRET+) and aggregate-negative (FRET-) cells were then quantified by flow
cytometry. The presence of FRET- cells in certain conditions reflects the fact that some
strains lose the aggregated state with cell division. Error bars represent S.E.M. of biological
triplicates. Technical sextuplicates were first averaged for each biological replicate. (E)
Aggregate-positive (FRET+) cells were quantified and plotted after one week of growth.
Error bars represent S.E.M. of biological triplicates. (F) Toxicity significantly correlates
with seeding ability for the strain library. The number of aggregate-positive (FRET+) cells
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for a strain was plotted against its peak seeding ratio in the tau split-luciferase
complementation assay. Strains that seed more efficiently are associated with reduced
growth of aggregate-positive cells. (G) Sedimentation analysis was performed on the strain
library. Lysates were ultracentrifuged and tau as well as a loading control protein (cofilin)
were probed in the total, supernatant, and pellet (Tot = total, Sup = supernatant, Pel =
pellet). Blots are representative for biological quadruplicates. (H) Sedimentation analysis
indicates that all strains feature the majority of tau in the insoluble pellet fraction.
Densitometric analysis of tau in the total, supernatant, and pellet fractions was used to
calculate supernatant to total ratios (a higher ratio indicates a smaller proportion of tau in
the insoluble pellet). Error bars represent S.E.M. of biological quadruplicates. (I)
Densitometric analysis of tau in the insoluble pellet fraction suggests variability in the
extent of aggregated tau in the various strains. Error bars represent S.E.M. of biological
quadruplicates. (J) Despite differences in the quantity of insoluble tau for various strains,
this metric does not correlate with seeding ability as reflected by the peak seeding ratio.
(K) Quantity of insoluble tau does not correlate with a strain’s toxicity.
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Figure 3.4. Seeding ability but not total tau correlates with toxicity in vitro. (A) A tau
strain’s seeding ability correlates with its toxicity. The number of aggregate-positive
(FRET+) cells for a strain was plotted against its associated EC50 in the tau splitluciferase complementation assay. Strains that reached their half-maximal seeding at
lower protein concentrations were associated with decreased cell growth. (B) The
association between greater seeding and toxicity was further strengthened by a significant
correlation between cell growth (FRET+ cells) and inflection point, the amount of lysate
required for a strain to show significant seeding in the tau split-luciferase
complementation assay. (C) Densitometric analysis of tau in the total fraction suggests
variability in the extent of total tau in the various strains. Error bars represent S.E.M. of
biological quadruplicates. (D) Despite differences in total tau, this property does not
correlate with a strain’s peak seeding ratio. (E) There is no correlation between a strain’s
total tau and its toxicity as assessed by relative growth of aggregate-positive (FRET+)
cells.
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Figure 3.5. Tau prion strains induce diverse patterns of hippocampal tau pathology.
(A) Tau strains (10 µg) were injected into the left hippocampus of young PS19 mice (n=3
per condition). Mice were sacrificed 8-weeks post injection. Relevant hippocampal
regions are diagramed onto a representative mouse hippocampus (DG, dentate gyrus; mf,
mossy fibers; Sub, Subiculum). (B) DS1 injection produced no AT8 tau pathology.
Representative images of CA1 and CA3 are displayed for whole hippocampal images for
DS1-19. Scale bars represent 50 µm. (C) DS10 produced AT8 positive mossy fiber (mf)
“dot” pathology, with limited CA1 pathology as observed previously. (D) DS14 seeded
mf dots similar to DS10, as well as tangle-like pathology, indicating that it is a dinstinct
strain despite its other similar features to DS10. (E) DS7 induced “wisps” that resemble
neuropil threads, but may fall within axon terminals and the dendritic tree of pyramidal
neurons. (F) DS18 pathology included wisps and mf dots similar to DS7 and 10
respectively, as well as “grains” that were found throughout much of the hippocampus.
(G-H) Several strains produced different levels of tangle-like AT8 pathology in CA1 and
CA3 of the hippocampus. (G) DS2, 3, 11, 19 induced rare AT8 pathology in pyramidal
CA1 neurons. The localization of AT8 staining varied in certain cases (DS2 primarily in
cell bodies), but this may simply represent different levels of maturity of tangles. (H)
DS4, 8, 12, 13, 16, 17 induced slightly stronger tangle-like pathology in CA1 of the
hippocampus (“low tangles”). CA3 showed limited or no tangle pathology at this time
point. (I) DS5 and 9 produced AT8 tangle-like tau pathology that reached CA3 of the
hippocampus as well as CA1 pyramidal cells (“medium tangles”). Tangles appeared
relatively consolidated within the soma of neurons. (J) DS6 and 15 display the highest
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level of tangle-like AT8 pathology (“high tangles”). Highly consolidated pathology was
observed throughout cell bodies and axons of CA1 and CA3 neurons.
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Figure 3.6. Strains induce unique tau pathology in various brain regions. (A) AT8
pathology present in the ipsilateral hippocampus of DS1-19. Morphology refers to the
original cell line phenotype inoculated into the hippocampus. Scale bars represent 250
µm. (B) Spread of AT8 tau pathology to the contralateral hippocampus and ipsilateral
entorhinal cortex in DS5 and 9 (medium tangles), and DS6 and 15 (high tangles). Low
levels of DS1 baseline staining can be observed in the ipsilateral EC, and is at the level
expected for animals at this age. Scale bars represent 250 µm for the whole hippocampus,
and 50 µm for EC. (C) DS10 and 14 show mossy fiber dots in the contralateral
hippocampus. DS14 CA1 AT8 tangle-like pathology is much stronger than DS10. Scale
bars represent 250 µm for the whole hippocampus, and 50 µm for CA1 and CA3. (D)
DS18 shows grains throughout CA1, and wisps in the ipsilateral EC, showing the unique
features induced by this strain can spread to distant regions. Scale bars represent 250um
for the whole hippocampus, and 50um for CA1 and EC.
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Figure 3.7. Specific strains induce astrocytic tau pathology. (A) AT8 tau pathology 8weeks after injection with DS1, 6, 7, or 9. DS1 did not induce tau pathology. DS6, 7 and
9 developed strong AT8 staining in ipsilateral and contralateral hippocampi. DS7 and 9
developed diffuse, circular-shaped accumulations of AT8 staining that did not appear to
localize to a neuronal cell body (black arrow heads). Scale bars represent 250 µm for the
whole hippocampus, and 50 µm for CA1. (B) Co-staining of AT8 (green) for phosphotau, GFAP (red) for astrocytes, and DAPI (blue) for cell nuclei. DS1 showed limited
GFAP staining, and no AT8 pathology. DS6 showed strong AT8 staining with limited
overlap of AT8 staining. DS7 and 9 injected mice showed astrocytic plaque-like
pathology that either deposited within or around GFAP-positive processes of astrocytes.
Scale bars represent 25 µm for left-most column, and 10 µm for all remaining images.
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Figure 3.8. Certain strains reliably produce robust astrocytic pathology that
increases over time. (A) Quantification of the number of mice that displayed astrocytic
tau pathology at 4, 8, or 12 weeks post-inoculation with different strains. Two
experimental inoculations were assessed for astrocytic pathology. Greater than 85% of
animals inoculated with DS7 or 9 display astrocytic plaque-like pathology by 8-weeks.
Other strains do not show any consistent plaque pathology until 12-weeks. (B) Average
number of plaques counted in ipsilateral hippocampus of time course inoculation mice.
Several other strains begin to develop astrocytic pathology by 12-weeks, but the number
of plaques is far lower than that observed in DS7 and 9. (C) Representative images of the
astrocytic plaque-like pathology observed in 1/3 animals inoculated with DS12, 15, 16,
and 18 at 8-weeks post injection. Scale bars represent 50 µm.
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Figure 3.9. Tau strains preferentially seed pathology in specific brain regions. (A)
Six tau strains were injected simultaneously into six brain regions: sensory cortex (SC);
caudate/putamen (CP); visual cortex (VC); hippocampus (Hip); thalamus (Thal); inferior
colliculus (IC) (5 µg per region). Mice that received DS1 (negative control), 4, 6, 7, 9, 10,
or 11 strain injections were kept for 5-weeks post-inoculation before collection and
assessment of AT8 tau pathology (n=3 per condition). (B) Strains preferentially induce
tau pathology in specific brain regions. Slices that contained the injection sites were
stained for AT8 phospho-tau. Each injection site was assessed in a blinded fashion for tau
pathology on a 0-3 scale (none, low, medium, high pathology). The level of background
AT8 pathology at each injection site was accounted for by subtracting the level of
pathology present in DS1 mice within each brain region. A binned heat map was
generated to represent the level of pathology observed at the injection site for each strain.
(C) Representative images are displayed for each brain region injected with the different
tau strains. Scale bars represent 100 µm.
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Figure 3.10. DS10 reliably produces mossy fiber dot pathology. (A) Mice inoculated
with DS10 for the regional vulnerability experiments develop mossy fiber dots as
expected in the ipsilateral and contralateral hippocampus. Scale bars represent 250 µm
for the whole hippocampus, and 50 µm for CA3.
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Figure 3.11. Strains induce different rates of tau pathology spread. (A)
Sedimentation analysis was performed on cell lysate used for this time course inoculation
experiment. Each strain contains a large amount of insoluble material (T, total; S, soluble;
I, insoluble). Western blot analysis of insoluble tau was performed on three biological
replicates. For each experiment, the soluble fraction was loaded at 2x the concentration of
the total and insoluble fractions. A cofilin loading control was performed on the blots to
verify the same amount of cell lysate was added for each strain. (B) The level of
insoluble tau present in each strain was quantified by measuring the mean grey value of
the insoluble tau western blot band. Samples were normalized to the mean grey value of
cofilin in the total cell lysate fraction. An ANOVA shows strains have significantly more
insoluble tau than DS1. A two-way t-test demonstrates DS10 and DS4 do not contain
significantly different levels of insoluble tau (ns for P > 0.5; * for P ≤ 0.05; ** for P ≤
0.01). Error bars represent S.E.M. of biological triplicates. (C) Strains were inoculated
into the hippocampus of young PS19 mice (n=6 per condition per time point). DS6 and 9
lysate diluted 1:10 in HEK293 cell lysate was also injected as part of this experiment
(n=4-5 per condition per time point). Mice were collected at 4, 8, or 12 weeks and brain
slices were stained for AT8-positive tau pathology. (D) Representative images of
ipsilateral and contralateral CA1 are displayed for each strain at 4, 8 and 12 weeks postinjection. Tau pathology spreads to the contralateral hippocampus at different time
points. Diluted DS6 and 9 lysate showed faster spread than concentrated DS4, and more
robust spread than DS7 and 10 at 8-weeks post-injection. Scale bars represent 50 µm. (E)
Spread of mossy fiber dot pathology occurs by eight weeks in DS10 mice. Dot pathology
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appears to eventually develop in DS4 mice, but that spread appears to be delayed
compared to DS10.
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Figure 3.12. Conformation affects the rate and pattern of spread of tau pathology.
(A) Slices from mice injected with each strain at each time point were stained for AT8
pathology. Tau pathology was quantified in a blinded fashion on a 0-3 scale, and
averaged for each location within a given condition (n=6 per condition). A continuous
heat map was generated. Regions are listed on the x-axis, and conditions/time points are
on the y-axis. (B) Limited heat maps were generated from the above data set (Figure
3.12A). Ipsilateral (Ip) and contralateral regions were included to assess pattern and rate
of spread of pathology (retrosplenial cortex, RS; entorhinal cortex, EC; sensory cortex,
SC; thalamus, Thal; CA1 of hippocampus, CA1; locus coruleus, LC; subiculum, Sub).
Time points are arranged in order from earliest (4-weeks) to latest (12-weeks). Diluted
DS6 and 9 lysates were also displayed (DS6 1:10 and DS9 1:10). (C) Homogenized
tissue from the hippocampus, thalamus, or sensory cortex of mice 8-weeks after
inoculation with strains was applied to tau biosensor cell lines. After 48-hours, cells were
collected and flow cytometry was performed to quantify the level of seeding activity in
each region by integrated FRET density (IFD = percent FRET-positive cells*median
fluorescent intensity of FRET positive cells). DS4 showed lower spread of seeding
activity to the contralateral hippocampus at 8-weeks. DS10 displayed high seeding
activity despite limited AT8 pathology, while DS7 showed low seeding activity despite
high AT8 pathology. DS6 and DS9 showed seeding activity in ipsilateral thalamus. A
one-way ANOVA with Bonferroni correction for multiple comparisons was performed
between ipsilateral DS1 and every other sample within a given region. (* P ≤ 0.05; ** P ≤
0.01; *** P ≤ 0.001; **** P ≤ 0.0001). Error bars represent S.E.M., n = 4-5.

190

Figure 3.12
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Figure 3.13. Summary of mice used in inoculation experiments. List of experimental
mice discussed in this study, including sex, age at time of surgery, and age at time of
tissue collection.
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Chapter 4: Conclusions and Future
Directions
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4.1

PREFACE

This chapter contains reference to unpublished data (see Appendix) that will be
used in a future manuscript:
Sanders D.W., Vaquer-Alicea, J., Saha, I., Spasova, A., Grinberg, L.T., Mirzaei, H.,
Hartl, F.U., Hipp, M.S., Diamond, M.I. (In Preparation). Characterization of the tau
aggregate interactome.

Note: In section 4.4, three tau aggregate-associated proteins are termed “Protein A”,
“Protein B”, and “Protein C”. See Appendix, which is redacted for one year to protect
ongoing research, for identity of these proteins.
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4.2

SUMMARY OF RESULTS

Over the past decade, extensive data has been amassed, which supports the hypothesis
that fibrillar aggregates (amyloids) spread along neuronal networks to drive the
progression of neurodegenerative diseases (Guo and Lee, 2014; Sanders et al., 2016;
Walker and Jucker, 2015). However, the mechanisms that underlie the phenotypic
diversity observed in the tauopathies (e.g. Alzheimer’s disease, Pick’s disease,
corticobasal degeneration) and other common proteopathies have remained elusive. How
is it that one pathogenic protein fibril (e.g. tau) can drive such diverse clinical outcomes?
Decades of research have suggested why such phenotypic diversity exists in the
prionopathies (e.g. Creutzfeldt-Jakob disease). The prion protein (PrP) can form a
multitude of amyloid structures that stably replicate with remarkable fidelity over
tremendously long time scales in animal models of prion disease (Collinge and Clarke,
2007). Based on simple polymorphism at the level of amyloid structure, diverse
syndromes can result, each having its own characteristic incubation period, regions of the
brain affected, and cell types featuring pathogenic accumulations of PrP prions (Collinge
and Clarke, 2007; Gambetti et al., 2011). In my dissertation work, I asked whether selfpropagating tau prion strains are similarly responsible for the phenotypic diversity
observed in the tauopathies, a category of diseases that features over a dozen major
neurodegenerative syndromes (Lee et al., 2001) (Figure 4.1). I reasoned that for this to be
the case, tau must form numerous different conformations (i.e. prion strains) that
replicate themselves with fidelity through living systems over time scales that would
approach those seen in the gestation of patient diseases. Moreover, these strains must
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result in distinct experimental tauopathies that re-capitulate unique features of human
diseases (e.g. selective vulnerability of different cell types and brain regions). Further, I
hypothesized that different tauopathies should be able to be differentiated based on the
tau amyloid conformations (strains) that they feature.
In order to test these hypotheses, I developed a reductionist approach to study tau
aggregate biology, generating a dividing, monoclonal human cell line (DS1) that stably
expresses a truncated version of tau fused to a YFP reporter (Chapter 2) (Sanders et al.,
2014). These cells never spontaneously develop tau aggregates. However, when one adds
recombinant tau amyloids (but not other fibrils such as α-synuclein and amyloid beta) to
the media, tau-YFP within the cells rapidly converts from a soluble to an aggregated
state. The aggregated state then becomes self-propagating, inherited as an epigenetic trait
by daughter cells. Similar epigenetic inheritance of the aggregated state had previously
been reported for PrP, (Taraboulos et al., 1990a), Sup35 (Krammer et al., 2009), and
SOD1 (Münch et al., 2011) prions, indicating that mammalian cells feature a remarkable
ability to replicate fibrillar amyloids. Next, I isolated numerous monoclonal lines that
featured aggregates, and identified two clones (DS9 and DS10) that appeared distinct
based on their patterns of tau aggregate accumulation (DS9: small juxtanuclear
aggresome with nuclear speckles; DS10: large juxtanuclear aggresome with no nuclear
speckles). These inclusion morphologies remained unaltered following six months of cell
division. Further analyses (limited proteolysis, sedimentation analysis, seeding efficacy,
aggregate size, toxicity) confirmed that each cell line stably replicated a different
aggregate structure.
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But to be true prion strains, phenotypes must be independent of the original cellular
context. A stringent test of this is to passage individual conformations into naïve cells or
through living animals to determine whether associated characteristics are maintained.
Were DS9 and DS10 bona fide prion strains? Identical phenotypes were reproduced after
introduction of denatured (boiled) lysates into naïve DS1 cells. More amazingly, in
collaboration with Sarah Kaufman, I found that these strains produced different patterns
of tau pathology in transgenic mice and maintained their associated characteristics
following intracerebral passage through three generations of mice. Immunoprecipitated
full-length tau from the third generation of mice was inoculated into naïve DS1 cells, and
12 clones were blindly isolated for both DS9 and DS10 conditions. For each strain, in 11
of 12 cases, newly derived clones recapitulated the parent strain’s distinctive inclusion
morphology, limited proteolysis fingerprint, and seeding efficiency. To summarize this
portion of the dissertation (Chapter 2), I found that tau is capable of forming at least two
amyloid structures (prion strains) that stably propagate over months of cell division, are
resistant to harsh denaturation, and maintain their properties following serial passage in
vivo. Thus, it is conceivable that such long-term, stable information transfer via tau
amyloid strains could contribute to the development of human tauopathies, which
progress over years or decades.
There are over a dozen neurodegenerative tauopathies and each affects distinct brain
regions and exhibits discrete patterns of tau aggregate accumulation in neurons and glia
(Lee et al., 2001). Moreover, within individual syndromes, patients may develop
neurodegeneration that progresses at very different rates (Armstrong et al., 2000; Huang
et al., 2014; Mann et al., 1992; Thalhauser and Komarova, 2012). Could tau amyloid
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polymorphism account for these diverse clinical features? In collaboration with Sarah
Kaufman, I examined the degree to which tau can form diverse amyloid conformations
and their resulting biological consequences (Chapter 3). I inoculated my monoclonal cell
line lacking tau aggregates (DS1) with diverse recombinant, transgenic mouse, and
patient sources of tau aggregates to generate hundreds of monoclonal lines that stably
propagate tau aggregates. Based on numerous assays (inclusion morphology, limited
proteolysis fingerprint, sedimentation analysis, seeding efficiency, toxicity), a panel of 18
putatively distinct tau prion strains (DS2 to DS19) was established. I determined that
there was a strong correlation between a strain’s seeding efficiency and toxicity in vitro,
which was independent of the amount of insoluble tau that it featured. In other words,
conformation alone likely accounts for differential toxicity. It appears that the faster a
strain replicates (i.e. adds monomer to the free ends of fibrils), the more deleterious it is
for a cell. Next, we inoculated the panel of 18 strains into the hippocampi of transgenic
mice and found eight different patterns of tau aggregate accumulation. Seven putative
strains, which featured the most divergent properties by various in vitro and in vivo
metrics, were examined in additional longitudinal, in vivo experiments. Several strains
were unique in causing astrocytic pathology, and this was independent of the amount of
neuronal pathology they induced. Moreover, when inoculated into a series of brain
regions, strains caused different degrees of pathology in each location. In other words,
specific regions of the brain feature selective vulnerability to different tau amyloid
conformations. Finally, we found that strains spread at different rates along neuronal
networks to distant locations of the brain. Seeding ability in vitro predicted this
propensity to spread. To summarize, it appears likely that simple differences at the level
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of tau aggregate structure are sufficient to account for diverse criteria (inclusion
morphologies, selective cell and network vulnerability, rates of progression) that
differentiate human tauopathies (Chapter 3).
Finally, I asked whether individual tauopathies could be differentiated based on strain
composition (Chapter 2). I inoculated cells expressing tau-YFP with immunoprecipitated
tau from the brains of 29 patients with 5 different tauopathies (Alzheimer’s disease,
corticobasal degeneration, Pick’s disease, argyrophilic grain disease, progressive
supranuclear palsy). Numerous monoclonal lines were isolated per patient and a separate
observer blindly scored them based on tau inclusion morphology, a proxy for unique tau
strains. I found that Alzheimer’s disease, corticobasal degeneration, and Pick’s disease
were relatively homogenous but distinct from each other based on strain composition,
whereas argyrophilic grain disease and progressive supranuclear palsy were significantly
more diverse. This suggested that some tauopathies likely feature a dominant tau prion
strain, which spreads throughout neuronal networks to drive disease progression.
Contemporary work from two other labs, which used inoculation paradigms and
compared tau lesion profiles in patients and treated mice, supported this hypothesis
(Boluda et al., 2015; Clavaguera et al., 2013a). However, it should be noted that in our
cell reporter system, specific inclusion morphologies have been associated with several
distinct strains (see Chapter 3). Moreover, the reporter cell line can only detect strains
that it can stably propagate. This combined with the fact that some patients feature
multiple strains suggests that individual tauopathies may be defined by a population or
“cloud” of strains that evolve over time (Bateman and Wickner, 2013; Collinge and
Clarke, 2007). Nevertheless, it is likely that improved assays will be able to differentiate
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human tauopathies based on their strain composition, which will have major implications
for how we diagnose and treat this incurable class of neurodegenerative diseases.
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4.3 TOWARD A STRUCTURAL UNDERSTANDING OF TAU
PRION BIOLOGY

In my dissertation work, I created a panel of 18 putatively distinct tau prion strains
propagated on the same monoclonal human cell line background (Chapter 3). These
strains have very different biological consequences for the cell and for the organism. For
example, in dividing cells, strains are differentially trafficked to distinct locations,
resulting in unique distributions of tau aggregates in the nucleus and cytoplasm. In
transgenic mice, certain strains preferentially affect different regions of neurons and
cause different degrees of pathology in specific regions and cell types (e.g. astrocytes).
Moreover, strains seed monomeric tau with efficiencies that span several orders of
magnitude, resulting in very different rates of spread in vivo. The biophysical basis for
these differences is completely unknown.
A structural understanding of what differentiates our panel of tau prion strains is essential
to making further progress toward linking tau amyloid conformation and phenotype. This
problem can be tackled on several different fronts, each of which will benefit from
improved protocols for purifying tau aggregates from cell lines. In work outside the scope
of this dissertation, I developed a protocol to purify tau aggregates to approximately
~50% purity by taking advantage of their relative size and detergent insolubility (Figure
AP.1). We can now grow individual strains in large flasks to isolate micrograms of tau
fibrils putatively featuring a single amyloid structure. Currently, we are using size
exclusion chromatography and fluorescence-activated cell sorting (FACS) techniques to
improve purity and yield. We hypothesize that the tremendous size and stability of

201

micron-sized tau aggresomes, which pellet along with nuclei at 250xg, will allow us to
isolate these structures using a FACS protocol similar to that used for fluorescently
labeled inflammasomes (Franklin et al., 2014). This project is currently ongoing with
methods being optimized by a new graduate student in the lab.
Following the optimization of purification methodologies, numerous experiments are
planned to examine the structure and biophysical characteristics of various tau aggregate
conformers. Initial efforts will aim to determine structural differences between our most
well characterized strains, DS4, DS6, DS7, DS9, DS10, and DS11, which have strikingly
divergent properties in vitro and in vivo. First, we plan to look at ultrastructural features
of aggregates using electron microscopy, determining whether there are disparities in
width and periodicity, similar to differences that have been described for tau fibrils
isolated from different tauopathy brains (Crowther, 1991; Crowther and Wischik, 1985;
Lee et al., 2001) and those generated from unique sources in vitro (Morozova et al.,
2013). Next, we will perform a series of experiments to test whether the biophysical
model proposed by Weissman (yeast prions) (Tanaka et al., 2006; Toyama et al., 2007)
and Prusiner (PrP prions) (Colby et al., 2009; Legname et al., 2006), which posits that
there is a direct correlation between a conformer’s frangibility and its seeding propensity,
is generalizable to intracellular mammalian prions such as tau. We will examine the
fragility of our strains by taking advantage of sonication protocols previously used by our
lab to differentiate tau conformers formed in vitro (Frost et al., 2009b). We hypothesize
that strains that seed more efficiently (e.g. DS6, DS9) will fragment more readily than
those that seed poorly (e.g. DS7, DS11) as determined by sedimentation analysis and
EM-based fibril length measurements before and after sonication. We also plan to use a
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guanidinium hydrochloride (GdHCl) denaturation assay, which I previously developed to
differentiate tau conformers formed in vitro (unpublished data), to examine the stability
of our various strains. Together, these experiments will determine whether differential
frangibility of tau fibril conformers drives the rate of pathology progression in vivo or
whether a more complex interplay of fibril growth (Safar et al., 2015) and co-factor (e.g.
chaperone) recruitment (Frederick et al., 2014; Stein and True, 2014a; 2014b) should be
considered.
The experiments outlined above would provide broad insights into the relationship
between fiber stability and rates of seeding and spread. Ultimately, however, we would
like to develop an appreciation of different tau amyloid conformations at an atomistic
level in order to better understand why these structures drive very different biological
outcomes. Amyloid polymorphism can result from differences in beta-strand peptide
composition (i.e. portion of protein that forms fibrillar core), alignment of beta-sheets
(parallel vs. antiparallel), and whether identical amino acids on different monomers
interact (in register vs. out of register) (Toyama and Weissman, 2011; Tycko, 2015).
Although x-ray crystallography has given us an appreciation of the packing arrangements
of amyloidogenic hexapeptides from model amyloids (Nelson et al., 2005; Sawaya et al.,
2007), this technique has not been amenable to studying the full-length versions of these
proteins, which likely contain amino acid stretches critical to encoding conformational
diversity. Rather, much insight into amyloid structure has been gleaned from solid-state
nuclear magnetic resonance spectroscopy (ssNMR) studies (Tycko, 2015), including
recent work that determined potential structures for the amyloid beta fibrils derived from
the brains of different AD patients (Lu et al., 2013). However, this method requires
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synthesizing proteins with 15N and 13C residues at specific sequences and milligram
quantities of protein (Tycko, 2015). Thus, in order to use ssNMR to differentiate our
fibril conformers, the structures will have to be templated onto synthetic peptides in vitro
using successive seeding reactions, an experimental set-up comparable to protein
misfolding cyclic amplification (Saborio et al., 2001) and RT-QuIC (Wilham et al.,
2010). Such serial seeding reactions are prone to generating new amyloid conformations,
independent of the source material, which evolve with time (Guo et al., 2013; Meyer et
al., 2016; Paravastu et al., 2008; Qiang et al., 2011; Tycko, 2015). Thus, stringent
controls (e.g. EM determination of periodicity and width of fibrils, limited proteolysis
fingerprints, seeding profiles, etc.) will need to be included to ensure that the end
structures are representative of the original strains generated in cells. To circumvent
confounding by-products that could conceivably arise in serial amplification reactions,
long-term ssNMR structural studies of tau prion conformers should aim to make use of
newly developed in-cell NMR techniques, directly templating synthetic tau containing
15

N and 13C residues with strain lysate (Frederick et al., 2015; Theillet et al., 2016).

However, such experiments will require further refinement of current protocols and
external collaborations.
Alternative methods that require lower quantities of protein will also afford insights into
tau prion strain structures. We plan to subject FACS-purified tau aggregates to pronase
(i.e. limited proteolysis) and will then use mass spectrometry to determine how the
protected amyloid cores differ between strains. In addition, UT Southwestern features
state-of-the-art cryo-EM core facilities. Currently, we are in discussions with a new
faculty recruit about using single-particle electron cryomicroscopy to differentiate tau
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strains at atomic resolution. Overall, numerous complementary studies, both internal and
with collaborators, will allow tremendous insights into the structural rules that govern tau
prion strain biology. This should allow the rational design of compounds, dyes, and
antibodies that target and/or differentiate specific tau fibril structures. Moreover, we hope
to ultimately decipher the fundamental logic that determines why strains replicate at
different rates and affect different regions of the cell and brain.
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4.4 TAU STRAINS AS A TOOLKIT FOR PROBING DIVERSE
ASPECTS OF INTRACELLULAR PRION BIOLOGY
The trans-synaptic spread of intracellular prions such as tau requires specific events:
escape from a pre-synaptic terminal, adherence to a post-synaptic membrane,
endocytosis, escape into the cytosolic compartment, conversion of soluble monomer to
the aggregated state, and replication/fragmentation to continue the “prion life cycle”
(Sanders et al., 2016). Further, fibrillar aggregates must be actively cleared by the cell,
since in transgenic mouse models of proteopathies, amyloidogenic inclusions disappear
once expression of the associated protein is abrogated (Mallucci et al., 2007; Polydoro et
al., 2013; Walker et al., 2015; Yamamoto et al., 2000). Finally, individual amyloid
conformations (strains) must differentially “infect” specific networks, cell types, and
regions of the cell to account for histopathological observations in patients and mouse
models of disease (Boluda et al., 2015; Clavaguera et al., 2013a; Sanders et al., 2014).
The tau strain library documented in this dissertation affords tremendous opportunities to
glean mechanistic insights into the cellular biology of intracellular prion metabolism (i.e.
its “life cycle”) (Figure 4.2). We plan to use biased (based on known pathways and
proteomic results) and unbiased genetic and pharmacological screens to begin to
interrogate these mechanisms.
Of the steps of the prion life cycle, uptake has been most well characterized. Previously,
we established that heparan sulfate proteoglycans (HSPGs) are essential for recombinant
tau aggregate uptake and seeding in vitro and in vivo (Holmes et al., 2013a). Entry into
the cell depends on trimeric and larger tau assemblies triggering a critical mass of HSPGs
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to actively stimulate fluid-phase macropinocytosis (Mirbaha et al., 2015). Further, in
unpublished work, we have determined that different patterns of HSPG sulfation are
critical for the uptake of amyloid beta, α-synuclein, and tau fibrils (Stopschinski, Holmes,
et al., in preparation). We plan to test whether this is also the case for tau strains. It is
conceivable that different cell types and regions of the brain display selective
vulnerability to distinct strains based on their sulfated HSPG profiles. In order to test this
hypothesis, we will examine whether seeding of a tau aggregation biosensor cell line
(Furman et al., 2015; Holmes et al., 2014) by various tau strains (DS4, DS6, DS7, DS9,
DS10, DS11) is differentially inhibited by heparin with specific sulfation profiles (fully
sulfated, 2-O desulfated, 6-O desulfated, and N-desulfated heparin). If there are
differences, we will confirm the results via gene editing, knocking out a panel of genes
that regulate HSPG sulfation using CRISPR/Cas9 technology (gRNA constructs
generated by B. Stopschinski). Ultimately, we will validate interactions using
carbohydrate arrays (Stopschinski, Holmes, et al., in preparation) and purified tau
aggregate conformers (see Section 4.3). This work will represent a first step toward
determining potential mechanisms that contribute to strain-cell selective vulnerability.
Dividing mammalian cells propagate fibrillar amyloids indefinitely to daughter cells
(Krammer et al., 2009; Münch et al., 2011; Sanders et al., 2014). It is unknown whether
this is a passive process (i.e. shearing forces in cytoplasm contribute to further
fragmentation and seed generation) or whether disaggregation machinery exists
analogous to Hsp104 in yeast to actively generate new seeds (Chernoff et al., 1995;
Glover and Lindquist, 1998; Lee et al., 2003; Shorter and Lindquist, 2004). Further, the
mechanisms that cause distinct tau strains to accumulate in specific regions of the cell are
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unknown (Clavaguera et al., 2013a; Sanders et al., 2014). Finally, whether different
proteins and pathways contribute to the degradation of distinct strains remains
unexplored. I have begun to investigate these questions in work that is outside the scope
of this thesis, by coupling tau aggregate interactome data with targeted CRISPR/Cas9
genetic screens (see Appendix). Taking advantage of the size and insolubility of
juxtanuclear aggresomes (Figure AP.1), I purified tau aggregates from DS9 and DS10
cells and identified 79 candidate proteins that putatively associate with tau amyloids
(Figure AP.2). 33 of these 79 proteins were involved in the ubiquitin-proteasome system
or selective autophagy/vesicular trafficking, pathways critical for the clearance of
misfolded proteins and insoluble aggregates (Schreiber and Peter, 2014). Four of these
proteins have previously been linked to genetic forms of ALS/FTD and multisystem
proteopathy. Surprisingly, I also identified four SR-rich proteins, which likely play a role
in constitutive RNA splicing (Figure AP.2). 9 (out of 9 tested) of the 79 hits were
confirmed to co-localize with DS9 and DS10 tau aggregates by immunocytochemistry,
whereas a panel of other proteins not identified in the proteomic analysis (n=11) failed to
co-localize (Figure AP.3-6). Many of the identified proteins also co-localized with fulllength tau aggregates (Figure AP.7) and huntingtin polyQ inclusions (Figure AP.8).
Overall, co-localization analysis confirmed the power of the proteomic approach to
identify proteins that associate with intracellular amyloids. However, it must be noted
that the approach failed to identify striking interactome differences between DS9 and
DS10 aggregates.
Next, I designed a targeted CRISPR-Cas9 screen (n=25 proteomic hits, n=9 negative
controls) to examine whether the most abundant proteins in tau aggregates affected their
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maintenance, trafficking, turnover, or seeding into naïve cells. First, I demonstrated that
the designed protocol was effective at knocking out a variety of endogenous proteins
(Figure AP.9A-D). Knockout of the panel of genes failed to identify any one protein that
is essential for aggregate maintenance or seeding into naïve cells (data not shown).
However, knockout of two proteins (Protein A and Protein B) altered aggresome
architecture (Figure AP.9). Knockout of Protein B, but not master regulators of
autophagic pathways, greatly extended tau aggregate lifespan (Figure AP.9). This
suggests that Protein B plays a pivotal role in tau aggregate metabolism (Figure AP.9).
Currently, another graduate student is examining whether knockout of proteins that
interact with Protein B affect tau aggregate turnover or maintenance of the aggregated
state. Further, I identified an SR protein (Protein C) that is essential for DS9 tau
aggregate entry into splicing speckles (Figure AP.10). Future studies will expand the
breadth of knockouts and will examine whether specific proteins are critical to tau
aggregate turnover in non-dividing cells (e.g. primary neurons or induced pluripotent
stem cells with tau aggregates), where aggregate dilution does not occur by cell division.
In collaborative and future work, we also plan to use unbiased chemical and
CRISPR/Cas9 genetic screens to interrogate steps of the proteopathic seed life cycle.
Recently, several labs have made critical advances in generating platforms that make use
of CRISPR/Cas9 technology to allow for unbiased genome-wide screens in mammalian
cells (Gilbert et al., 2014; Shalem et al., 2014). Each of these platforms utilizes stable
Cas9 (or catalytically dead Cas9) expression in a dividing cell population, along with a
lentivirus-encoded library of pooled guide RNAs that are stably inserted into the genome
to drive knockout (Shalem et al., 2014), knockdown (Gilbert et al., 2014), or upregulation
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(Gilbert et al., 2014) of individual genes at a single cell level. With a sufficiently large
cell population, genome-wide coverage can be achieved with multiple guide RNAs
targeted against every gene. A stimulus is applied and cells containing a specific
phenotype (e.g. fluorescence, viability) are selected. Deep sequencing is then performed
to determine gRNAs that are enriched in the selected population relative to cells prior to
stimulus application. To date, these screens have been successful in determining critical
regulators of cell death (e.g. by certain chemotherapeutic drugs) (Shalem et al., 2014).
We have developed several cell assays that are amenable to such screens (Furman et al.,
2015; Holmes et al., 2014). In unpublished work, I created a tau RD-CFP/YFP FRET cell
line that stably propagates the DS9 strain (LM39-9). This cell line can be differentiated
from a parent line (LM39-1), which lacks tau aggregates, by measuring single cell FRET
using a flow cytometer (Furman et al., 2015; Holmes et al., 2014). We can use FACS to
sort cells containing aggregates from those that lack inclusions based entirely on FRET
signal. We will use a genome-wide knockout (GeCKO) screen (Shalem et al., 2014) to
determine whether there are essential proteins for maintenance of the aggregated state,
selecting for cells that decrease in FRET following infection with specific gRNAs.
Second, we will use a tetracycline-regulated tau aggregate FRET line (OFF11::DS11,
unpublished) to determine proteins whose knockout phenocopies that of Protein B (see
Figure AP.9). We will turn off tau expression for 8 days and will then re-initiate
expression for two days. We will then use FRET flow cytometry to isolate cells that
contain aggregates, thus enriching the population for gRNAs that prolong aggregate
lifespan. This screen should elucidate key regulators of tau aggregate turnover in dividing
cells and may determine the pathway in which Protein B acts. Third, we will perform a
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viability screen that makes use of LM10, a cell line overexpressing tau RD-CFP/YFP,
which features 100% lethality when exposed to DS9 lysate (Figure 3.2). We will expose
LM10 cells to DS9 lysate, select for cells that contain aggregates by FACS, and will then
identify gRNAs that prevent cell death. Future work will repeat these screens using
CRISPRa (upregulation) (Gilbert et al., 2014). Finally, the Stanley Prusiner lab (UCSF)
in collaboration with Daiichi Sankyo is pursuing a drug discovery program to identify
chemicals that inhibit seeding of DS1 by DS9 lysate (Woerman et al., 2015). Several
promising compounds have been identified and target drugs are currently being tested in
transgenic mouse models of tauopathy (Yoshiyama et al., 2007) to determine whether or
not they slow the progression of pathology. Together, these unbiased screens should
begin to elucidate critical regulators of tau aggregate seeding, maintenance, turnover, and
toxicity.
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4.5 IMPLICATIONS FOR DIAGNOSTICS, THERAPEUTICS, AND
OTHER PROTEOPATHIES

Based on this dissertation work, it is now clear that specific tauopathies (e.g. Alzheimer’s
disease, corticobasal degeneration, Pick’s disease) can be differentiated based on tau
strain composition (Chapter 2) (Sanders et al., 2014). However, the methodology
required to categorize specific patients is time-intensive and laborious, demanding weeks
of cell culture and the selection of numerous monoclonal lines (Sanders et al., 2014). We
are now developing assays that are more quantitative and high-throughput. As a first step,
a post-doctoral scholar (Jenny Furman) and graduate student (Jaime Vaquer-Alicea) have
generated a panel of monoclonal cell lines that express various tau RD point mutants with
FRET pair tags (unpublished). Individual cell lines respond very differently to unique
strains. For example, mutant tau in line A is seeded strongly by DS9, whereas mutant tau
in line B is seeded more robustly by DS7. Remarkably, using biological triplicates from
our strain library, individual conditions can be binned based on how they induce tau
aggregation in the panel of lines. In other words, we can determine the identity of a strain
purely based on how the cell panel responds to its lysate. Based on this data, we
determined that DS12 and DS16 are in fact identical strains, whereas all others in the
panel are unique. This cell panel assay is now being utilized to group patients based on
strain composition. Thus far, it can reliably identify CBD and AD patients, which further
supports the hypothesis that distinct tau strains cause these diseases (Boluda et al., 2015;
Clavaguera et al., 2013a; Sanders et al., 2014). Generation of additional cell lines
expressing various truncated versions and isoforms of tau may allow further
differentiation of patients. Finally, our lab is pioneering epitope-based antibody mapping
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approaches to differentiate tau conformers in biological samples. Together, we believe
that such techniques will prove to be superior to traditional histopathological approaches
in grouping patients based on the causative pathogen (i.e. tau prion strain) of their
disease. Ultimately, we envision coupling such assays to sensitive methods (Atarashi et
al., 2011; Colby et al., 2007; Wilham et al., 2010) of seed amplification (e.g. PMCA and
RT-QuIC approaches) to diagnose patients using fluid samples (e.g. CSF, blood).
It is also important to emphasize that the findings of this dissertation have important
implications for how tauopathies are treated. We believe that our data strongly supports
the validity of the prion hypothesis in patients, as a trans-cellular templating mechanism
would most parsimoniously explain how different patients could feature dissociable but
homogenous strain populations throughout their brains. Therefore, future therapeutics
should target tau in the extracellular space to prevent the trans-cellular spread of tau
amyloids and the resulting progression of neurodegeneration. Antibodies (Asuni et al.,
2007; Boutajangout et al., 2011; d'Abramo et al., 2013; Funk et al., 2015; Yanamandra et
al., 2013; 2015) and heparinoids (Holmes et al., 2013a) should be effective in this regard.
Nevertheless, we also wish to emphasize that not all tau aggregates are created equal. It is
likely that strains will respond differently to distinct therapeutics. For example, an
antibody that is effective at clearing an AD tau strain may not be as effective at removing
a CBD tau strain due to their unique amyloid structures. There is precedent for this in
prion disease models, where certain strains are cleared by specific drugs leading to the
emergence of drug-resistant strains (Ghaemmaghami et al., 2011; 2009; Giles et al.,
2010; Li et al., 2010). In other words, prion strains are prone to Darwinian evolution
based on selection pressures (Li et al., 2010; Oelschlegel and Weissmann, 2013;
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Weissmann et al., 2011). Thus, therapies that target diverse tau aggregate species should
be favored over those that target individual conformers. Finally, we envision that it will
be possible to develop different PET imaging agents to differentiate unique tauopathies
(Okamura et al., 2014; 2013; Ossenkoppele et al., 2016; Schöll et al., 2016; Schwarz et
al., 2016). Unpublished work indicates that current tracers identify AD tau tangles but not
many other types of tau aggregates. We believe that this is due to the fact that different
tau strains arise in different diseases and animal models of tauopathy. Future studies
should attempt to identify specific tracers that respond to different strains. Finally, we
wish to highlight that techniques developed to probe phenotypic diversity in the
tauopathies are likely relevant to the study of other proteopathies. Synucleinopathies and
TDP43opathies also feature tremendous diversity in clinical presentation (Halliday et al.,
2011; Van Langenhove et al., 2012). In fact, work from the Prusiner lab and unpublished
work from our lab suggests that multiple systems atrophy and Parkinson’s disease may be
caused by different α-synuclein strains (Prusiner et al., 2015; Woerman et al., 2015).
Thus, the concepts underscored in this dissertation likely have broad implications for the
development of therapeutics and diagnostics for all non-infectious neurodegenerative
proteopathies.
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4.6

CONCLUDING REMARKS

The prion hypothesis is a unifying mechanistic paradigm that accounts for diverse
features of sporadic neurodegenerative diseases (Prusiner, 2013; Sanders et al., 2016;
Walker and Jucker, 2015). Not only does it elucidate why fibrillar protein aggregates
spread hierarchically along neuronal networks in diverse syndromes, but it also explains
how a single pathogenic protein can give rise to distinct diseases. In this dissertation, I
have built the foundations for linking tau amyloid structure to clinical phenotype through
the generation of diverse tau prion strains. Based on simple yet to-be-defined differences
at the level of tau amyloid conformation, strains affect specific regions of individual cells
as well as different cell types, which likely contributes to the characteristic
neuropathological phenotypes observed in distinct tauopathies. Moreover, it appears
likely that individual strains have the ability to affect dissociable networks to drive
clinical phenotypes. Ultimately, a structural understanding of the tau amyloid
conformations that drive distinct tauopathies (Figure 4.1) and mechanistic interrogation
of their biological effects (Figure 4.2) will enlighten therapeutic and diagnostic
interventions for this class of neurodegenerative diseases.
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4.7

FIGURES

Figure 4.1. Strains: linking structures and disease phenotypes. Different selfpropagating tau amyloid conformations (i.e. strains) drive unique phenotypes that span
from the cell to the clinic. Well-characterized tau strains, which feature structural
differences that have yet to be elucidated, are deposited in specific patterns in individual
cells. In humans, this is reflected by the unique patterns of tau aggregate deposition in
neurons and glia that are characteristic of each individual tauopathy. Via unknown
mechanisms, specific cell types and regions of the brain are preferentially affected. The
work described in this doctoral dissertation represents a starting point for determining
how a specific amyloid conformation can drive a unique experimental tauopathy.
Ultimately, this will allow a further appreciation of the individual tau amyloid structures
that drive specific phenotypes in human diseases.
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Figure 4.2. Tau strains as a toolkit for probing diverse aspects of aggregate biology.
The ability to propagate an array of tau prion strains on the same monoclonal background
will open up many avenues of future research. Currently, we are developing more
sensitive and quantitative assays for differentiating strains derived from patient
specimens. We are actively improving our aggregate purification protocols, with the
ultimate goal of determining structural variations between our strains. Specifically, we
seek to determine why it is that certain fibril conformations spread at such different rates
and why they are trafficked into distinct inclusion types. Elucidation of the tau aggregate
interactome (see Appendix) is guiding targeted screens, which seek to determine
mechanisms of tau aggregate degradation and disaggregation. Finally, we will be
employing unbiased genetic and drug screens to determine whether there are active
mediators of tau aggregate inheritance, toxicity, degradation, and seeding.

In#Progress#and#Future#Direc2ons#

Unbiased Screens/Drug Discovery
-Aggregate inheritance?
-Aggregate toxicity?
-Seeding into naïve cells?

Identification of Tau
Interactome

Classification of Patient Strains
-Epitope mapping approaches
-Microscopy and feature extraction
-Biosensor panels

Tau Strains

Biased Genetic Screens
Aggregate inheritance?
Aggregate metabolism/
degradation?
Inclusion morphology and
localization?
Novel functions for tau?

Biophysical Analysis
of Conformers
-Biophysical correlates of seeding?
-Structural basis for seeding?

In Vivo Assessment of Selective Vulnerability
-Different patterns of spread?
-Different cell populations affected?
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Appendix: Characterization of the Tau
Aggregate Interactome
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AP.1 PREFACE

This chapter contains unpublished data and text that will be used in a future
manuscript:
Sanders D.W., Vaquer-Alicea, J., Saha, I., Spasova, A., Grinberg, L.T., Mirzaei, H.,
Hartl, F.U., Hipp, M.S., Diamond, M.I. (In Preparation). Characterization of the tau
aggregate interactome.

Author contributions: D.W.S. and M.I.D. designed the experiments. D.W.S. collected and
analyzed the data. J.V.-A. performed DNAJC7 Western blots and has performed
additional experiments not included in this write-up. A.S. and L.T.G. performed
immunohistochemistry on patient samples. H.M. performed mass spectrometry. I.S.,
F.U.H., and M.S.H. performed complementary SILAC studies (data not included). M.I.D.
supervised the work. D.W.S. wrote the text.

219

AP.2 ABSTRACT
In mammalian cells, tau amyloids stably propagate distinct fibrillar structures (“prion
strains”) to daughter cells indefinitely. However, it is unknown whether there is a
mammalian amyloid replication machine, similar to the Hsp104 chaperone system in
yeast, which allows for the efficient inheritance of amyloids (“seeds”). Further, the
mechanisms of tau aggregate clearance in cells and in vivo are unclear. In this study, we
establish an unbiased, mass spectrometry approach to identify proteins that co-purify with
micron-sized, insoluble tau aggregates (“aggresomes”) in dividing mammalian cells. We
identify 79 candidate proteins that putatively associate with tau amyloids and use
immunocytochemistry to confirm 9 of these hits. We report preliminary studies using
CRISPR-Cas9 to knockout 25 of the top hits. We were unable to identify a single nonessential protein necessary for tau aggregate inheritance. However, DNAJC7 and
SQSTM1 knockout both have major effects on the organization of tau aggregates. Using
a tetracycline-regulated tau aggregate cell line, we demonstrate that DNAJC7 is critical
for tau aggregate clearance. Mechanistic studies of DNAJC7’s role in tau aggregate
metabolism are in progress. Identification of the pathological tau aggregate interactome
will inform future studies examining mechanisms underlying tau aggregate metabolism in
non-dividing cells and in vivo.

220

AP.3 INTRODUCTION
Prions are higher-order assemblies of protein that are capable of communicating
information stably by template-based propagation of a specific fibrillar conformation
(Prusiner, 1998; Sanders et al., 2016). These self-amplifying structures may be
pathological, leading to progressive and fatal neurodegenerative diseases (Walker and
Jucker, 2015), or physiological, allowing the inheritance of beneficial traits, as in the case
of Saccharomyces cerivisiae (yeast) (Halfmann et al., 2012; Holmes et al., 2013b; True
and Lindquist, 2000; True et al., 2004). Remarkably, the prion form for any given protein
is not a single structure. Rather, individual prions can take a variety of forms or “strains”
that link structure to syndrome in animals or severity of phenotype in yeast (Collinge and
Clarke, 2007; Toyama and Weissman, 2011). In mice, prion strains can replicate their
associated fibrillar structures with remarkable fidelity, leading to distinct incubation
times, histopathological profiles, and behavioral phenotypes, which maintain themselves
even after years of passage (Collinge and Clarke, 2007). In cells and mice, tau prion
strains are especially robust, maintaining their structures over months of cell division and
passage through multiple generations of transgenic mice (Sanders et al., 2014). Whether
there are active mechanisms that govern the continued replication of specific prion strains
in mammalian systems is unclear.

In yeast, the mechanisms that govern the inheritance of the aggregated or prion state have
been well defined. The Hsp104 chaperone protein forms a two-tiered, hexameric complex
that interacts with other co-chaperones to thread fibrils through its central pore, further
fragmenting (or “disaggregating”) them into smaller assemblies in an ATP-dependent
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fashion (Chernoff et al., 1995; Glover and Lindquist, 1998; Lee et al., 2003; Shorter and
Lindquist, 2004). These smaller assemblies are then capable of “seeding” further
aggregation by growth of monomer on their free ends, thus amplifying the prion state
(Collins et al., 2004a). Notably, there is no mammalian homologue to this protein.
However, recent work has suggested that three-component chaperone systems are
capable of disaggregating both amorphous and fibrillar aggregates in vitro (Gao et al.,
2015; Nillegoda et al., 2015; Rampelt et al., 2012; Shorter, 2011). To date, there is no
clear evidence that the same machinery (or analogous systems) fragment fibrillar
aggregates in mammalian cells.
Further, it is also now clear that fibrillar aggregates are capable of being degraded in
mammalian systems. In inducible mouse models of neurodegenerative diseases, fibrillar
deposits will be cleared once expression of the associated protein is turned off (Mallucci
et al., 2007; Polydoro et al., 2013; Walker and Jucker, 2015; Yamamoto et al., 2000).
Protein degradation can occur via the ubiquitin-proteasome system, chaperone-mediated
autophagy, or selective autophagy (Schreiber and Peter, 2014). The latter appears to be
the most likely scenario by which these fibrillar assemblies are actively degraded due to
their immense size. Intriguingly, mutations to proteins that regulate selective autophagy
of ubiquitinated aggregates cause familial forms of several neurodegenerative diseases
including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and
multisystem proteopathy (Cirulli et al., 2015; Deng et al., 2011; Johnson et al., 2010;
Laurin et al., 2002; Maruyama et al., 2010). This suggests that failure to degrade fibrillar
aggregates is sufficient to cause specific neurodegenerative syndromes. Although much
work has been performed delineating the mechanisms by which selective autophagy of
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ubiquitinated cargo occurs (see (Khaminets et al., 2016) for Review), additional work is
required to identify all the major proteins that recognize and mark seeding-competent
prions for degradation. Furthermore, whether all fibrillar assemblies are degraded using
the same pathway requires elucidation.
In the present work, we performed an unbiased, mass spectrometry study of proteins that
co-purify with micron-sized tau aggregates (“aggresomes” (Johnston et al., 1998))
derived from two monoclonal tau prion strains to gain insights into fundamental
mechanisms of tau aggregate metabolism, trafficking, and degradation. We show by
immunocytochemistry that proteins identified by this method do in fact co-localize with
tau aggregates. We use CRISPR-Cas9 to knockout top hits from our analysis and find
that no single protein is essential to inheritance of the prion state by dividing mammalian
cells. We identify a co-chaperone, DNAJC7, which affects the organization of tau
aggresomes and influences the rate at which tau seeds are cleared. Further work will
determine the mechanisms by which this poorly characterized chaperone influences tau
aggregate metabolism.
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AP.4 MATERIALS AND METHODS
Molecular cloning. With the exception of gRNA constructs, all plasmids used were
described previously (Sanders et al., 2014). The pCRISPRv2 plasmid, which contains
both Cas9 and a site to insert gRNAs, was a kind gift from the Feng Zhang lab
(Massachusetts Institute of Technology). For each gene selected for knock-out, six
separate twenty base-pair Guide RNAs (gRNAs) were designed according to previously
published protocols and datasets (Shalem et al., 2014). Forward and reverse
oligonucleotides containing the gRNA, a PAM site, and BsmBI overhangs were
generated (Integrated DNA Technologies). Oligonucleotides were then sub-cloned into
the pCRISPRv2 vector according to the following protocol. 5 µg pCRISPRv2 was
digested with 3 µL FastDigest BsmBI (Fermentas) and backbone DNA was purified
using QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s protocol.
Meanwhile, forward and reverse oligonucleotides were annealed at a concentration of 10
µM by placing them at 95°C and dropping the temperature by 5°C per minute until 25°C
was reached. Annealed oligonucleotides were then diluted 1 to 100 in molecular grade
water. Next, annealed oligonucleotides were ligated into BsmBI-digested pCRISPRv2 by
combining 50 ng digested product with 1 µL annealed oligonucleotide (diluted 1:100)
and 1 µL Quick Ligase (New England Biolabs) in a total volume of 10 µL. Ligation
reactions were then transformed into Stbl3 bacteria (Invitrogen) according to
manufacturer’s protocol, and individual colonies were amplified and selected. Correct
insertion of gRNAs was confirmed by DNA sequencing.
Cell culture. HEK293T and HEK293 cell lines were cultured in complete media:
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) with 1% penicillin/streptomycin
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(Gibco) and 10% fetal bovine serum (HyClone). Cell lines were maintained in a
humidified incubator at 37°C, 5% CO2. For washing cells, Dulbecco’s phosphate
buffered saline (Life Technologies) was used. Trypsinization for passaging was achieved
using 0.05% Trypsin-EDTA (Life Technologies).
Lentivirus production. Lentivirus was generated as described previously (Araki et al.,
2004; Sanders et al., 2014). For production of pCRISPRv2 gRNA lentivirus, six gRNA
plasmids were first pooled at equivalent DNA concentrations. HEK293T cells were
plated at 1x106 cells/well in a 6-well plate. 18 hours later, cells were co-transfected with
three plasmids: PSP (1200 ng), VSV-G (400 ng), and FM5 or pCRISPRv2 (400 ng), after
incubating the DNA mix with 250 µL OptiMEM (Gibco) and 7.5 µL TransIT-293
(Mirus) for 15 minutes. 48 hours later, media was collected from the dying cells. The
media was spun at 250xg for 5 minutes to remove dead cells and debris. Lentiviruscontaining supernatant was then stored at -80°C until addition to cells.
Stable HEK293 cell line generation. Monoclonal Tau RD (amino acids 244-372 of the
2N4R isoform of tau) P301L/V337M-EYFP HEK293 cell lines (DS1, DS9, DS10,
OFF1::DS10) were generated and described previously (Sanders et al., 2014). To
generate additional polyclonal lines, HEK293 cells were plated at 50,000 cells/well in a
12-well plate. 24 hours later, 1 mL media containing lentivirus (FL tau 4R1N P301S or
Huntingtin Exon1 Q72-EYFP) was added to the wells. For both polyclonal lines, cells
were grown for 72 hours in the presence of virus. Cells were then passaged into a 6-well
plate and grown to confluency, followed by subsequent passage and amplification in a 10
cm dish. Once confluent, cells were stored in liquid nitrogen until use.
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To generate monoclonal lines, the polyclonal Htt Exon1 Q72-EYFP line was diluted
sparsely in 10 cm dishes, so that there were fewer than 25 cells per dish. Next, cells were
grown for a week until they formed discrete, visible colonies. Cloning cylinders (Bel-Art
Products) were then used to pick single colonies, and these were passaged into wells of a
12-well plate. Upon confluency, the lines were passaged into 6-well plates. A monoclonal
Htt Exon1 Q72-EYFP line that stably propagated polyQ aggregates to daughter cells
(Q72E) was amplified to confluency in a 10 cm dish and was stored in liquid nitrogen
until use.
Immunocytochemistry. Monoclonal cell lines were passaged from 10 cm dishes to
coverslips in 24-well plates and were grown for 48 hours. Media was removed and cells
were fixed with either 300 µL 3% PFA (most ICC experiments) or 300 µL ice-cold
methanol (100%) (MLF2, VCP ICC) for 15 minutes. Fixative was removed and replaced
with PBS. Cells were then permeabilized with 0.25% Triton-X in PBS for 15 minutes.
Permeabilized cells were blocked with blocking buffer (0.1% Triton-X, 10% Normal
Goat Serum, PBS) for 60 minutes at room temperature. Primary staining was performed
overnight in blocking buffer at 4°C with the following antibodies: Rb α-Coilin (1:200, H300 sc32860), Mo α-SAFB (1:500, 6F7 ab8060), Mo α-FBL (1:100, 38F3 ab4566), Mo
α-SMN1 (1:200, 2B1 sc-32313), Mo α-PSF/SFPQ (1:100, Sigma P2860), Rb α-SRRM2
(1:2000, ab122719), Mo α-phospho-SR/Sc35 (1:2000, ab11826), Mo α-PML (1:50,
sc966), Rb α-Pinin (1:25, ProteinTech 18266-1-AP), Mo α-Ubiquitin (1:100, Enzo FK2),
Mo α-SQSTM1 (1:50, ab56516), Rb α-NBR1 (1:25, ProteinTech 16004-1-AP), Mo αTRAFD1 (1:50, ThermoScientific MA5-17190), Mo α-MLF2 (1:50, B-6 sc-166874), Rb
α-VCP (1:25, H-120 sc-20799), Rb α-DNAJC7 (1:50, ProteinTech 11090-1-AP), Mo α226

SRSF1 (1:100 sc-36532), Rb α-SRSF11 (1:100, Atlas HPA008762), Rb α-ACIN1 (1:50,
CST 4934), Rb α-SRSF7 (1:100, Sigma HPA043850), Rb α-snRNP70 (1:50, EMD
Millipore 06-1297), or Mo α-Tau (1:200, HJ9.3). Cells were washed three times with
0.1% Triton-X in PBS and were then counter-stained with goat α-mouse or goat α-rabbit
AlexaFluor-546 (1:400, Life Technologies) for 1 hour in the dark at room temperature.
Cells were washed thee additional times with 0.1% Triton-X in PBS and nuclei were
stained with 1:1000 DAPI in 0.1% Triton-X for 10 minutes in the dark. DAPI solution
was replaced with PBS and coverslips were mounted on Prolong Gold Antifade reagent
(Life Technologies), sealed with nail polish, and placed at 4°C prior to confocal analysis.
Immunohistochemistry. Patient tissue sections were dewaxed in fresh xylene using
three 10-minute washes. Sections were then dehydrated by serial treatment with 100%
ethanol then 96% ethanol then 80% ethanol. Next, sections were blocked with BloxAll
(Vector Laboratories) for 15 minutes followed by three PBS washes. Antigen retrieval
was performed using citrate buffer and autoclaving for five minutes. Sample were then
blocked for lipofuscin using 0.8% Sudan Black in 100% ethanol. Additional blocking
was performed with 5% milk/PBS (with 0.05% Tween). Primary staining was performed
overnight with mouse α-tau (1:500, CP13, gift from Peter Davies) and rabbit α-SRRM2
(1:200, ab122719) in blocking buffer. After three additional washes, secondary staining
was performed with horse α-mouse Dylight-488 (1:300, Vector Laboratories) and goat αrabbit Dylight-488 (1:300, Vector Laboratories). Sections were washed four additional
times and were then mounted with VECTASHIELD HardSet (Vector Laboratories).
Slides were placed at 4°C prior to confocal analysis.
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Confocal microscopy. For confocal microscopy, a Zeiss Axiovert 200M microscope was
coupled to a Zeiss LSM 5 PASCAL system. For the collection of all images, a pinhole
size of 0.8 µm was used.
Western Blots. OFF1::DS10 cell pellets were thawed on ice and lysed in PBS with
0.05% Triton X-100 and a cOmplete mini protease inhibitor tablet (Roche) by triturating
10x and incubating at 4°C for 15 minutes. Sequential 5-minute centrifugations were then
performed at 500xg and 1000xg to clarify the lysate. A Bradford assay (Bio-Rad) with
BSA standard curve was performed and protein concentrations were normalized to 4
µg/µL with addition of lysis buffer. 10 µg of total protein was denatured in 2x sample
buffer (2.5 µL sample, 2 µL BME, 5.5 µL PBS, 10 µL 2x Laemmli buffer) with the aid of
five minutes of boiling. 13 µL of each sample was loaded onto a NuPAGE 10% Bis-Tris
gel (Life Technologies). Gels were run at 150 V for 60 minutes. Protein was transferred
to Immobilin P (Millipore) using a semi-dry transfer apparatus (Bio-Rad). Membranes
were blocked for 1 hour in 5% milk/TBS-T. Membranes were then probed with either Mo
α-SQSTM1 (1:500, ab56516), Mo α-TRAFD1 (1:1000, ThermoScientific MA5-17190),
or Rb α-DNAJC7 (1:1000, EPR13349 ab179830) overnight at 4°C. The next day,
membranes were washed four times with TBS-T and counter-probed with goat α-mouse
HRP (1:4000, GE Healthcare) or goat α-rabbit HRP (1:4000, Jackson Immunotherapy)
for 1.5 hours. Membranes were washed four additional times with TBS-T and finally
with plain TBS. Membranes were exposed to ECL Prime Western Blotting Detection
System (Fisher Scientific) for 3 minutes and were developed using a digital Syngene
imager.
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Identification of aggresome-associated proteins by mass spectrometry. DS1, DS9,
and DS10 were grown to confluency in two T300s per condition. Cells were harvested,
pelleted, and washed, prior to storage as 0.5 T300 pellets (four total) at -80°C. For each
condition, three pellets were thawed on ice, and each was lysed by trituration in 1 mL icecold PBS with 0.25% Triton-X and a dissolved protease inhibitor tablet (cOmplete Mini,
Roche) followed by a 15 minute incubation on ice. Aggresomes and nuclei were collected
by centrifuging at 1000xg for 15 minutes followed by re-suspension in 400 µL lysis
buffer. An Omni-Ruptor 250 probe sonicator was then used at 30% power for thirty 3second pulses to partially dissolve the pellets. Samples were centrifuged at 250xg for 5
minutes, and the supernatant was set aside as Fraction B. Pellets were re-homogenized in
an additional 400 µL lysis buffer and sonication and centrifugation was repeated. The
final supernatant was added to the previous Fraction B (800 µL volume total). A
Bradford assay (Bio-Rad) with BSA standard curve was performed and the protein
concentrations were calculated for the nine fractions. Protein concentrations were
normalized to 1.1 µg/µL. 72 µL of 10% sarkosyl was added to 650 µL of each sample in
ultra-centrifuge tubes (Beckman Coulter) and samples were rotated end-over-end at room
temperature for one hour. Samples were then spun at 186,000xg for 60 minutes,
supernatant was set aside, and pellets were washed with 1 mL lysis buffer prior to an
additional 30 minute 186,000xg spin. Final pellets were re-suspended in 30 µL 2%
SDS/2% BME/PBS by boiling and trituration. 5 µL of Fraction B supernatants and pellets
were loaded onto NuPAGE 10% Bis-Tris gels (Life Technologies) and were run at 150 V
for 60 minutes. Gels were washed 1x with water and were then stained with SimplyBlue
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SafeStain (Life Technologies). Images of gels were captured using a digital Syngene
imager.
For LC-MS/MS-based detection of proteins, 20 µL re-suspended Fraction B pellets were
run 1 cm onto an Any kD Mini-Protean TGX gel (Bio-Rad) followed by Coomassie Blue
staining. Whole lanes were excised using ethanol-washed razor blades and gel samples
were cut into 1 mm3 chunks. Gel pieces were reduced with DTT and alkylated with
iodoacetamids (Sigma-Aldrich) and were then digested overnight with trypsin (Promega).
Next, excised proteins were subjected to solid-phase extraction cleanup with Oasis HLB
plates (Waters). The processed samples were then analyzed by LC-MS/MS using a Q
Exactive mass spectrometer (Thermo Electron) coupled to an Ultimate 3000 RSLC-Nano
liquid chromatography system (Dionex). Samples were injected onto an 180 µm i.d., 15cm long column packed with reverse-phase material ReproSil-Pur C18-AQ, 1.9 µm resin
(Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). Peptides were eluted with a
gradient from 1-28% buffer B (80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.08%
formic acid in water) over 60 minutes. The mass spectrometer was capable of acquiring
up to 20 MS/MS spectra for each full spectrum obtained. Raw mass spectrometry data
files were converted to a peak list format and analyzed using the central proteomics
facilities pipeline (CPFP), version 2.0.3 (Trudgian and Mirzaei, 2012; Trudgian et al.,
2010). Peptide identification was performed using the X!Tandem (Craig and Beavis,
2004) and open MS search algorithm (OMSSA) (Geer et al., 2004) search engines against
the human protein database from Uniprot, with common contaminants and reversed
decoy sequences appended (Elias and Gygi, 2007). Fragment and precursor tolerances of
20 ppm and 0.1 Da were specified, and three miscleavages were allowed.
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Carbamidomethylation of Cys was set as a fixed modification and oxidation of Met was
set as a variable modification. Label-free quantitation of proteins across samples was
performed using SINQ normalized spectral index Software (Trudgian et al., 2011).
Finally, Spectral counts were added across triplicates. Proteins with a spectral count of
greater than 5 in DS9 and/or DS10, but not identified in DS1 were reported, as were
proteins with at least two-fold enrichment in DS9 or DS10 relative to DS1.
Seeding of Full-Length Tau Aggregation. Polyclonal HEK293 cells overexpressing
untagged Full-Length Tau 4R1N P301S (FL PS) were generated and plated in 24-well
plates at 120,000 cells/well. 18-hours later, cells were transduced (lipofectamine-2000)
with either 50 µg of DS1 or DS9 lysate. 24 hours later, cells were re-plated into 6-well
plates and grown to confluency. On Day 4, cells were re-plated 1:40 onto coverslips in
24-well plates. 48 hours later, cells were fixed and stained for tau and indicated proteins.
Knockout of Endogenous Proteins using CRISPR-Cas9. Lentivirus encoding Cas9
and indicated pooled gRNAs was produced (see Lentivirus Production). OFF1::DS10 or
DS9 cells were plated at 5000 cells/well in 96-well plates. 18 hours later, 150 µL of
media was removed and replaced with 150 µL lentivirus supernatant. 72 hours later, cells
were passaged 1:8 into new 96-well plates and virus addition was repeated. 72 hours
later, cells were passaged into 24-well plates for maintenance. Experiments examining
the effect of knockouts were performed at two to three weeks following the first addition
of lentivirus. For lethal knockouts, cells stopped growing or died within ten days
following lentivirus addition. Knockout of overexpressed tau RD-YFP protein was
achieved within a week in >99% of cells. Toxicity (VCP) and YFP knockout controls
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were performed in all experiments as a proxy for sufficient viral titer to achieve high
efficiency of knockout.
Flow Cytometry. Single cell YFP fluorescence measurements were performed using a
MACSQuant VYB (Miltenyi).
“On-Off-On” Tau Aggregate Degradation Time Courses. OFF1::DS10 cells were
treated with two rounds of indicated pooled gRNA lentivirus (see Knockout of
Endogenous Proteins using CRISPR-Cas9) and were maintained in 24-well plates to
assess viability. Two weeks later, a time course examining the decay of tau aggregate
seeding activity in the various non-lethal knockouts was performed as follows. Confluent
24-wells were re-suspended in 1 mL media and 3.5 µL cells were re-plated into 200 µL
total volume in 96-well plates. Tau RD-YFP expression was turned off using 30 ng/mL
doxycycline for 1 day, 2 days, 3 days, 4 days, or 5 days. After five days, cells reached
confluency and were passaged onto coverslips. 48 hours later, at which point tau RDYFP expression reached its maximum, cells were fixed and cells containing or lacking
inclusions were manually counted. Six replicates of 150+ cells were counted per
condition and averages were calculated.
Statistical analysis. One-way analysis of variance with Bonferroni’s multiple
comparison test was used to assess statistical significance relative to non-target controls.
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AP.5 RESULTS
Identification of putative tau aggresome-associated proteins. In previous work, we
created a monoclonal human embryonic kidney cell line (DS1) that overexpresses an
aggregation-prone, truncated version of tau with two patient-derived mutations and a
fluorescent YFP protein tag (Tau RD-YFP) (Sanders et al., 2014). These cells never form
intracellular tau aggregates unless first exposed to preformed fibrillar tau seeds.
Remarkably, once formed, tau aggregates become self-amplifying and propagate the
prion state to daughter cells indefinitely (Sanders et al., 2014). Moreover, we found that
tau could form discrete strains (DS9 and DS10), which replicated themselves with
tremendous fidelity over months of cell division, and display dissociable biochemical and
biological properties (Sanders et al., 2014). These strains feature accumulation of tau in
different regions of the cell (DS9: nuclear speckles and a small cytoplasmic aggresome;
DS10: a single, large aggresome) and display significant differences in their ability to
seed further aggregation of monomeric tau (DS9: high, DS10: low). Limited proteolysis
revealed that these divergent properties were likely due to different structural properties
of the propagated tau aggregates. However, the mechanisms by which these structures
drove divergent phenotypes were unclear. We hypothesized that examining the
interactomes of these two strains would not only be informative in this regard, but would
also reveal potential pathways by which tau aggregates are disaggregated, degraded, and
trafficked.

Thus, we developed a protocol to purify tau aggregates and their associated proteins,
taking advantage of the immense size and insolubility of micron-sized juxtanuclear
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aggresomes (Figure AP.1A). Coomassie Blue staining demonstrated that this method
resulted in significant enrichment of tau RD-YFP in the insoluble pellet relative to the
soluble supernatant (Figure AP.1B). We thus sent this material (biological triplicates for
each condition) for analysis by mass spectrometry, using the background parent line
lacking tau aggregates (DS1) as a negative control. We identified 1530 proteins present in
at least one of the samples. In most cases, spectral counts associated with specific
proteins were similar between the conditions (data not shown). However, we noted that a
subset of proteins was only present in DS9 and/or DS10 analyses but not that of DS1. To
identify putative tau aggresome-associated proteins, we set an arbitrary cutoff for these
proteins as a spectral count >5 in DS9 or DS10 (Figure AP.2A). We also examined
proteins that were >2-fold enriched in DS9 or DS10 insoluble fractions relative to DS1
(Figure AP.2B). Both lists featured a preponderance of proteins whose canonical
functions were in pathways of ubiquitin-dependent protein degradation (n=33 of 79),
including the ubiquitin-proteasome system and selective autophagy/vesicular trafficking.
Intriguingly, four of these proteins (SQSTM1, CHMP2B, UBQLN2, VCP) have been
implicated as being causative to specific neurodegenerative syndromes (Deng et al.,
2011; Johnson et al., 2010; Laurin et al., 2002; Parkinson et al., 2006; Skibinski et al.,
2005; Watts et al., 2004). We also identified several SR-rich proteins (SRRM2, Pinin,
CWC22, ARGLU1), which likely play a role in constitutive RNA splicing. Many of the
identified proteins are uncharacterized or poorly characterized and could potentially play
important roles in protein aggregate degradation or processing. For example, the
Drosophila homologues of MLF1/MLF2 and DNAJC7 were previously identified as
modifiers of polyQ toxicity (Kazemi-Esfarjani and Benzer, 2000; Kim et al., 2005).
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Importantly, a separate, parallel SILAC-based analysis of proteins that were enriched in
tau aggregates from DS9 to DS10 relative to soluble tau in DS1 (n=126 proteins)
identified 25 of the same proteins, including 3 of the 4 proteins associated with familial
forms of neurodegeneration (SQSTM1, CHMP2B, VCP), 3 of the 4 identified SR-rich
proteins (SRRM2, Pinin, CWC22), all three uncharacterized modifiers of polyQ toxicity
(MLF1, MLF2, DNAJC7), and two completely uncharacterized proteins (FAM199X and
FAM63A) (Figure AP.2C). Overall, DS9 and DS10 interactomes were similar, although
more putative aggresome-associated proteins were identified in the DS10 analysis.
However, this may merely reflect the fact that a greater quantity of tau was partially
purified from DS10 than DS9 (Figure AP1.B).
Immunocytochemistry confirms the presence of candidate aggresome-associated
proteins in tau inclusions. Next, we examined whether the putative tau aggresomeassociated proteins were truly present in this compartment. We ordered antibodies against
9 of the 25 proteins identified by both parallel mass spectrometry analyses of tau
aggregate-associated proteins (Figure AP.2). We performed immunocytochemical colocalization studies in DS1, DS9, and DS10 cells. Seven proteins with putative functions
in protein degradation (UBB, SQSTM1, NBR1, TRAFD1, VCP, MLF2, DNAJC7)
displayed diffuse distributions in DS1 cells (Figure AP.3). However, in both DS9 and
DS10 cells, these proteins displayed heavy co-localization with juxtanuclear tau
aggresomes (Figure AP.3, AP.4). DS10 aggresomes featured a greater accumulation of
these proteins. We also confirmed that two specific SR proteins (SRRM2 and pinin) were
sequestered into tau aggresomes in the cytoplasm, but were exclusively in nuclear
speckles in the DS1 negative control (Figure AP.5, AP.6). Importantly, five other SR-rich
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splicing proteins (SRSF1, SRSF11, ACIN1, SRSF7, snRNP70) not identified by the
proteomic analysis were absent from cytoplasmic tau aggresomes. This highlights not
only the specificity of the potential interaction between tau and these proteins, but also
the predictive power of the proteomic analysis.
DS9 nuclear aggregates are present in splicing speckles. Unlike DS10, DS9 features
spherical nuclear aggregates, the identity of which is unknown (Sanders et al., 2014). The
nucleus is remarkable in that it features a tremendous diversity of membraneless
organelles (Zhu and Brangwynne, 2015). Most, if not all, of these compartments arise by
liquid-liquid phase separation, a phenomenon by which proteins with similar RNA- and
protein-binding multivalent domains form selectively permissible coacervates
(Brangwynne, 2013; Hyman et al., 2014). Thus, we examined whether nuclear tau
aggregates co-localize with any of these bodies. As noted previously (Sanders et al.,
2014), DS9 nuclear aggregates never co-localize with PML bodies, despite the fact that
these organelles are thought to be organizing centers for the degradation of misfolded
nuclear proteins (Fu et al., 2005; Guo et al., 2014; Janer et al., 2006) (Figure AP.6C).
Similarly, DS9 aggregates did not co-localize with Cajal bodies, nuclear gems, nucleoli,
paraspeckles, or nuclear stress bodies (Figure AP.6C). Rather, DS9 aggregates showed
strong co-localization with splicing speckles, as marked by a phospho-SR antibody
(Figure AP.6C). It is possible that DS9 aggregates deposit to this location due to an
interaction between SRRM2 and tau. Notably, CRISPR-Cas9-based knockout of SRRM2
obliterates nuclear tau aggregates (Figure AP.10). However, cytoplasmic DS10
aggregates sequester SRRM2 but do not show re-distribution to nuclear splicing speckles
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(Figure AP.5). Thus, the mechanisms that underlie the differential subcellular distribution
of tau aggregates in DS9 and DS10 require further elucidation.
Immunocytochemistry suggests similarities and differences between tau RD and
full-length tau and polyQ aggregate interactomes. Next, we asked whether proteins
identified in the tau RD-YFP aggresome interactome were present in other types of
inclusions. That is, were these specific markers of tau aggregates or were they likely to be
more general markers of cytoplasmic amyloids? First, we performed ICC on HEK293
cells expressing untagged full-length 4R1N tau P301S, that had previously been exposed
to tau seeds (DS9) (Figure AP.7B) or inoculate lacking seeds (DS1) (Figure AP.7A). As
expected, cells exposed to DS9 lysate formed tau inclusions in the cytoplasm of the
majority of cells (Figure AP.7B). Relative to the canonical, spherical aggresome
structures observed in DS9 and DS10, these aggregates were not as dense and ordered.
These structures stained positive for SQSTM1 and NBR1, but not TRAFD1, VCP, or
MLF2 (Figure AP.7B). SRRM2 was sequestered in significant quantities, thus
demonstrating that recruitment of this RNA-binding protein by tau is not an artifact of
truncated tau RD expression in the nucleus. Knockout of SRRM2 was found to be lethal
to dividing cells (Figure AP.10), which suggested that sequestration of this protein from
the nucleus to the cytosol could potentially contribute to the toxicity of tau aggregates.
Therefore, we asked whether SRRM2 is recruited into tau aggregates in the brains of
tauopathy patients. We performed dual-color IHC (tau and SRRM2) on tissue sections
from patients with several tauopathies: Alzheimer’s Disease, Pick’s Disease, corticobasal
degeneration, progressive supranuclear palsy. In all cases, SRRM2 was observed only in
the nucleus and never in tau inclusions. Thus, it is unlikely that mislocalization of
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SRRM2 from its physiological context in the nucleus to tangles in the cytoplasm is a
contributing factor in the etiology of tauopathies. Rather, sequestration of SRRM2 by tau
aggregates in HEK293 cells may instead be an artifact of nucleo-cytoplasmic mixing
during cell division.
Unlike full-length tau inclusions, huntingtin exon1-Q72 (htt Q72) aggregates are dense
and display features of canonical aggresomes (Waelter et al., 2001). Thus, we created a
monoclonal cell line that stably propagated htt Q72-YFP aggregates and examined the
presence of tau aggresome-associated proteins in these juxtanuclear inclusions. Similar to
DS9 and DS10 tau aggresomes, polyQ inclusions stained positive for SQSTM1, NBR1,
TRAFD1, VCP, MLF2, and DNAJC7 (Figure AP.8). This suggests that these proteins,
and likely many others identified in proteomic analysis of tau aggresomes, play roles in
the metabolism and degradation of diverse amyloids. Unlike tau RD and full-length tau
aggregates, however, polyQ aggregates did not co-localize with SRRM2, suggesting that
specific SR-motif proteins are not globally sequestered by cytoplasmic amyloids.
Examining the functional consequences of aggresome-associated protein knockout.
Having confirmed that our proteomic analysis indeed identified bona fide aggresomeassociated proteins, we next asked whether these proteins play a role in the inheritance of
tau aggregates or their degradation. In order to examine these questions, we turned to a
monoclonal cell line that propagated the DS10 strain and whose tau expression was under
a tetracycline regulated promoter (OFF1::DS10) (Sanders et al., 2014). Similar to DS10
on the DS1 background, these cells feature large juxtanuclear aggresomes and lack
nuclear aggregates (Figure AP.9A). First, we asked whether knockout of specific proteins
resulted in spontaneous curing of the aggregated state. In other words, did any of the
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aggresome-associated proteins that we identified play a similar role to the yeast Hsp104
disaggregase machinery? As it could conceivably take weeks for cells to spontaneously
cure in the absence of such machinery and low levels of protein may be sufficient for
amyloid disaggregation, we decided to use CRISPR-Cas9 to knockout proteins of
interest. We used a lentiviral vector that expressed Cas9 and a gRNA that targeted a gene
of interest. For each gene of interest, we cloned and pooled six gRNAs (Shalem et al.,
2014) prior to lentivirus production. We then treated OFF1::DS10 with lentivirus
supernatant. This method was extremely effective at introducing indels and disrupting
expression of an exogenously expressed gene, tau RD-YFP, present in numerous copies
(Figure AP9.A). In fact, knockout was “all-or-none” (Figure AP9.B), demonstrating that
introduction of a single gRNA into a cell was sufficient to disrupt all copies of the
associated gene. Further, by biochemical approaches, we found that this method was
effective at reducing levels of select endogenous proteins (SQSTM1, TRAFD1,
DNAJC7) by >99% (Figure AP9.D). Next, we used this method to knockout our top 25
candidate genes as well as 6 additional controls in five cell lines: DS1, DS9, DS10,
OFF1::DS1, OFF1::DS10. 9 of the genes were essential, as all cells died within a week of
lentivirus treatment (Figure AP9.C). This was not dependent on the presence of
aggregates in the cells. One month after treatment, spontaneous curing was not observed
in any of the aggregate-containing lines (data not shown). Thus, none of the non-essential
genes are critical to the maintenance of the aggregated state in dividing mammalian cells.
Was it possible that knockout produced more subtle effects? Two weeks after lentivirus
treatment, OFF1::DS10 cells were observed by confocal microscopy. SQSTM1 knockout
resulted in less dense aggresomes and more tau present in diffuse accumulations
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throughout the cytosol (Figure AP9.E). Conversely, DNAJC7 knockout resulted in
aggresomes that were denser, with decreased quantities of extra-aggresomal tau (Figure
AP9.E). No other non-lethal gene knockout produced an observable phenotype. We asked
whether knockout of specific genes influenced the clearance of tau seeds in this cell line.
We turned off tau expression for 0 to 5 days, re-started expression for 2 days, and
counted the percentage of cells with inclusions. ADRM1 knockout resulted in more rapid
clearance of tau aggregates (Figure AP9.F, AP9.G). Conversely, DNAJC7 knockout
resulted in greatly decreased rates of clearance (Figure AP9.F-H). Knockout of SQSTM1
and other proteins had no effect. Importantly, knockout of control proteins (ATG5,
autophagy; LAMP1, chaperone-mediated autophagy) had no effect, thus indicating that
selective autophagy does not play a significant role in the clearance of tau seeds in this
cell culture system. Rather, dilution of aggregated material by cell division or possibly
the ubiquitin-proteasome system is responsible for the clearance of seeds over several
days.
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AP.6 DISCUSSION
Like yeast, mammalian cells feature a remarkable ability to stably propagate the
aggregated state to daughter cells as an epigenetic phenotype (Krammer et al., 2009; Ren
et al., 2009; Sanders et al., 2014). Similar to yeast, metazoans also feature the capacity to
replicate unique fibrillar structures (prion strains) (Krammer et al., 2009; Sanders et al.,
2014). However, unlike yeast, a disaggregase system that efficiently generates additional
seeds for the replication of fibrillar amyloids has not been defined in mammalian cells.
Further, the mechanisms that regulate trafficking and degradation of specific prion strains
have not been elucidated. In the present work, we used an unbiased mass spectrometry
approach to identify proteins that co-purify with specific tau aggregate structures (prion
strains DS9 and DS10) with the goal of identifying critical mediators of prion inheritance,
degradation, and trafficking. We identify 79 proteins that putatively target to micronsized aggresomes, organizing sites for protein aggregate degradation (Johnston et al.,
1998). We confirm that 9 of these proteins co-localize with tau aggresomes by
immunocytochemistry, demonstrating the power of this analytical approach. By
examining the presence of these same proteins in huntingtin polyQ aggresomes, we
conclude that most of these proteins appear to generically target to these aggregate
organizing centers. Thus, the provided resource will likely be informative to examining
the metabolism of diverse amyloids.
Using CRISPR-Cas9, we examined the consequences of knockout of many (n=25) of
these proteins. We were unable to find proteins that were essential to the continued
inheritance of the prion state. However, we cannot rule out that essential proteins (e.g.
VCP) or proteins that transiently interact with smaller aggregates do not play a role in
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disaggregation of amyloids. Nevertheless, we identify three proteins whose knockout
alters the morphological phenotypes of tau inclusions. SRRM2, an essential SR-motif
containing gene that functions in constitutive RNA splicing (Gautam et al., 2015), is
necessary for the deposition of DS9 tau aggregates in nuclear splicing speckles. However,
SRRM2 is also recruited into DS10 aggresomes, suggesting that differential binding of
this protein to different tau aggregate structures is not the critical mediator of the unique
inclusion profile patterns observed in specific strains (Sanders et al., 2014). Removal of
SQSTM1, a selective autophagy adaptor protein that forms filaments to recruit other
autophagy cargo (Ciuffa et al., 2015), disrupts the formation of tau aggresomes, resulting
in more diffuse accumulations of aggregated tau. This suggests that the protein likely
plays a role in the 3D organization of juxtanuclear aggresomes. Conversely, DNAJC7
knockout results in denser inclusions. Moreover, it greatly impairs the kinetics of tau seed
removal. This is in contrast to the knockout of essential proteins for selective autophagy
(ATG5) and chaperone-mediated autophagy (LAMP2). This suggests that these pathways
are not critical to the clearance of seeds in dividing mammalian cells. Rather, seeds are
likely removed by dilution via cell division or possibly the ubiquitin-proteasome system
(UPS). Partial knockdown of critical UPS components by shRNA or CRISPRi will be
necessary to dissociate these possibilities. Moreover, additional studies will be required
to determine the mechanisms by which DNAJC7, a poorly understood co-chaperone that
has nonetheless been previously implicated as a moderator of polyQ toxicity (KazemiEsfarjani and Benzer, 2000), influences tau aggregate trafficking and degradation.
Notably, knockout of other DNAJC proteins (DNAC9 and DNAJC14) do not phenocopy
this effect. Current work seeks to examine the effects of knockout of all mammalian
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chaperones in these systems to see whether this striking effect is specific to DNAJC7.
Moreover, this work will determine whether other chaperone proteins that are not as
enriched in aggresomes and may transiently interact with smaller species mediate the
inheritance of the aggregated state. Overall, the present work provides a list of proteins
that are likely to be critical to tau aggregate degradation and trafficking. Further work
must be performed in non-dividing cells to determine the relative roles of these various
proteins in tau seed degradation.
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AP.7 FIGURES

Figure AP.1. Partial purification of tau aggresomes. (A) A method was generated to
partially purify tau aggresomes from tau RD-YFP cells, with the goal of identifying tau
aggregate-associated proteins. (B) Sarkosyl-soluble and sarkosyl-insoluble fractions were
run on gels and proteins were stained with SimplyBlue. DS9 and DS10 (contain tau
aggregates) but not DS1 (lacks tau aggregates) insoluble fractions featured a significant
enrichment of tau RD-YFP. Whole lanes for pellet fractions were analyzed by mass
spectrometry (biological triplicates).
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Figure AP.2. Mass spectrometry identifies potential proteins present in tau
aggresomes. (A) Spectral counts were combined across biological triplicates to identify
proteins present in DS9 and/or DS10 but not DS1 insoluble fractions (arbitrary cutoff =
spectral count of > 5). (B) Proteins, whose spectral counts were greater than two-fold
increased in tau aggregate-containing lines, were identified. Many of the proteins in both
lists function in selective autophagy and the ubiquitin-proteasome system. Unexpectedly,
SR-motif containing proteins were also identified. (C) A separate SILAC proteomic
analysis of proteins that co-immunoprecipitated with tau aggregates identified many of
the same proteins (data not shown).
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A

B

Proteins Only Present in DS9, DS10
(Insoluble Fraction)

Protein
DS1 Count DS9 Count DS10 Count Putative Function
NBR1
0
90.31
167.62 Autophagy/protein degradation
MLF2
0
23.98
94.80 Sequesters polyQ inclusions
TRAFD1
0
0
100.74 Vesicle trafficking and acidification
UBQLN2
0
0
71.50 Autophagy/protein degradation
SQSTM1
0
21.74
57.29 Autophagy/protein degradation
UBQLN1
0
0
49.50 Protein degradation
PJA2
0
6.00
48.00 Ubiquitin ligase
PSMD4
0
0
51.33 Proteasome/protein degradation
KRT18
0
1.00
37.98 Keratin
FAM199X
0
17.00
22.00 Uncharacterized
UFD1L
0
0
37.49 Autophagy/protein degradation
SUMO2
0
15.00
19.00 Protein degradation
AP3B1
0
0
33.93 Lysosome biogenesis
ADRM1
0
0
32.00 Proteasome/protein degradation
VPRBP
0
2.00
28.00 E3 ubiquitin ligase
MOXD1
0
12.00
13.00 ER monooxygenase enzyme
VCP
0
0
18.99 Autophagy/protein degradation
AHCYL1
0
0.99
22.85 Inositol phospholipid signaling
UBQLN4
0
1.00
20.00 Autophagy/protein degradation
PSMD14
0
0
19.00 Proteasome/protein degradation
ADCK1
0
8.00
11.00 Uncharacterized kinase
MLF1
0
1.98
15.85 Uncharacterized
CHMP2B
0
0.99
15.94 Autophagy/protein degradation
SOX4
0
3.00
12.00 Transcription factor
FAF1
0
0
13.91 Autophagy/protein degradation
PKN3
0
1.00
12.00 Kinase
RNF34
0
0
13.00 E3 ubiquitin ligase
SUMO1
0
4.95
7.92 Protein degradation
SNAP29
0
0
13.00 Autophagy/protein degradation
VPS51
0
0
10.00 Vesicle trafficking
RAD23B
0
0
9.00 Nucleotide excision repair
HECTD1
0
0
8.00 E3 ubiquitin ligase
FTL
0
1.00
6.00 Ferritin light chain
TRIM26
0
0
7.00 Proteasome/protein degradation
KANK1
0
0
6.93 Cell proliferation
FAM63A
0
0
7.00 Uncharacterized
NIPSNAP3A
0
0
8.00 Uncharacterized/vesicular trafficking
ARFGAP2
0
0
5.94 Secretory pathway
CALCOCO2
0
0
5.94 Autophagy/protein degradation
CUEDC2
0
0
5.00 Ubiquitination
TRIM37
0
0
5.00 E3 ubiquitin ligase

Proteins Enriched in DS9, DS10
(Insoluble Fraction)

Protein
DS1 Ct
SRRM2
10.97
TAX1BP1
2.94
CNTN1
1.00
DNAJC7
15.65
CPNE8
2.00
CIR1
1.00
SNAP23
2.98
ULBP2
2.00
CD55
1.00
LTV1
2.00
ISG20L2
3.00
CD59
2.00
FYN
0.98
UBB
155.82
CWC22
7.00
ARL6IP4
2.96
PNN
30.97
CACNA2D2
2.00
UBTF
19.89
PSMD3
3.00
SMPDL3B
16.85
LAMTOR1
14.94
EPPK1
4.00
DNAJB1
2.00
FTH1
10.89
CACNA2D1 10.92
EFTUD2
13.97
MYL6
3.96
NAP1L1
5.92
ASCC3
4.00
DIEXF
3.00
MTCH1
7.91
SRPK1
3.00
CAD
5.00
AP3D1
5.00
ARGLU1
11.00
PSMB7
25.00
REXO4
13.00

DS9 Ct DS10 Ct DS9/DS1 DS10/DS1
198.73 238.62
18.12
21.75
4.95
69.18
1.68
23.53
1.00
16.99
1.00
16.99
202.34 297.41
12.93
19.00
12.00
14.00
6.00
7.00
14.94
5.97
14.94
5.97
7.93
42.57
2.66
14.29
11.00
14.00
5.50
7.00
3.00
11.99
3.00
11.99
18.00
23.00
9.00
11.50
14.00
10.00
4.67
3.33
15.00
17.00
7.50
8.50
3.95
12.79
4.03
13.05
453.38 803.38
2.91
5.16
18.00
19.00
2.57
2.71
1.98
14.80
0.67
5.00
102.92 184.88
3.32
5.97
0.00
13.00
0.00
6.50
59.75 180.19
3.00
9.06
3.00
11.00
1.00
3.67
57.43
77.22
3.41
4.58
54.69
80.51
3.66
5.39
23.00
20.00
5.75
5.00
1.00
10.93
0.50
5.47
11.88
43.56
1.09
4.00
16.91
36.81
1.55
3.37
22.94
64.87
1.64
4.64
2.97
12.87
0.75
3.25
0.00
19.74
0.00
3.33
11.00
20.00
2.75
5.00
16.00
17.00
5.33
5.67
25.73
16.83
3.25
2.13
1.00
12.00
0.33
4.00
7.00
13.00
1.40
2.60
5.00
15.00
1.00
3.00
7.00
21.00
0.64
1.91
18.00
54.00
0.72
2.16
32.00
31.00
2.46
2.38
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Figure AP.3. Verification of putative tau aggresome-associated proteins in DS10.
DS1 and DS10 cells were stained with antibodies raised against proteins putatively
present in tau aggresomes: Ubiquitin, SQSTM1, NBR1, TRAFD1, VCP, MLF2,
DNAJC7. In all cases, proteins showed co-localization with DS10 aggresomes.
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Figure AP.4. Verification of putative tau aggresome-associated proteins in DS9. DS9
cells were stained with antibodies raised against proteins putatively present in tau
aggresomes: Ubiquitin, SQSTM1, NBR1, TRAFD1, VCP, MLF2, DNAJC7. In all cases,
proteins showed co-localization with DS9 aggregates, although in many cases, they
showed weaker co-localization than in the case of DS10 aggregates.
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Merge (w/ DAPI)

Figure AP.5. Specific SR proteins are sequestered in DS10 tau aggresomes. (A)
SRRM2 and pinin, two SR-motif containing proteins identified by insoluble proteomics,
co-localize with DS10 aggresomes. (B) Other SR-motif containing proteins (SRSF1,
SRSF11, ACIN1, SRSF7, snRNP70) are not sequestered by tau aggresomes, which
further confirms the specificity of the list of proteins identified in the insoluble proteomic
analysis to aggresome-associated proteins.
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Figure AP.6. DS9 nuclear aggregates are in splicing speckles not other nuclear
bodies. (A) SRRM2 and pinin, two SR-motif containing proteins identified by insoluble
proteomics, co-localize with DS9 aggresomes. (B) Other SR-motif containing proteins
(SRSF1, SRSF11, ACIN1, SRSF7, snRNP70) are not sequestered by DS9 tau
aggresomes. (C) ICC with a panel of antibodies (phospho-SR, PML, Coilin, FBL, SMN1,
PSF/SFPQ, SAFB) against canonical markers of specific nuclear bodies demonstrates
that nuclear DS9 aggregates are present in splicing speckles but not other RNP bodies.
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Figure AP.7. Full-length tau aggregates do not display the same interactome as tau
RD in cells and patients. (A) In unseeded (DS1-treated) full-length tau P301S cells,
SRRM2, SQSTM1, NBR1, TRAFD1, and VCP do not re-localize to cytoplasmic puncta.
(B) SRRM2, SQSTM1, and NBR1 (but not other putative aggresomes markers), colocalize with seeded (DS9-treated) FL tau P301S aggregates. (C) SRRM2 remains
confined to nuclear splicing speckles in both control and tauopathy brains (representative
AD sample shown).
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Figure AP.8. Many tau aggresome-associated proteins co-localize with polyQ
aggregates. A monoclonal Huntingtin Exon 1 Q72-EYFP cell line that stably propagates
the aggregated state was generated and stained with shown antibodies. All putative
aggresome markers (SQSTM1, NBR1, TRAFD1, VCP, MLF2, DNAJC7) co-localize
with cytoplasmic polyQ inclusions. An SR-motif protein (SRRM2) did not, confirming
the specificity of this marker to tau inclusions in cells.
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Figure AP.9. DNAJC7 KO inhibits removal of tau aggregate seeds. (A) A
monoclonal Tet-regulated tau RD-YFP aggregate line (OFF1::DS10) was exposed to two
treatments of the indicated pCRISPRv2 lentivirus, which demonstrated that this method
was effective at disrupting multiple copies of an exogenously introduced gene (tau RDYFP). (B) Flow cytometry shows that knockout of expression is “all-or-none.” (C)
CRISPR-Cas9 was used to knockout top candidate genes identified by proteomic
analyses as well as several controls in OFF1::DS10 cells. Some of these genes were
essential (marked in red) and killed all cells. These genes were also essential to viability
of cells lacking tau aggregates (OFF1::DS1), suggesting that knockout of these genes
does not cause toxicity through altered tau aggregate metabolism. (D) Western blot was
used to show that the method (1 or 2 treatments with pCRISPRv2 lentivirus) was
effective at knocking-out the expression of endogenous proteins (SQSTM1, TRAFD1,
DNAJC7), without subsequent selection. (E) Of knockouts that were not lethal, only
DNAJC7 and SQSTM1 had a significant effect on tau aggregate phenotypes. SQSTM1
KO resulted in less dense aggresomes, with greater amounts of tau diffuse in the
cytoplasm. DNAJC7 KO caused a phenotype whereby tau inclusions became denser,
with lower quantities of extra-aggresomal tau. (F) Tau expression was turned off for three
or five days, and was then re-started for two additional days. Percentage of cells
containing inclusions was quantified (n=6 fields, each with >150 cells). Only ADRM1
and DNAJC7 KO had significant effects on tau seed clearance (** = p<0.01, **** =
p<0.0001). Error bars represent S.E.M. (G) Tau expression was turned off for the
indicated number of days, and was then re-started for two additional days. Percentage of
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cells containing inclusions was quantified (n=6 fields, each with >150 cells). Only
ADRM1 and DNAJC7 KO had significant effects on tau seed clearance (* = p<0.05, ** =
p<0.01, *** = p<0.001, **** = p<0.0001). Error bars represent S.E.M. (H) Confocal
images of select KOs with five days of repressed expression.
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Figure AP.10. SRRM2 is required for tau aggregate entry into splicing speckles.
DS9 cells were treated with two rounds of NonTarget or SRRM2 gRNA lentivirus and
cells were imaged after six days. Nuclear tau aggregates (splicing speckles) were
disrupted in SRRM2 knockout cells. Other lethal knockouts did not produce this same
phenotype (data not shown).
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